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CHAPTER 1 
GENERAL INTRODUCTION 
GROWTH FACTORS 
Cell proliferation and differentiation in mammals is regulated by a vanety of extracellular signals 
Hormones are a group of signal molecules that are synthesized in specialized tissues and can act on 
cells throughout the body, while polypeptide growth factors and cytokines are synthesized in all cell 
types and act locally Growth factors and cytokines act by high-affinity binding to specialized 
transmembrane receptor molecules in the plasmamembrane of their target cells This is thought to 
result in a conformational change affecting the extracellular as well as the intracellular domain of the 
receptor, carrying the extracellular signal into the cytoplasm This releases a cascade of intracellular 
signals, the so-called second messengers, generally resulting in effects on gene transciption, and 
therefore protein synthesis Growth factors have been shown not to act on their own, but to be 
influenced by each other and by other signal molecules, while their effect is also dependent on cell 
type and the physiological state of the cell 
Since the discovery of the first growth factors, over 30 years ago, this group of protein molecules 
has continuously been expanding The interest in the actions of growth factors rapidly increased when 
it became clear that viral oncogenes, causing cancer in rodents and birds, have normal cellular 
homologues functioning in the regulatory machinery associated with growth factor action 
Malfunctioning of proteins from the regulatory pathways due to mutations or modified expression is 
able to transform a normal cell into a cancer cell (1,2) This knowledge can in principle be used for 
the design of effective therapies against cancers One type of defect, coexpression of a secreted 
signalling molecule and its cognate receptor, resulting in continuous proliferative autostimulation (1), 
seems to lend itself very well to intervention This mechanism is generally referred to as autocrine 
stimulation The autocrine signal can potentially be blocked by competitive binding of either an 
antibody that blocks the interaction between ligand and receptor, by a soluble ligand binding domain 
of the receptor, or by a receptor antagonist, a ligand analogue that is able to bind, but unable to 
activate the receptor A receptor antagonist can be found by the "shotgun approach" (the chemical 
synthesis and/or screening of thousands of compounds) or can be designed by a more rational 
approach The design of an antagonist requires knowledge of the structure and the functional 
domains of the ligand molecule, but has the advantage that also new information on the mechanism 
of growth factor action is obtained, making it easier to synthesize variants of an antagonizing 
substance The advantages and disadvantages of the different ways to block the autocrine loop will 
be discussed more elaborately later in this chapter 
In this thesis focus will be laid on the epidermal growth factor receptor (EGF-R) and two of its 
hgands, epidermal growth factor (EGF) and transforming growth factor-alpha (TGF-a) Coexpression 
of TGF-a and the EGF-receptor has been found in many solid tumors (3,4) and a lot of knowledge of 
the structure and function of the hgands and receptor is available This makes the EGF-receptor an 
attractive target for the design of an antagonizing ligand analogue In this chapter the literature on the 
structure and function of EGF, TGF-a and the EGF-receptor will be reviewed and the aim of the study 
described in this thesis will be further explained As the available literature is extensive, the reader will 
be referred to reviews where possible 
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NSDSECPLSHDGYCLHDQVCMYIEALDKYA CNCWGYIGERCQYRDLKWWELR ( 9 ) 
NSYPGCPSSYDGYCLNGGVCMHIESLDSYT CNCVIGYSGDRCQTRDLRWWELR ( 10) 
NSNTGCPPSYDGYCLNGGVCMYVESVDRYV CNCVIGYIGERCQHRDLR (11) 
QDAPGCPPSHDGYCLHGGVCMHIESLNTYA CNCVIGYVGERCEHQDLDLWE (11) 
NSYSECPPSHDGYCLHGGVCMYIEAVDSYA CNCVFGYVGERCQHRDLKWVfELR ( 12 ) 
WSHFNDCPDSHTQFCFH-GTCRFLVQEDKPA CVCHSGYVGARCEHADLLA ( 13 ) 
WSHFNKCPDSHTQYCFH-GTCRFLVQEEKPA CVCHSGYVGVRCEHADLLA ( 14 ) 
WSHFNDCPDSHSQFCFH-GTCRFLVQEEKPA CVCHSGYVGARCEHADLLA ( 15 ) 
1PAIRLCGPEGDGYCLH-GDCIHARDIDGMY CRCSHGYTGIRCQHVVLVDYQ ( 16) 
IIKRIKLCNDDYKNYCLNNGTCFTVALNNVSLN-PFCACHINYVGSRCQFINLITIK ( 17 ) 
IVKHVKVCNHDYENYCLNNGTCFTIALDNVSIT-PFCVCRINYEGSRCQFINLVTY ( 18 ) 
VKTHFSRCPKQYKHYCIH-GRCRFWDEQTPS CICEKGYFGARCERVDLFY ( 19 ) 
KKRDPCLRKYKDFCIH-GECKYVKELRAPS CICHPGYHGERCHGLSL ( 20 ) 
R-KKKNPCNAEFQNFCIH-GECKYIEHLEAVT CKCQQEYFGERCGEK ( 21 ) 
RKKKKNPCAAKFQNFCIH-GECRYIENLEWT CHCHQDYFGERCGEKTM ( 22 ) 
GTSHLVKCAEKEKTFCVNGGECFMVKDLSWPSRYL-CKCQPGFTGARCTENVPMK (23) 
GTS HLIKCAEKEKTFCVNGGECFTVKDLSNPSRYL-CKCQPGFTGARCTENVP (24) 
ELNRTC CLNGGTC MLGSF-CACPPSFYGRNCEHDVRKE ( 25 ) 
С ASLCCGHGTC—IDGIGSFS CDCRSGWEGRFCQREVSFLN ( 26 ) 
CPDGPDSGRQFARSCYQDPVTLQLA CVCDPGYIGSRCDDCASGFF (27) 
IDEC XSNPCQNGGTC XDXVGSYXCXCPPGFTGKXCEXN ( 2B ) 
Figure 1.1. Comparison of the amino acid sequences of the EGF-like domains of different members of the EGF-family. 
Roman numerals at the top indicate the cysteine bordered domains. The consensus sequence for EGF-receptor 
binding growth factors and the residue numbenng of EGF are shown at the top Abbreviations used for sequences 
derived from different animal species h human; m:mouse, r.rat; gp.guinea pig, ρ pig, b bovine References are given 
behind the sequences A. Proteins binding to the EGF-receptor Numbers preceding the sequence designate the 
ammo acid residue number initiating the sequence shown В EGF-like growth factors with mitogenic activity, but 
without affinity for the EGF-receptor С A few examples of EGF-like domains of much larger proteins with different 
functions Dashes indicate gaps introduced in the sequence to maximize sequence homology 
EGF AND RELATED GROWTH FACTORS 
EGF, the first mitogenic growth factor described (reviewed in 3), acts through binding of the EGF-
receptor, a 170 kDa receptor tyrosine kinase. EGF is the prototype of a rapidly expanding family of 
structurally related growth factors from vertebrates (fig.1.1), characterized by a cysteinyl-bounded core 
sequence of 36-40 residues in length, with the consensus sequence CX7CX45CXl0.13CXCXeC 
(Cxysteine, X:other amino acid). The EGF-like growth factor family includes TGF-a, amphiregulin 
(AR), heparin-binding EGF-like factor (HB-EGF), and betacelluhn (BTC), which all compete with EGF 
for binding to the EGF-receptor. Of these proteins, both amphiregulin and HB-EGF contain a heparin 
binding extension which contributes significantly to the receptor affinity and biological activity of the 
proteins. The EGF-like family also includes vaccinia virus growth factor (VGF), Myxoma virus growth 
factor (MGF) and Shope fibroma virus growth factor (SFGF). The affinity of SFGF and MGF for the 
EGF-receptor has only been shown using synthetic partial proteins spanning their EGF-like domain 
(5,6). In addition, growth factors designated heregulins (HRGs) containing the EGF consensus motif 
have been characterized which bind to receptors (c-erbB3 and c-erbB4) related to the EGF-receptor, 
but not to the EGF-receptor itself (see ref. 7 for a review), while Cripto, which is a related mitogenic 
protein, binds a yet unknown receptor (8). EGF-like proteins have also been identified in 
invertebrates, like the product of the lin-3 gene from Caenorhabditis eleqans (C. eleqans) and the 
product of the delta, notch and spitz genes from Drosophila melanoqaster (D. melanoqaster), which all 
play an important role in development (3). Several other, non-growth factor, proteins like the LDL-
receptor, proteases and extracellular matrix proteins contain EGF-like motifs, although in these 
domains the cysteine-spacings may deviate considerably from the consensus EGF-sequence. 
Although some of these proteins, such as laminin, seem to be capable of mitogenic stimulation (29), 
they have no affinity for the EGF receptor (see 3,4,30,31 for reviews). 
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EGF AND TGF-α: PRECURSOR FORMS 
EGF and TGF-α are both synthesized as large transmembrane proteins from which soluble forms 
are processed. The hEGF precursor is a 1207 amino acid protein containing nine EGF-like sequences 
in its extracellular domain of which only the most C-terminal sequence is excised to form active EGF 
(9). Only the EGF-like motif of this authentic EGF sequence exactly matches the consensus sequence 
and is capable of mitogenic stimulation, while the other EGF-like sequences from the precursor have 
a slightly more variable spacing between their cysteine residues (3). Another conspicuous difference 
between these nine EGF-like sequences is that the authentic EGF sequence, similarly as observed in 
TGF-α, is encoded by two exons, separated between the fourth and fifth cysteine residue, while the 
other are encoded by one exon each (9,13). The hTGF-a precursor, with a size of 160 amino acids, 
contains only one EGF-like sequence (13). Apart from the membrane-bound precursors and the 
6 kDa soluble mature forms, partly processed soluble forms of EGF and TGF-α have been isolated 
(32,33). Despite their name, the EGF and TGF-α precursors should be considered as structural and 
functional isoforms of the growth factors, rather than inactive molecules from which the active 
molecules are excised (34). The membrane bound precursors of EGF (35,36) and TGF-α (37,38) 
have been shown to be able to activate EGF-receptors on adjacent cells, a process called juxtacrine 
stimulation. It has been shown that the processing of the TGF-α precursor is a regulated process 
(34), and that both the EGF-precursor and the TGF-α precursors are processed to their soluble forms 
in most, but not all tissues (34). Different forms of the growth factor may serve different functions, as 
has been shown in intact animal models for other membrane-anchored growth factors. Mice 
expressing the soluble, but not the transmembrane form of stem cell factor, or expressing a bride of 
sevenless (boss) protein truncated after the third transmembrane region, show defective phenotypes 
(34). Processing may therefore serve to change the stimulation of adjacent cells (juxtacrine) to 
stimulation of nearby cells (paracrine), more distant cells (endocrine) or even autostimulation (auto­
crine). There are indications that the C-terminal valine of proTGF-a is the critical determinant for the 
release of soluble TGF-α from its transmembrane precursor, and thus the signal to process the 
precursor may be transmitted from the cytoplasm to the extracellular domain via the precursor itself 
(34). 
MATURE FORMS 
Mature EGF is a soluble, non-glycosylated protein with a molecular size of about 6 kDa (fig. 1.2). 
Its six cysteine residues (C1-C6, numbered according to their position in the sequence) form three 
disulfide bonds (C1 to C3, C2 to C4 and C5 to C6) which determines to a large extent the three-
dimensional structure of the molecule, its acid and heat stability and its resistance to gastric proteases 
(3). EGF, first isolated from the mouse submandibular gland and thereafter from human urine, is 
present in most body fluids, and transciption of the EGF gene has been found in several adult mouse 
tissues, but is highest in salivary gland and kidney (4,39). The mEGF gene seems not to be 
transcribed until after birth (32). The exact physiological role of endogenous EGF remains elusive, 
although renewal of epithelial tissues is probably one of its functions. Early studies have shown that 
administration of exogenous EGF to the intact animal causes precocious eyelid opening and incisor 
eruption in newborn mice, and inhibition of gastric acid secretion, while many different physiological 
effects have been measured in the intact animal and in cell and organ culture systems, most but not 
all related to the mitogenic stimulation of epithelial cells (4,32,39). Administration of EGF to sheep 
causes regression of wool follicles and has been used to induce fleece shedding (40), while methods 
are being devised to administer high concentrations of this growth factor for longer periods of time to 
wounds in order to accelerate wound repair (41). 
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EGF TGF-α 
Figure 1 2 Schematic representation of structural features of hEGF and hTGF-α Solid lines indicate disulfide bridges Loops 
are indicated by А, В and С 
Mature TGF-α, a single-chain unglycosylated polypeptide of 50 amino acids, has been isolated for 
the first time from a virus-infected rat cell line. The isolated transforming activity, initially termed 
sarcoma growth factor, and capable of blocking the binding of EGF to its receptor (42), proved to 
result from the action of two growth factors, TGF-α and TGF-ß respectively, of which only the first 
binds to the EGF-receptor (43) TGF-α has the same overall three-dimensional structure and shows 
the same mitogenic activity as EGF in in vitro assays (4) In contrast to EGF, TGF-α is produced by 
fetal tissues and expressed by many tumor cells often in combination with a high level of expression 
of EGF-receptors, but the protein has also been found in many tissues of mature mammals (4,32,39) 
STRUCTURE OF EGF AND TGF-α 
Mature EGF and TGF-α show only limited amino acid homology (about 40 %), but their overall 
structures are highly similar For convenience these proteins can be divided in homologous domains 
or loops based on the conserved cysteine residues connected by disulfide bridges Figure 1 1 shows 
a division in domains in which the cysteine residues are the border between domains, with the 
exception of the single residue between Cys32 and Cys34 which is not considered to be a separate 
domain. This single residue can be also considered to be the border between the N-terminal and 
C-termmal domain of the molecule, since these two domains are coded by different exons and seem 
to fold separately The molecule can also be divided into the three looped domains (loop A residues 
6-20, B· 14-31 and С 32-42) formed by the three disulfide bridges and two linear regions (fig 1 2) 
None of these three classifications is based on characterized functions of these domains Crystal 
structures of EGF or TGF-α are not yet available, but the solution structure of mEGF (44-46), hEGF 
(47,48) and TGF-α (49-54) has been described on the basis of NMR studies The N-termmal domain 
of TGF-α consists of a triple stranded antiparallel ß-sheet, involving interactions between Phe5-Asn6 
(strandl) and Phe23-Leu24 (strand2), and between Gly19-Leu24 (strand2) and Lys29-Cys34 
(strand3), with strand 2 and 3 forming an anti-parallel ß-hairpin loop (50-52) The C-terminal domain 
forms a double anti-parallel hairpin structure involving interactions between residues Cys34-His35 
(strand4), Tyr38-Val39 (strand5) and His45-Ala46 (strand6) The N- and C-termmal domains 
connected by аІЗЗ, which functions as a hinge, form an interdomain cleft, involving interactions 
between residues Phe15-Gly19 from the N-termmal domain and Cys34-His35 and Arg42-Glu44 from 
the C-termmal domain, which has been suggested to be involved in binding to the EGF-receptor (53) 
A comparable structure has been observed for EGF (48) 
Differences between the three-dimensional structures of EGF and TGF-α have, however, been 
noticed It has become apparent that the structure of TGF-α is much more pH sensitive than that of 
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EGF (50-53) In TGF-α, the first strand of the tnple stranded N-termmal domain is disrupted at low pH 
(pH 3 5), while also the relative onentation of the N- and C-terminal domains changes, possibly 
involving a flexing of the polypeptide backbone of the "hinge" residue аІЗЗ. This pH-induced change 
in the conformation of the molecule may be induced by the protonation of the side-chains of one or 
more of the five histidine residues, and to a lesser extent of the three aspartic acids and two glutamic 
acids (53) Most notably His18 and His35 may play a central role in the relative onentation of the 
N-and C-terminal domains These residues have abnormal pKa's (7.6 and 5 4 respectively) which may 
be indicative of the formation of hydrogen bonds between these two histidines (53) Disruption of 
these bonds may explain the extreme flexibility of the TGF-α molecule at low pH In mEGF these 
residues have been replaced by an asparagme and a valine residue respectively, and in this molecule 
little difference has been observed between the structure at pH 6 θ and 2 0 (46), except for the 
C-terminal tail region (residues Leu47-Trp50) EGF and TGF-α adopt very different conformations 
after the reduction of the disulfide bonds TGF-α is more easily reduced and its structure changes 
only slightly, while EGF shows a dramatic increase in the amount of α-helix upon reduction This 
indicates that the structure of the native growth factors is mainly determined by the disulfide bridges 
(55) 
STRUCTURE/FUNCTION RELATIONSHIP STUDIES 
Synthetic growth factor fragments 
Several approaches have been used to localize the residues that are essential for receptor binding 
and/or activation Some groups have used partial peptide sequences of the growth factor molecules to 
assess the contribution of the different loops to the binding to the receptor (56-65) On basis of results 
from this approach, the B-loop (56,62) as well as the C-loop (57,59,60) have been mentioned as 
being essential for receptor binding and/or activation, while others reported contributions of the A- and 
C-loop or B- and C-loop in combination with the carboxy-terminal segment (63-65), all three loops and 
the C-terminal segment (61) or inconclusive results (58) The reason for these discrepancies is 
probably that extremely high concentrations of partial peptides have to be used to measure inhibition 
of binding to the receptor of the native molecule, since a correct structure of the ligand is essential for 
binding, while in addition the binding domain of the ligand may not be continuous 
Domain-specific antibodies 
Efforts to locate the binding domain by using domain-specific antibodies that block receptor binding 
have also produced conflicting results In one study monoclonal and monospecific polyclonal 
antibodies against residues 22-32 and 33-53 of hEGF inhibited the binding of lodinated hEGF to the 
receptor, while antibodies against 1-13 and 13-32 were ineffective (65), while in another study 
monoclonal antibodies directed to the B-loop of TGF-α did not compete with TGF-α in binding the 
EGF-receptor (66) A monoclonal antibody raised against the native TGF-α molecule and reacting 
with residues 33-53, was able to block binding of this growth factor to the receptor (67), while a 
polyclonal antipeptide antibody also directed against these residues was not (60), although both these 
antibodies are probably directed against the C-terminal tail (60,68) 
N- and C-terminal modifications 
Chemical modification of EGF has shown that the 1-48 fragment displays full biological activity, the 
1-47 fragment a 3-7 fold lower activity, while the 1-46 fragment shows a more than 100-fold decrease 
in binding and mitogenic activity (69) This indicates that the five C-terminal residues of EGF are fully 
dispensible for binding to the receptor, while Leu47 seems to be essential Other studies have 
indicated that the C-terminal tail may play an essential role in receptor binding (discussed below). 
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Ammo-terminal additions or deletions seem to have no effect on receptor binding (4), although 
precursor forms of EGF (soluble 30 kDa "big" EGF) and the solubilized transmembrane form of 
TGF-a show reduced biological activity (3,38). 
Site-directed mutagenesis studies 
Site-directed mutagenesis experiments have been used to study the role of individual residues in 
EGF and TGF-a. The choice of residues to be changed is generally based on their conservation 
among EGF-like proteins that bind to the EGF-receptor, and on NMR-studies Conserved residues are 
considered to be either important in the determination of the overall three-dimensional structure of the 
protein or to have a function in the binding to or activation of the receptor. Among all EGF-like growth 
factors with affinity for the EGF-receptor, the six cysteine residues, as well as an aromatic residue at 
positions 13 and 37 (mostly Tyr), Gly18, Gly 39 and Arg41 are absolutely conserved (see fig. 1.1) A 
leucine residue is found at position 47 in all growth factors that bind the EGF-receptor, with the 
exception of amphiregulin. The cysteine and glycine residues and Tyr37 probably fulfill a structural 
role, while the other conserved residues lie close together in the molecule (see also above) as part of 
a hydrophobic pocket, leading to the suggestion by one group that residues Tyr13 (Phe15), Leu15 
(Phe17), His16 (His18), Arg41 (Arg42), Gln43 (Glu44) and Leu47 (Leu48) of hEGF (hTGF-a) form the 
receptor binding site (70), while other groups indicate either Tyr13, Tyr22, Ile23, Leu26, Asn32, Arg41 
and Leu47 (71,72) as the receptor binding site of hEGF, or Phe15, Phe17, ТугЗ (possibly), Arg42 
and Leu4B as the binding site of hTGF-a (73) 
The structural importance of all six cysteine residues has been amply verified by the use of 
reducing agents and site-directed mutagenesis (74,75), while also Gly to Val mutations at position 19 
and 40 of TGF-a result in loss of binding to the receptor due to structural alterations of the growth 
factor protein (73). Substitution of the five histidine residues of TGFa (His4,12,18,35 and 45) by lysine 
reduces the receptor affinity slightly (His35) to about 13-fold in the case of His45 (74,76). 
Tyr13 from the Α-loop of hEGF is in contact with Arg41 as well as with residues of the major 
β-sheet, and may form a hydrogen bond with Tyr29. Mutation of Tyr13 affects therefore residues that 
play a dominant role in building the structural scaffold of EGF (77). Substitution of this residue with 
leucine (Y13L) has, however, little effect on receptor affinity (77) The Y13R mutation on the other 
hand markedly reduces receptor affinity Comparison of the structural changes induced by these 
mutations using circular dichroic (CD) spectroscopy, shows that the structure of the latter mutant 
deviates less from native hEGF than the former, suggesting that structural changes do not account for 
the loss of binding of the Y13R mutant and that a hydrophobic residue is essential at this position 
(78,79). The double mutants Y13H/I23T and Y13H/L47A showed a reduction of binding affinity 
approximately equal to the product of the effects of the separate mutations, from which it was 
concluded that the mutated residues have a direct effect on receptor binding (71). In accordance with 
these results, it was found that mutation of the homologous residue Phe15 to Ala in TGF-a resulted in 
а 71-fold reduction in binding efficiency (74). Replacement of Leu15 of hEGF by Ala decreased the 
biological activity by a factor 104 (79), while the conservative mutation F17Y at the homologous 
position in TGF-a reduced the receptor affinity approximately 12-fold (73), but in these cases the 
structure of the mutants has not been tested. 
The contribution of residues from the ß-sheet formed by the B-loop to receptor binding is disputed 
Mutation of Vali 9, Met21, Glu24, Ala25, Asp27 and Lys28 of hEGF resulted in normal to slightly 
reduced binding affinity (80,81), while mutation of Tyr22, Ile23, Leu26, Tyr29 and АІаЗО reduced 
affinity more strongly (72,80-83) The loss of activity of mutants Tyr22, Ile23 (see also below), Tyr29 
and Leu26 may however be at least partly due to structural alterations (78,80). Pairwise deletion of 
corresponding residues from either side of the B-loop (Tyr22/Tyr29 and Ile23/Lys28 or Ile23/Lys28 
and Glu24/Asp27) seem to indicate that the tyrosine residues are essential for biological activity, while 
Ile23, Glu24, Asp26 and Lys27 are dispensable (84). Combination of Y22H or L26G mutations with 
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the L47A mutation resulted, however, in a cumulative effect on the relative receptor binding affinity, 
which could indicate separate interactions with the receptor (71). 
Residue Ile23 from the B-loop of hEGF has been examined more closely, and the results from 
substitutions with several other residues (71,82,85) or unnatural amino acid residues (86) and double-
site mutations with T13H, L26A or L47A (71) all indicated that Ile23 is directly involved in receptor 
binding by a hydrophobic interaction with the receptor. Feild et al. (73) conclude on the other hand on 
the basis of L24N, E27A, K29Q and K29A mutations in TGF-a that residues in the ß-sheet are not 
critical in receptor binding 
Substitutions of the "hinge" residue Asn32 led to the conclusion that a hydrogen bonding side chain 
at this position is essential for optimal interaction with the EGF-receptor (72,83), although its role 
might also be the stabilization of the receptor binding epitope, rather than a direct interaction with the 
receptor (72). Introduction of a valine residue, found in TGF-a at this position, reduced the binding 
affinity of hEGF by almost 50% (83) Introduction of a proline at this position in EGF as well as in 
TGF-a severely decreased receptor binding affinity, caused by a disruption of the native protein 
structure (72,73) 
The C-terminal domain shows the highest level of conservation among the EGF-hke proteins and 
therefore the function of several residues has been studied. In all EGF-hke proteins an aromatic 
residue is found at position 37 (Tyr37 in hEGF, Tyr38 in TGF-a). They seem, however, to play 
different roles in these molecules. An aromatic side-chain is found to be not essential in hEGF 
(87,88), although this has been disputed by an other group (79), while it Is found to be essential in 
TGF-a receptor binding affinity (73-75), where it may also play a structural role (73) A functional role 
as well as an important structural role in the binding to the EGF-receptor for residue Arg41 (Arg42) is 
generally recognized, while conservative as well as non-conservative substitutions drastically reduce 
receptor binding affinity in EGF (77,79,87,89,90) and TGF-a (73-76). The guanidmium group is 
probably involved in ligand-receptor association (89) It may also be noted that the arginine residue is 
strictly conserved among the proteins binding to the EGF-receptor, while other residues are 
sometimes found at this position in the other EGF-hke proteins (fig 1 1). The role of the other charged 
residues in the carboxy-terminal domain of hEGF was evaluated in one study The electrostatic 
properties of Glu40, Gln43, Arg45 and Lys48 do not seem to play a role in receptor interaction, while 
a negative charge seems to be preferred at position Asp46 (90). In TGF-a the role of Asp47 has not 
been clearly established (74,91) 
Leucine 47 (Leu48) has been studied thoroughly Replacement of this residue senously affects 
binding affinity to the receptor, without disturbing the tertiary structure of the protein in mEGF, hEGF, 
and TGF-a (71-73,74,77,81,82,91-94) Recent reports have stressed the importance of the variant 
residues of the C-termmal tail in receptor binding Residues Trp49 and Trp50 of hEGF may form a 
hydrophobic pocket with residues Val35, Gly36 and Tyr37 (48,95) and the five C-termmal residues 
may be involved in the binding of Leu47 to the putative hydrophobic pocket of the EGF-receptor 
(95-97) The C-termmal tail of TGF-a, which is shorter than that of EGF and lacking tryptophan 
residues, undergoes a severe restnction in its mobility upon binding to the EGF-receptor, while the 
N-terminus retains its mobility, which underlines the importance of the carboxy-termmus in receptor 
binding (54) Deletion of the C-termmal dipeptide of TGF-a resulted in seriously diminished binding 
affinity and activity in some assays (98) 
None of these mutations have been able to make a distinction, however, between residues involved 
in biological activity and residues involved in receptor binding It will be difficult to judge which amino 
acids are directly involved in receptor binding and/or activation, as long as no X-ray diffraction data 
are available of the ligand/receptor complex. 
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THE EGF-RECEPTOR 
The 170 kDa EGF-receptor, which mediates 
the biological effects of EGF and TGF-a, is а 
single chain transmembrane glycoprotein (fig. 
1.3). The molecule can be divided into three 
domains: a 621 amino acid extracellular 
domain which contains the ligand binding site, 
a 23 amino acid hydrophobic transmembrane 
domain and a 542 amino acid intracellular 
domain, containing the tyrosine kinase activity 
and the major sites of autophosphorylation 
(99,100). Binding of ligand induces a change in 
the conformation of the extracellular domain 
and oligomerization with other EGF-receptors 
or other members of the EGF-receptor family 
(100-102). The tyrosine kinase becomes 
activated and phosphorylates tyrosine residues 
in the C-terminal tail (Tyr992, 1068, 1148, 1173 
and 1186) by an intra- and/or intermolecular 
mechanism (100-102). This is believed to 
release a constraint of the tyrosine kinase 
activity, which leads to phoshorylation of a 
variety of cytoplasmic substrates and proteins 
containing src-homology (SH2) domains 
including phospholipase C-γ (PLC-γ), PI-3-
kinase and SHC, that form a complex with the 
receptor by binding its tyrosine phosphorylated 
residues (100,102). These proteins initiate a 
cascade of intracellular signals, resulting in the 
activation or suppression of transcription of 
specific genes in the nucleus and the triggering of a cellular response (100,102). 
For a more detailed description, the reader is referred to recent reviews of the signal transduction 
pathways of tyrosine kinase receptors (4,100,102-106). The signal is attenuated by the ligand induced 
internalization and degradation of the ligand-receptor complex, as well as by other mechanisms (107). 
зш< 
к< 
Domains 
<1H«P-V-
Residues 
Figure 1.3. Structural features of the human EGF-receptor. The 
cross-hatched area indicates the transmembrane domain, filled 
dots represent cysteine residues and tree-like stuctures indicate 
potential sites of N-linked glycosylation. The stippled area indicates 
the tyrosine kinase domain, P~Y represents a phosphotyrosine 
residue, P~S and P~T phosphoserine and phosphothreonine 
residues respectively. Lysine 721 is involved in ATP-binding. The 
figure is taken from reference 4. 
LIGAND BINDING 
EGF and TGF-a bind the mammalian EGF-receptor with a comparable apparent binding affinity. 
NIH-3T3 cells transfected with the human EGF-receptor (HER cells) bind EGF with two affinities, a 
high affinity (K^ of 0.5 nM) and a low affinity binding site («¡, of 15 nM), while TGF-a is bound with а 
single intermediairy affinity (Kd of 1.5 nM) by these cells (108), although two affinities have been 
reported by others (109). The nature of the two affinity classes is unknown. According to some 
authors, the high-affinity class is formed by oligomeric receptors (110-112), but the matter is still 
unresolved. In A431 cells, the high and low affinity sites can be selectively recognized and blocked by 
monoclonal antibodies, and using these antibodies it has been shown that in this cell type only the 
high affinity binding site is involved in signal transduction (113,114). 
The ligand binding domain of the EGF-receptor has been determined using chimeras between the 
human and chicken EGF-receptor, which show a 100-fold difference in affinity for EGF (115). The 
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MER 322 Τ Y A К ~~K R E D W 
CER 323 Gì DS К N VS L A К L KK VFR S D A Y Y 
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MER 4 1й G R PN MN A KD VNH NP S О 
rZR Ί17 Ν Κ ς) ΙΑ ΜΚ D Μ RS A OS О NK D Τ DRH DP DV G FH F FF О 
Figure 1 4 Amino acid sequence comparison of the region of the human, mouse and chicken 
EGF-receptor (HER, MER and CER respectively) extracellular domain, encompassing the ligand-bindmg 
domain (115) Identical residues are indicated by dots Residues 322-467 form region III of the human 
EGF-receptor, while residues 468-508 form part of the cysteine-nch domain IV The binding epitope 
recognized by the monoclonal antibody blocking hgand binding according to Wu (ref 117) is underlined 
Data are taken from reference 116 
domain is located in domain III, between residues 324-50B (116; see figs. 1.3 and 1.4), between the 
two cysteine rich regions of the extracellular domain. The binding epitope (residues 351-364) of an 
EGF competitive monoclonal antibody was also localized within this domain (116, 117; see fig. 1.4). 
Mutational analysis of this antibody binding epitope indicated that this may not be the hgand binding 
site itself, but lies probably close to it (118). 
EGF and TGF-a may bind to a slightly different domain of the EGF-receptor or stabilize different 
conformations, for a monoclonal antibody has been charactenzed that is able to block TGF-a, but not 
EGF binding to the receptor (119). To our knowledge the binding epitope of this antibody has not 
been reported. Residues carboxy-terminal of the binding domain may also influence binding and 
signal transduction. A variant EGF-receptor (R497K) has been isolated from CHO-cells, which binds 
EGF with high and low, but TGF-a with only low affinity, in contrast to the wild type receptor that 
binds TGF-a also with two affinities, and this variant receptor induces a reduced ligand-induced 
growth response despite normal tyrosine kinase activity (109) HER cells transfected with this receptor 
were growth inhibited by high concentrations of TGF-a, but not EGF (109) 
PROCESSING OF THE LIGAND-RECEPTOR COMPLEX 
EGF binding induces a rapid increase in receptor internalization and a 8-10 fold decrease in the 
half-life of the receptor (120). Empty receptors are internalized at a rate of 2-3% per minute, and are 
recycled rapidly to the cell surface (t1/2 approximately 5 mm), whereas occupied receptors are 
internalized at a rate of 0.24 mm ', but recycle at a much slower rate (t1/2 between 10-23 mm) due to 
trafficking to endosomal compartments and partial sorting to the lysosomes (120,121) Internalization 
and recycling of the unoccupied receptors appears to occur independent of cytoplasmic receptor 
sequences or signals, while the rapid internalization induced by occupation of the receptor, requires 
tyrosine kinase activity and multiple endocytic codes in the carboxy-terminal domain of the receptor, 
distal to the kinase domain (121,122) Internalized ligand-receptor complexes move through 
intracellular compartments of decreasing pH (early endosomes, pH 6 0-6 5 and late endosomes or 
multivesicular bodies, pH 5 5-6 0) to the lysosomes (pH 4 5-5 5), where they are both degraded (120). 
Sorting seems to take place in the multivesicular bodies and part of the receptors are routed back to 
the plasmamembrane, escaping degradation (120,121,123) EGF does not seem to dissociate from 
the receptor until degradation and activates the tyrosine kinase during its route to the lysosome (120). 
TGF-a on the other hand, is most likely released from the receptor shortly after internalization which 
results in a high rate of recycling of both receptor and hgand (124, see chapter 7) 
The role of tyrosine kinase activity in internalization and sorting is disputed. Some authors claim 
that kinase activity is essential for hgand induced internalization (120-122,125), while others propose 
that it regulates receptor trafficking at the recycling step (100,123,126) Apart from cytoplasmic 
receptor sequences, the extracellular domain may contain trafficking information, as was found in the 
case of the mannose 6-phosphate receptor (127) Internalization and degradation induced by hgand 
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binding results in a net loss of cellular receptors This mechanism of signal reduction is termed down-
regulation (107) 
OUTLINE OF THIS THESIS 
Overexpression of the EGF-receptor and co-expression of TGF-oc has been shown in many tumors 
and tumor cell-lines (128-132), while increased expression of TGF-oc has also been found in psoriatic 
epidermis (133) In these cells, activation of the receptor probably takes place at the cell surface and 
therefore the stimulation seems to occur by an extracellular autocrine pathway (130) The involvement 
of an autocrine loop in tumongenesis is supported by the finding that antibodies against either TGF-a 
or the EGF receptor, capable of blocking the binding of ligand to the receptor, are able to inhibit tumor 
cell growth in several transformed cell types and in nude mice (134-138) This indicates that 
substances that interrupt the autocrine loop could be useful in the treatment of tumors overexpressing 
EGF-receptors Several methods can be used to inhibit the binding of ligand and receptor First of all 
antibodies, as mentioned above, can be used, secondly, soluble receptors and third, ligand analogues 
that bind to but do not activate the receptor, the so-called receptor antagonists 
The use of antibodies against TGF-a has the advantage over other methods, that the action of 
EGF and other hgands for the EGF-receptor is not affected The action of anti-receptor antibodies 
may, on the other hand, be easier to concentrate on the desired place Disadvantage of the use of 
antibodies is, that foreign antibodies will be readily cleared from the blood, while humanized 
antibodies against the receptor may block the receptors on all EGF-receptor bearing cells Antibodies 
against TGF-a must have a very high affinity and must be present in high concentrations, for cells 
beanng high numbers of EGF-receptors are very sensitive to EGF-hke growth factors The use of 
soluble EGF-receptors is hampered by the fact that they have a much lower affinity for the ligand than 
the membrane bound receptor and are difficult to produce in large amounts 
EGF-receptor antagonists may be chemically synthesized in the traditional way or be designed on 
the basis of known EGF-like proteins and be produced by heterologous expression The design of 
antagonists on the basis of existing hgands requires knowledge of the structure-function relationship of 
these ligands Their affinity for the EGF receptor should be at least as high as that of TGF-a, and 
they will probably be cleared from the blood at the same (high) rate as EGF and TGF-a When 
knowledge has been gained of the ligand-receptor interaction and the requirements for the synthesis 
of an antagonist, variants may be developed that are relatively resistant to degradation and have a 
long half-life in the blood stream Once designed, they are easy to produce in large amounts No such 
substance, however, has sofar been reported for any growth factor which activates tyrosine kinase 
receptors 
The synthesis of a receptor-antagonist based on the known receptor hgands is only possible if the 
receptor-binding and activation domains of the ligand are located in different parts of the molecule In 
the present study we have set up a strategy to localize the functional domains of TGF-a based on the 
use of chimeric molecules The 100-fold higher affinity of TGF-a than EGF for the chicken EGF-
receptor has been used to locate that part of the binding domain of TGF-a, that is responsible for the 
high-affinity binding to the chicken EGF-receptor When the correct high-affinity binding domain is 
inserted into the EGF-sequence, it is expected to support high-affinity binding of the EGF/TGF-a 
chimera to the chicken EGF-receptor As described above, the EGF-family of hgands contains other 
(probably) structurally identical molecules which do not bind the EGF-receptor Chimeras between 
these sequences and EGF or TGF-a can be used to locate the other elements of the binding domain, 
if this EGFHOF-a chimeric protein approach proves fruitful In this way a rough localization of the 
important binding domains can be achieved rapidly, after which the exact residues involved in 
receptor binding can be determined by subsequent site-directed mutagenesis 
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This strategy has important advantages over the site-directed mutagenesis strategies used so far. 
Chimeras, constructed from related proteins with identical structure and known biological activity, most 
likely have a structure and biological activity similar to the parent molecules. An assay system to test 
the chimeras should be available, in which the parent molecules show significant quantitative 
differences in binding- or activity characteristics. These differences can be contributed to residues that 
are not conserved between these molecules, and therefore these residues are unlikely to be 
structurally important. This is in contrast to the site-directed mutagenesis strategy, in which residues 
are changed on basis of their conservation, in the assumption that these might be the functionally 
important. This carries the risk that conserved structurally important residues are mutated, which will 
also result in a loss of activity, due to a disruption of the correct protein structure. Whereas loss of 
function is measured after site-directed mutagenesis, which does not discriminate between changes in 
structural and functional residues, chimeras can be tested for gain of function, which is unlikely to be 
caused by a disruption of the protein structure. Finally, in site-directed mutagenesis studies each 
potentially important residue has to be replaced by several others to gain sufficient information on its 
function, whereas a rough localization can be achieved with a relatively small set of chimeras, after 
which the exact localization can be performed by a residue exchange strategy. 
In this thesis the construction and heterologous expression of chimeras between EGF and TGF-a 
is described. These two ligands are used to test the feasibility of the strategy, while they are 
structurally and functionally best characterized among the EGF-like proteins. A fusion expression 
system in Escherichia coli has been used to produce EGF, TGF-a and their chimeras with a protein A 
affinity-tag, which allows rapid purification from other bacterial proteins. The proteolytic enzyme 
Factor Xa has been used to separate growth factors with their authentic NH2-terminus from the 
protein A moiety, after which biologically active growth factors were largely purified from inactive 
isoforms (Chapter 2). The construction of the EGFATGF-α chimeras and their physicochemical 
properties are described in chapter 3. Chapter 4 describes assays developed and used for the 
quantification of the fusion proteins and the calibration of the amount of chimeric growth factors. The 
determination of the high-affinity binding domain of TGF-a for the chicken EGF-receptor by measuring 
the difference in affinity for the human and chicken EGF-receptors of these chimeras, is described in 
chapter 5. The mitogenic activity of the chimeras was tested on cells expessing chicken as well as 
cells expressing human receptors and was found not to match the binding affinity in all cases (chapter 
6). Chapter 7 describes differences in pH-sensitivity of receptor binding affinity of the various 
chimeras. These appear to be caused by the presence of specific histidine residues in the TGF-a 
sequence and to affect recycling and degradation of the receptor after binding of the ligands. In the 
following chapter a new method is presented for the determination of receptor-ligand binding con­
stants. They are calculated as a function of the added concentration which allows analysis of binding 
curves, obtained using tracers labeled using non-radioactive methods such as in ELISAs (chapter 8). 
The calculation of binding-constants from non-homologous displacement curves is detailed in 
chapter 9. 
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CHAPTER 2 
EXPRESSION AND PURIFICATION OF EGF AND TGF-a 
SUMMARY 
Synthetic genes coding for the mature epidermal growth factor (EGF) and transforming growth factor-α 
(TGF-a) sequences were N-terminally fused to sequences coding for the target recognition site of the 
proteolytic enzymes Factor Xa and Genenase I. The gene constructs, introduced into a protein A fusion 
expression vector containing the heat-inducible APR promoter and the protein A secretion signal, were 
expressed in the degP protease deficient E coli KS474 strain. The fusion proteins have been isolated 
from the bacterial penplasmic space, purified by IgG-Sepharose affinity chromatography and digested by 
the specific proteases, after which the affinity tag has been removed by a second IgG-Sepharose column 
step Biologically inactive multimers of the growth factors, formed by interchain disulfide bridging, have 
been separated from monomers by gel filtration chromatography after which the correctly folded 
monomers have been largely purified from incorrectly folded monomers by RP-HPLC This versatile 
expression system has produced highly pure EGF and TGF-a, and will be used to produce EGF/TGF-a 
chimeric proteins 
INTRODUCTION 
Epidermal growth factor (EGF) and transforming growth factor-α (TGF-a) are small single chain 
polypeptides stimulating the proliferation of various cell types, both in vivo and in vitro (1 -3). Their pnmary 
structure is characterized by the presence of six almost identically spaced cysteine residues Correct 
disulfide bridge formation between these cysteine residues is essential for receptor binding and biological 
activity (4-5) Despite a limited overall homology of about 40%, their three-dimensional structure is found 
to be almost identical (6-9) hEGF and hTGF-a exert their biological effects through binding to the human 
EGF receptor for which they show comparable affinity (3) Tissues contain minute amounts of EGF and 
TGF-a, but as EGF responsive cells react to exogenously added growth factor in the femtomolar range, 
the amounts secreted are most likely physiologically relevant (3) For structural studies hEGF and hTGF α 
have to be produced by chemical synthesis or heterologous expression, since the amounts that can be 
purified from natural sources are insufficient These methods are indispensable if mutated or chimeric 
growth factors are to be used in experiments To obtain large amounts of growth factor several expression 
systems have been developed, generally employing Escherichia coli (E coli) or Saccharomyces 
cerevisiae (S cerevisiae) as a host cell and using cloned or synthetic growth factor genes 
For the expression of EGF and TGF-a in E coli several strategies have been followed Expression in 
the cytoplasm either as a soluble protein or as retractile bodies generally results in a large amount of 
growth factor produced, but requires chemical refolding of the protein to obtain the correct disulfide bonds 
(10-13) Secretion to the penplasmic space has the advantage that formation of disulfide bonds occurs, 
probably due to the presence of the bacterial penplasmic protein disulfide isomerase (DsbA) and the 
proper redox conditions (14), but correctly folded growth factors have to be purified from forms containing 
mismatched disulfide bridges (15-18) Most studies use inducible promoters such as the alkaline 
phosphatase (rjhoA), tryptophan operon (trp_), lactose operan (jaç) and hybrid trp/lac (tac) promoters of 
E coli or the leftward promoter (XPL) of phage lambda To prevent degradation of the expressed protein 
two strategies have been followed: N-terminal fusion to parts of other proteins like trpE (10-12) and 
ß-qalactosidase (13,19) to stabilize the growth factor in the cytoplasm and the use of various signal 
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sequences (phoA, ompA, bla) to induce secretion (15-18,21,22). The signal sequences are processed 
correctly by E.coli, while removal of the other N-terminal fusions is generally performed by chemical rather 
than by enzymatical methods. A C-terminal poly-(arg) extension has been used as an affinity handle for 
purification by cation exchange chromatography (20). The amount of biologically active growth factor 
recovered after refolding and purification is about 5 mg per liter culture medium if the protein is expressed 
intracellularly (12). In most secretion expression systems only 100-450 μg of active growth factor per liter 
culture medium can be recovered from the periplasmic space (16-18,21), but there are two notable 
exceptions. Oka et al. (15,22) have reported the recovery of mg amounts of active EGF from the peri­
plasmic space per liter of culture medium under conditions where the competition for secretion with other 
proteins has been reduced. This can be achieved when the phoA promoter and signal sequence are used 
in an E. coli mutant lacking the chromosomal phoA gene and when the phoA promoter and ß-lactamase 
(bla) signal sequence are used in a plasmid carrying the kanamycin resistance marker instead of the bla 
resistance marker. Reduction of the culture temperature from 37 °C to 30 °C resulted in a two-fold 
increase in the amount of secreted EGF (15). Secretion of 2 mg of active EGF per liter, as quantified by 
HPLC, into the culture medium has been reached by using the signal sequence of E. coli enterotoxin 
ST-II in combination with a trp_ promoter and the tetracyclin resistance marker (23). 
The pathways of protein transport and secretion in yeast have much in common with those in other 
eukaryotic organisms (24), in which the enzyme protein disulfide isomerase (PDI; EC 5.3.4.1) catalyzes 
the accurate formation of disulfide bonds during protein biosynthesis (25). The proportion of correctly 
folded growth factor into the culture medium is higher than in E. coli and may get near 100%, depending 
on the protein produced. The correct formation of disulfide bridges seems to be a limiting factor in the 
production of proteins. The introduction of an extra copy of PDI can result in a ten-fold increase in the 
production of heterologous proteins containing disulfide bridges (26). Secretion of EGF using the promoter 
of the mating factor-α (MFot; 27-29), phosphoglycerate kinase (PGK: 30) or PGK and GAL 1-10 (31) and 
the prepro-leader sequence of the mating factor o (ppα F) has been performed successfully, resulting in 
2-13 mg of active EGF per liter of culture medium. For unknown reasons expression of TGF-oc in the MFot 
expression system resulted in a production of only 500 μg of active growth factor per liter of culture 
medium (32). We have used the MFa system initially for the production of TGF-oc and EGF and our 
results confirmed these values. Purification of TGF-ot from the medium was very tedious, however, and 
resulted in a low recovery of pure growth factor protein. Yeast expression vectors are less advanced than 
E. coli expression vectors and do not generally contain affinity handles to facilitate purification. 
Introduction of the IgG-binding domains of the protein A gene of Staphylococcus aureus N-terminal of the 
growth factor genes seriously reduced the transformation efficiency of the yeast strain used and we have 
not been able to produce protein A fusion proteins in this way. 
Recently, advanced expression vectors for E. coli have been described that combine secretion, protein 
fusion and purification of the fusion protein by affinity chromatography (33). The desired protein and the 
affinity tag are later separated by proteolytic cleavage or chemical methods. Affinity purification vectors 
based on staphylococcal protein A have been claimed to produce IGF-I with the same specific activity 
as native IGF-I using only IgG-Sepharose columns and hydroxylamine cleavage for purification (34,35). 
IGF-I is somewhat larger than EGF-like growth factors but also contains three disulfide bonds that have 
to be formed correctly for biological activity. The conditions used for purification perfectly match the 
requirements for EGF and TGF-ot. We decided to use the protein A fusion expression system for the 
production of human EGF and TGF-oc. Instead of using the basically constitutive protein A promoter of 
which it is known that it can only be induced to a slightly higher production level by heat-shock (34,35), 
we have used the heat-inducible rightward promoter (APQ) promoter of phage λ in combination with 
enzymatical cleavage of the fusion protein rather than cleavage by chemical means. 
In this paper we describe the synthesis of the hTGFoc gene from only six synthetic oligodeoxyribo-
nucleotides. Nucleotide sequences coding for the Factor Xa (FXa)- and Genenase I target sequences were 
synthesized and joined to the exact 5'-end of the hTGF-oc and a synthetic hEGF gene. These target 
2Θ 
sequence/growth factor gene combinations were introduced into the pHEMA 153 expression vector, 
containing part of the staphylococcal protein A coding sequence under the heat-inducible λΡ„ promoter, 
and were subsequently expressed in E. coli The fusion proteins generated were directed to the pen-
plasmic space by the protein A signal sequence After purification by IgG-Sepharose affinity chromato­
graphy the fusion proteins were cleaved enzymatically and the growth factor moiety was recovered by 
a second affinity chromatographic run. Gel permeation chromatography and reverse-phase high 
performance liquid chromatography (RP-HPLC) were used to further purify the active growth factors from 
multimers and incorrectly folded isoforms. 
EXPERIMENTAL PROCEDURES 
Construction and cloning of the hTGF-α gene 
A synthetic gene coding for mature hTGFa was designed, based on a human TGF-oc cDNA (12) The 
six constituent oligodeoxynbonucleotides, four 65-mers and two 37-mers, were synthesized using 
phosphoro-amidites (36) After preparative purification by electrophoresis on 20% Polyacrylamide gels 
(PAGE) they were dissolved in 10 mM Tns-HCI, 1 mM EDTA (pH В 0) at a concentration of 10 pmol/μΙ 
The four 65-mers (100 pmol each) were phosphorylated by addition of 2 units of T4 polynucleotide kinase 
in 25 μΙ of kinase buffer (100 μΜ spermidine, 20 mM drthiothreitol (DTT), 10 mM MgCI2, 50 mM Tns-HCI, 
pH 9 0) to which 5 pmol of [γ - 32P] ATP and 250 pmol of ATP were added, followed by incubation for 
45 minutes at 37 °C After ethanol precipitation, equimolar amounts of the six oligonucleotides were 
dissolved in 30 μΙ of ligase buffer (20 mM DTT, 10 mM MgCI2, 50 mM Tns-HCI, pH 7 6). pooled and 
heated for 2 mm at 90 °C After slowly cooling to room temperature T4 ligase was added together with 
ATP to a final concentration of 250 μΜ in 40 μΙ ligase buffer After 14 h at 14 °C the DNA was recovered 
by ethanol precipitation and the 167 bp Bam Hi/Sal I fragment separated by 6 % non-denatunng PAGE 
and excised from the gel After elution in 1 mM Tris the gene was ethanol precipitated, phosphorylated 
with T4 polynucleotide kinase and ligated in the Bam Hi/Sal I site of a dephosphorylated pBluescnpt SK 
(pBS SK ) vector (Stratagene, La Jolla, USA) 
Cloning of the hEGF gene 
The hEGF gene, synthesized choosing E coli preferred codons (37) and cloned between the Hind III 
and Bam HI site of pUC 18, was obtained from R&D Systems, Abingdon, Oxon, UK) The З'-end Bam HI 
site was changed into a Sal I site by cutting the plasmid with Bam HI, removing the single stranded tails 
with nuclease SI, cutting with Hind III and cloning of the gene in the pBS SK vector between the Hind III 
site and the Sal I site that was filled in with the Klenow fragment of DNA polymerase I 
Synthesis of oligonucleotides encoding the recognition site of proteolytic enzymes 
A 30-mer palindromic oligonucleotide (5'-GATCCATCGAGGGTAGGCCTACCCTCGATG-3') was 
synthesized encoding the tetrapeptide Factor Xa (FXJ recognition sequence (lle-Glu-Gly-Arg) with Bam HI 
ends (38) This oligonucleotide was self-annealed, phosphorylated and ligated into the Bam HI site of 
pBS SK to form the vector pFX2 In a similar way the tetrapeptide recognition sequence for Genenase I 
(Phe-Ala-His-Tyr) was synthesized from a 42-mer palindromic oligonucleotide (5 -GATCCCCAGGTTTC-
GCACATTACGTAATGTGCGAAACCTGGG-3') and introduced into pBS SK to form pGen2 Genenase I 
is an engineered form of subtihsin BPN'containing the mutations C24A H64A E156S G169A Y217L 
(described in ref 39) These recognition sequences were ligated to the 5'-end of the genes as described 
in the Results section 
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Expression and purification 
Both growth factor genes fused to the Factor Xa or Genenase I recognition sequence were excised 
from the cloning vector using a Bam Hi/Sal I digest and cloned into the Bam Hi/Sal I site of the protein A 
fusion expression vector pHEMA 153 (40; a generous gift from Drs. H. Engel and W. Keck, University of 
Groningen, The Netherlands). This vector contains the signal sequence and the IgG-binding domains of 
staphylococcal protein A under the control of the λΡ„ promoter and the temperature-sensitive cl 857 
repressor The constructs were transformed into E.coli KS474 (41), a degP protease deficient strain (a 
generous gift of Drs. К. Strauch and J. Beckwith, Harvard University, Boston USA). The heat-shock 
procedure and purification by IgG-Sepharose were performed essentially as described (42). In short, five 
500 ml cultures were grown at 28 °C to a density of O D ^ = 0 7 in 2YTE (16 g bactotrypton, 10 g yeast 
extract, 8 g NaCI/hter) supplemented with 2 % glucose and 250 mg/ml ampicillin. To each culture, 500 ml 
of medium preheated to 62 °C was added. The cultures were incubated for 15 mm at 40 CC without 
shaking and subsequently for 2 hours at 40 °C in a shaker at 200 rpm. The cultures were then cooled 
on ice and cells were harvested by centnfugation (7 mm, 7000 rpm at 4 °C, Sorvall GS-3 rotor). The cells 
were resuspended in 1 liter of sucrose buffer (0 5 M sucrose, 0.1 M Tris-HCI, pH 8 2) and incubated on 
ice. After 10 mm, 16 mg of lysozyme and 1 liter of icecold water were added and after an incubation for 
5 mm on ice, 36 ml of 1 M MgSO„ was added. After centnfugation (20 mm at 4 °C, 7000 rpm, Sorvall 
GS-3 rotor) the supernatant was cleared by filtration and the fusion protein purified by IgG-Sepharose 
Fast Flow column chromatography (Pharmacia, Sweden). 
Proteolytic digestion of the fusion protein and purification of the growth factor moiety 
The fusion proteins eluted from the IgG-Sepharose column in 0.5 M acetic acid (HAc), pH 3.4, were 
lyophilized, subsequently solubihzed in FX0 buffer (100 mM NaCI, 1 mM CaCI2, 50 mM Tns-HCI, pH 8.0) 
to a concentration of 1.5 mg/ml, and digested by circulation through a FXa-Sepharose column (see below) 
for 12 hours at room temperature. Digestion with Genenase I (a generous gift of Dr. Paul Carter, 
Genentech Ine , San Francisco, USA) was performed by adding 40 μg enzyme per mg of fusion protein 
in Factor Xa buffer and incubating for 4 hours at 37 °C. After proteolytic digestion of the fusion protein, 
the growth factor moiety was purified by a second run on IgG-Sepharose. The flow-through containing 
the growth factor was made 0 1 % tnfluoro-acetic acid (TFA) and passed through a Sep-Рак C18 cartridge 
(Milhpore, Milford, USA) The bound growth factor was eluted in 60 % acetonitnl (MeCN)/0.1 % TFA, 
subsequently lyophilized, and dissolved in 1 M HAc Multimers of growth factors, formed by interchain 
disulfide bridges, were removed by gel permeation chromatography on a column (2.6 χ 85 cm) of BioGel 
P10 (BioRad Laboratories, Richmond, USA) in 1 M HAc at a speed of 12 ml per hour, collecting 3.5 ml 
fractions. Column fractions were assayed for EGF-like activity using an A431 cell growth inhibition assay 
or a biotm-EGF binding competition assay (see chapter 4). Fractions containing biological activity were 
pooled, concentrated using Sep-Рак C18 reverse-phase chromatography, lyophilized and dissolved in 
0 1 % TFA Misfolded monomers were removed by reverse-phase chromatography on a 3.0 χ 21 cm 
ΠΡ-300 Aquapore Octyl column (Brown Lee Laboratories, Santa Clara, USA) using a linear gradient of 
0-40 % (v/v) MeCN in 0.1 % TFA in 200 mm at a flowrate of 1 ml/mm. Biological activity in the column 
fractions was determined as described for the BioGel P10 column. 
Preparation of the FX„-Sepharose column 
Factor X was purified from human plasma by precipitation with BaCI2 as described (38). The enzyme 
was completely separated from other blood proteins by affinity chromatography on a column of an anti-
hFactor X monoclonal antibody (a generous gift of Drs. J.C.M. Meyers, С. van 't Veer, and G. Rijksen, 
Department of Hematology, University Hospital, Utrecht, The Netherlands) coupled to CNBr-activated 
Sepharose (Pharmacia, Sweden). FX was activated on a column with immobilized Rüssels viper venom 
(RVV) as described (38). Coupling of RVV, the anti-hFactor X monoclonal antibody and Factor Xa to 
CNBr-activated Sepharose was performed as prescribed by the manufacturer 
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ValValSerHisPheAsnAspCysProAspSerHisîhrGlnPheCysPheHisGlyThrCysArgPheLeuValGlnGlu 
1 ____ * t , 2 . 
ι t 
gatccgtggtgtcccattttaatgactgcccagattcccacactcagttctgcttccatggaacctgcaggtttttggtgcaggag 
gcaccacagggtaaaattactgacgggtctaagggtgtgagtcaagacgaaggtaccttggacgtccaaaaaccacgtcctc 
t , t 
Ваш HI 
AspLysProAlaCysValCysHísSerGlyTyrValGlyAlaArgCysGluHisAlaAspLeuLeuAla*** 
í " " 1 
gacaagccagcatgtgtctgccattctgggtacgttggtgcacgctgtgagcatgcggacctcctggcctgagatgataag 
ctgttcggtcgtacacagacggtaagacccatgcaaccacgtgcgacactcgtacgcctggaggaccggactctactattcagct 
Figure 2.1. Design of the synthetic human TGF-α gene. The nucleotide sequence and amino acid sequence are shown. The 
numbered lines indicate the single stranded oligonucleotides synthesized. 
SDS-PAGE and Western blot analysis 
Fusion protein samples were run in 12.5 % SDS-PAGE gels according to Laemmli (43). Purified growth 
factors were separated in 16.5 % SDS-PAGE gels according to Schägger and Von Jagow (44). Proteins 
were stained with Coomassie brilliant blue R-250 or transferred to nitrocellulose as described by Towbin 
(45). Protein A was visualized using rabbit-anti-goat antibodies coupled to peroxidase. For the detection 
of hTGF-ot, a monoclonal antibody raised against a synthetic peptide corresponding to residues 33-50 
of hTGF-a was used (a generous gift of Dr. F. van Meel, Organon, Oss, The Netherlands). A polyclonal 
antibody against hEGF was obtained from BTI (Stoughton, USA). Horse radish peroxidase conjugated 
secondary antibodies were obtained from Nordic (Tilburg, The Netherlands). 
RESULTS 
Gene constructs 
Figure 2.1 shows the design of the double stranded synthetic hTGF-a gene based on synthesis from 
six oligodeoxyribonucleotides. It was originally constructed for use in a yeast expression vector and the 
addition of a cleavage site for specific proteases was not taken into consideration at that stage. We have 
chosen to use long oligonucleotides for the construction of the gene, despite their relatively low yield after 
synthesis and more difficult purification. This approach greatly facilitates the construction of the gene, 
allowing its assembly in one reaction. This can only proceed efficiently if an equal amount of each 
oligonucleotide is added. Therefore the equimolarity of the oligonucleotides was checked after synthesis 
and purification by annealing each oligonucleotide to its counterpart(s). 
The autoradiogram (fig. 2.2) shows that the four 65-mer oligonucleotides have been largely purified 
(In. 2, 4, 6 and 8) and recognize their respective counterparts (In. 1, 3, 5 and 7). In these lanes only the 
bands of the double stranded products are seen indicating that indeed equimolar amounts were present 
in the reaction. The 37-mers were not phosphorylated and their presence can therefore only be inferred 
from the behaviour of the complementary oligonucleotides (In. 1 and 9). Lanes 10-14 show a pilot 
experiment in which the correct formation of the gene is checked on an analytical scale. Starting in 
lane 10 with the complementary oligonucleotides 1 and 4 forming the 5'-end of the gene, the following 
lanes show separate reactions in which the subsequent complementary oligonucleotide was added to the 
previous ones. Lane 14 shows the succesfull assembly of the 167 bp Bam Hi/Sal I fragment from all six 
oligonucleotides demonstrating the feasibility of the approach. Therefore the oligonucleotides were 
annealed and ligated on a preparative scale and the gene was further purified and cloned as described 
in the experimental procedures section. 
The hEGF gene was obtained as a 183 bp synthetic Hind Ill/Bam HI fragment, in which codons had 
been changed to incorporate useful restriction sites and to conform to the E. coli codon use (37). The 
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Figure 2.2. Autoradiogram showing the assembly of the 
double stranded hTGF-a gene from six oligonucleotides. Lane 
1-9 show the annealing of each nucleotide to its counterpart(s) 
to test the equimolarity of the oligonucleotides in the final 
react-ion. Ln 1: nr1+4; In 2: nr 4; In 3: nr 4+2; In 4: nr 2; In 5: 
nr 2+5; In 6: nr 5; In 7: nr 5+3; In 8. nr 3; In 9: nr3+6. Lane ΙΟ­
Ι 4 shows an analytical annealing of increasing numbers of 
oligonucleotides to form the hTGF-a gene. Ln 10; nr 1+4; 
In 11: nr 1+4+2; In 12: nr 1+4+2+5; In 13: 1+4+2+5+3 0; In 14: 
the 167 bp hTGF-a gene formed from equimolar amounts of 
the six constituent oligonucleotides. Ln 15: size marker 
pBR 322 χ Dde I. The numbering of the oligonucleotides is 
according to figure 2.1. 
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З'-end Bam HI site was changed to a Sal I site to facilitate further cloning as described in the 
experimental procedures section. 
Most fusion expression vectors include the coding sequence for one or more cleavage recognition sites 
of proteases in their polylinker to allow the separation of the N-terminal affinity handle and the protein of 
interest after expression and purification. Use of the cloning sites downstream of these sequences for the 
insertion of the desired gene will generally result, after cleavage of the fusion protein with the protease, 
in a protein with an unwanted N-terminal extension of a few amino acids. To circumvent this problem and 
to make the system as versatile as possible we have chosen to fuse the coding sequences of the 
cleavage recognition sites of two different proteases to the exact 5'-end of the growth factor genes. This 
will result in the production of proteins with their authentic amino terminus. To this end we have made 
both the hEGF and hTGF-a genes 5'-blunt end by cutting with a restriction enzyme close behind their 
5'-end and repairing the mature sequence with synthetic oligonucleotides. The cloning vectors pFX2 and 
pGENj contain the sequences coding for the cleavage recognition site of the proteases Factor Xa (38) 
and Genenase I (39), a modified form of subtilisin BPN' (C24A: H64A: E156S: G169A: Y217L) 
respectively. The plasmids were linearized with Stu I or Sna Bl respectively, in order to make blunt end 
cuts exactly after the target sequences and cut in the polylinker at the Sal I site. Thereafter the growth 
factor genes were ligated blunt/Sal I into the cloning vectors. 
S I G E R V V S H F N D C P D S H T Q F C F H G T C R F L V 
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gatccatcgagggtaggGTGGTGTCCCATTTTAATGACTGCCCAGATTCCCACACTCAGTTCTGCTTCCATGGAACCTGCAGGTTTTTGGTG 
gtagctcccatccCACCACAGGGTAAAATTACTGACGGGTCTAAGGGTGTGAGTCAAGACGAAGGTACCTTGGACGTCCAAAAACCAC 
FX"~ 16 
Bam HI Hst.· I 
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CAGGAGGACAAGCCAGCATGTGTCTGCCATTCTGGGTACGTTGGTGCACGCTGTGAGCATGCGGACCTCCTGGCCtgagatgataag 
GTCCTCCTGTTCGGTCGTACACAGACGGTAAGACCCATGCAACCACGTGCGACACTCGTACGCCTGGAGGACCGGactctactattcagct 
Sal I 
A 
S P G F A H Y N S D S E C P L S H D G Y C L H D G V C M Y I E A 
Gerr — ^1__~_ ' 
gatccccaggtttcgcacattacAACAGCGACTCTGAATGCCCGCTGAGCCATGATGGCTACTGCCTGCACGACGGTGTATGCATGTATATCGAAGCT 
gggtccaaagcgtgtaatgTTGTCGCTGAGACTTACGGGCGACTCGGTACTACCGATGACGGACGTGCTGCCACATACGTACATATAGCTTCGA 
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CTGGACAAATACGCATGCAACTGCGTAGTTGGTTACATCGGCGAACGTTGCCAGTACCGCGACCTGAAATGGTGGGAGCTCCGTtaataag 
GACCTGTTTATGCGTACGTTGACGCATCAACCAATGTAGCCGCTTGCAACGGTCATGGCGCTGGACTTTACCACCCTCGAGGCAattattcagct 
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Figure 2.3. Synthetic growth factor genes fused to the cleavage recognition sequences of Factor Xa and 
Genenase I. The figure shows the hTGF-a gene fused to the cleavage recognition sequence of Factor Xa (A) 
and the EGF gene fused to the recognition sequence of genenase I (B) The lines indicated with FX and Gen 
denote the oligonucleotides used for the construction of the recognition sequence, the numbered lines denote 
the oligonucleotides used to construct the blunt 5-end termini. The amino acid sequence is given in the single 
letter code, the amino acids forming the cleavage recognition sites are underlined. Only restriction sites 
mentioned in the text are indicated. 
1 2 3 4 5 β 7 8 9 10 11 12 13 14 
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Figure 2.4. Purification of protein A fusion proteins. 
A: Coomassie stained gel showing proteins purified from the 
periplasmic space of E.coli KS474 transformed with 
pHEMA 153 (In 2) and pHEMA/FX/EGF (In 3). Lane 4 shows 
the periplasmic proteins after removal of the Prot A/FX/EGF 
fusion protein by IgG-Sepharose affinity chromatography. Lane 
5 shows the purified ProtA/FX/EGF. Multimeric forms of the 
fusion protein run above 67 kDa, while degradation products 
run at about 30 kDa and lower. Lane 1 shows size markers. 
B: Blot of proteins isolated from E. coli KS474 visualized with 
RAG-PO showing multimeric fusion proteins. Ln 1: protein A 
running at 32 kDa. Several small size protein A degradation 
products are present. Ln 2: ProtA/FX/EGF running at 38 kDa, 
while a mayor degradation product runs at 32 kDa. 
Two examples of the resulting cleavage site/gene fragments as cloned in pBS SK are shown in 
figure 2.3. The coding sequence of hTGF-a fused to the nucleotide sequence coding for the Factor Xa 
cleavage recognition site is shown in fig. 2.3a. The sequence of the 14- and 16-mer oligonucleotides used 
to repair the 5'- end of the gene after digesting the original gene fragment with Mse I are indicated by two 
lines ("14" and "16"). The sequence originating from the oligonucleotide used to make the pFX2 vector, 
ending in the Arg codon forming the Stu I half-site (agg) is indicated by lines ("FX"). The amino acid 
sequence shows the Factor Xa target site (lle-Glu-Gly-Arg) at the correct amino terminus of the TGF-a 
sequence. The hEGF coding sequence fused to the sequence coding for the Genenase I target site is 
shown in figure 2.3b. The lines "7" and "10" indicate the oligonucleotides used to repair the 5'-end of the 
gene after the Hinf I digestion of the Hind Ill/Sal I fragment. The lines indicated by "Gen" mark the 
sequence of the oligonucleotide used to construct the pGen2 vector. The Genenase I target site (Phe-Ala-
His-Tyr) fused to the correct NH2-terminus of hEGF, is preceded by two amino acids (Pro-Gly) introduced 
to improve the accessability of the target sequence to the protease. 
The advantage of this method over the adaptation of the 5'-end of the gene to a specific cleavage 
recognition sequence in a polylinker, is that the fragments can be introduced using the Bam HI and Sal I 
sites in virtually all polylinkers, while the fragments made for use with different proteases can be readily 
exchanged and the fragments can be used in a fusion expression vector that does not contain the desired 
recognition site. 
Expression and purification of the fusion proteins 
Both the hEGF and hTGF-a genes fused to the proteolytic target sequences were excised from the 
cloning vectors by a Bam Hi/Sal I digestion and introduced into the pHEMA 153 expression vector (40). 
This vector contains the promoter APD, the heat labile СІ857 repressor gene and the signal sequence and 
five IgG-binding domains of the Staphylococcus aureus protein A gene. Heat shock induction directs 
synthesis of the protein A fusion protein and subsequent secretion into the periplasmic space. Figure 2.4a 
shows the proteins isolated from the periplasmic space of E.coli KS474 transformed with pHEMA 153 
(In. 2) or pHEMA/FX/TGF-α (In. 3). Protein A from the vector is expressed to high levels, giving rise to 
an expected 32 kDa protein product as can be seen in lane 2. The ргоіА/РХЯСР-ос fusion protein is 
expected to run at 38 kDa but at this size no conspicuous protein band can be seen. Affinity purification 
by IgG-Sepharose chromatography (In 4,5) shows that the fusion protein runs at the expected size, while 
fainter bands running at higher molecular sizes can be seen also (In. 5). The expression level of the 
fusion protein in this experiment is seemingly much lower than that of protein A. The bands at 76 kDa 
and higher are most likely multimers of fusion proteins formed by interchain disulfide bridges between the 
growth factor moieties. An immunoblot (fig. 2.4b) shows an extreme example of the multimerization of the 
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Figure 2.5. ProtA/FX/TGF-α purified by IgG-Sepharose column 
chromatography and cleaved by Factor X, and Genenase I. 
ProtA/FX/TGF-α, mock digested and digested with Factor X. 
or Genenase I was run on SDS-PAGE and visualized using 
Coomassie Blue stain. The gel was overloaded to show both 
the protein A and growth factor moieties. Ln 3: 
ProtA/FWGF-a, mock digestion; In 4: digestion with 
Factor Xa; Ln 5: digestion with Genenase I. Lane 1 and 2 show 
size markers. 
• 10 К » Ό BO M 70 К «0 IDO 110 
Frecttofi number 
Figure 2.6. Purification of TGF-o by BioGel P10 gel filtration 
chromatography. TGF-a separated from the protein A moiety by 
digestion with Factor X. and a second IgG-Sepharose affinity 
purification was concentrated using Sep-Рак chromatography 
and a speed-vac concentrator. After dialysis against 1 M HAc, 
two milliliter was loaded on the BioGel P10 column. The column 
was run at 12 ml/h and 3.5 ml fractions were collected. Samples 
(2 μΙ) of alternate fractions were tested in the A431 growth 
inhibition assay for EGF-like activity The fractions collected for 
further purification are underlined. Molecular weight standards 
(A: RNase 13.7 kDa, B: Insulin 6 kDa) are indicated by arrows. 
fusion proteins, with the monomeric and dimeric bands at 38 and 76 kDa and multiple bands larger than 
100 kDa. These forms of the fusion protein explain at least partly the difference in the intensity of 
theprotein A and fusion proteins bands as observed in fig. 2.4a. The level of degradation and 
multimerization varies considerably between individual experiments. The level of proteolytic breakdown 
observed in E. coli HB101 and DH-1 was far more extensive than observed in KS474 (not shown). The 
extent of proteolytic breakdown of protein A produced under the constitutive protein A promoter at 37 °C 
did not differ significantly from degradation observed after heat-shock (not shown). Presently there is no 
evidence that the degradation is solely caused by the induction of proteolytic enzymes as a consequence 
of the heat-shock response. Although only the fusion protein secreted into the periplasmic space was 
purified, almost the same amount was found to be secreted into the medium. A similar distribution of 
fusion protein between periplasm and medium was found in the "leaky" E. coli KS476 (KS474 lpp-5508) 
strain (not shown). 
Fusion proteins were purified by IgG-Sepharose affinity chromatography from other periplasmic proteins 
and cleaved by Factor Xa or Genenase I. Both enzymes are highly specific restriction proteases 
recognizing a tetrapeptide target sequence, while being rather insensitive to the sequence following the 
cleavage site. Figure 2.5 shows the digestion of protA/FX/TGF-α with Factor Xa and Genenase I. The gel 
has been heavily overloaded to allow detection the growth factor bands, separated from protein A by the 
protease digestion. The undigested fusion protein running at about 38 kDa has already been partly 
degraded as can be concluded from the bands running at about 32 kDa and shorter (In. 3). No protein 
band is observed at about 6 kDa however, indicating that the degradation has occurred before the affinity 
purification step and not during the mock incubation with protease. After digestion of the fusion protein 
with Factor Xa, the expected bands appear at 32 and 6 kDa (In. 4). Digestion of protA/FXTTGF-a with 
Genenase I results quite unexpectedly in the formation of two bands running at about 30 and 8 kDa, 
indicating that the protease digests fusion proteins which do not contain the Genenase I target site (In. 5). 
This experiment and a subsequent blotting experiment (not shown) indicated that the cleavage site is only 
a few kilo-Daltons from the Factors Xa recognition sequence within protein A. No sequence considered 
favourable for cleavage by Genenase I is known to be present in this region. No attempt was made to 
further establish the exact cleavage site. Apparently, Factor Xa cleaves the fusion protein correctly in a 
growth factor and a protein A moiety and therefore it was decided to use Factor Xa for further 
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experiments. The enzyme was coupled to Sepharose to enable its repeated use and to avoid the con­
tamination of the growth factors with the enzyme. Genenase I may be used in those cases when 
Factor Xa cleaves the desired protein or in other fusion constructs that are cleaved by the enzyme in a 
non-specific manner. 
Purification of EGF and TGF-ct 
After digestion by Factor Xa column 
chromatography and a second IgG affinity column 
purification, the growth factor monomers were 
separated from biologically inactive multimene 
forms by BioGel P10 gel permeation chromato­
graphy. Figure 2.6 shows that the biologically 
active peak in the BioGel P10 fraction during 
purification of hTGF-ot as determined by the A431 
cell growth inhibition assay is found between 
fractions 69 and 76. hEGF elutes from this column 
between fractions 104 and 118 (not shown). This 
is in agreement with a report of Stromberg and 
Hudgins (46), that hEGF elutes later from a BioGel 
P10 column run under acidic conditions than 
expected on the basis of its molecular size, while 
hTGF-ct elutes at an apparent molecular size of 
6.8 kDa. The absence of significant biological 
activity in the fractions containing the proteins of 
higher molecular weight confirms that the high 
molecular weight multimer forms are biologically 
inactive. 
The fractions containing biologically active 
growth factor were pooled and run on RP-HPLC to 
remove incorrectly folded monomers, a procedure 
that has been used previously to produce growth 
factors of high specific activity from heterogeneous 
mixtures that contain numerous disulfide bonding 
arrangements (10). Figure 2.7a shows the 
RP-HPLC protein elution pattern and fig. 2.7b the 
concomitant peak of biological activity as 
determined by the A431 cell growth inhibition assay for the purification of hTGF-ot. The separation of the 
peak containing EGF-like activity from several other peaks shows that the active growth factor protein is 
at least largely purified from other disulfide bonding arrangements. The small activity peaks observed 
between fraction 130 and 180 are most likely due to variations in the A431 growth inhibition experiment 
and not to active protein. Active TGF-a elutes between fraction 84-98, whereas EGF elutes between 
fraction 120-130 (not shown). It has been observed previously that TGF-a elutes prior to hEGF from 
RP-HPLC columns because of its more hydrophilic character (46,47). Also in this experiment there is no 
indication that growth factors containing mismatched disulfide bonds show significant biological activity. 
Figure 2.8 shows that hTGF-ct runs at the expected molecular size of about 6 kDa on PAGE and is 
pure to a high extent as judged from this Coomassie staining. This gel was run under reducing conditions 
and may therefore not give information on the percentage of misfolded growth factor in the sample. We 
have not determined the specific activity of the growth factors produced, based on biological activity per 
weight, but chosen to express their amount in nanogram activity units equivalent to purified mEGF 
В 
Figure 2.7. Purification of TGF-a by C„ RP-HPLC chromato­
graphy. Fractions 67 through 75 from BioGel 10 were pooled, 
concentrated using Sep-Рак chromatography, lyophilized and 
dissolved in 0.1 % TFA. The sample was separated using a 
linear gradient of 0-40 % acetonitril in 0.1 % TFA at a flow rate 
of 1 ml/min on a C8 RP-HPLC column. (A) Absorbance at 
229 nm. (B) Biological activity of samples (2 μΙ) taken from 
alternate fractions, assayed in the A431 growth inhibition 
assay. 
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instead. We have found that the amount of activity purified varied between 1.3 to 17.3 nmol per liter 
culture medium. Further details about the quantification of the growth factors produced are given in 
chapter 4. 
DISCUSSION 
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The pHEMA 153 protein A fusion expression 
system in combination with cleavage by Factor Xa 
offers a general and straight-forward method for the 
production of EGF-like growth factors. The protein A 
fusion protein is secreted into the periplasmic space 
which allows the formation of disulfide bridges. 
Additional advantages are, that only 4% of the 
bacterial proteins are secreted into the periplasmic 
space (48) which facilitates purification, while many t * 
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 Figure 2.8. Purified hTGF-a (18 μ$) separated on SDS-PAGE 
secreted into the periplasm than within the run under reducing conditions and visualized using Coomassie 
cytoplasm (49). Use of the degP protease deficient B l u e s t a i n ( l a n e C ) L a n e A a n d B s h o w s i z e m a r k e r s 
E. coli strain KS474 was, however, necessary to keep proteolytic degradation of protein A within 
acceptable limits. The protein A moiety of the fusion protein allows rapid purification on IgG-Sepharose 
columns, independent of the properties of the growth factor moiety, combined with fast and sensitive 
detection of the fusion protein on nitrocellulose filters. The fusion of the target sequence of a highly 
specific protease to the expressed genes, allows cleavage of the correct primary growth factor sequence 
from the protein A moiety. 
In the present experiments only the protein A fusion protein present in the periplasm was isolated and 
purified. We detected, however, a similar amount as secreted into the medium. Abrahmsén et al. (34) 
observed that secretion of protein A into the medium occurs as a result of the heat-shock (42 °C) treat-
ment. Raising the heat-shock temperature from 40 °C to 42 °C resulted in a higher percentage of fusion 
protein that was secreted into the medium. Use of the "leaky" KS476 mutant did not raise the level of 
fusion protein in the medium significantly, as compared to KS474 at a heat-shock temperature of 40 °C, 
but at 42 °C the shift of fusion protein towards the medium was more pronounced (not shown). Extensive 
proteolytic breakdown of protein A fusion proteins produced in E. coli grown at 37 °C and 42 °C was 
observed by us and by others (50,51) indicating that this is not the consequence of the heat-shock 
treatment. The majority of the fusion protein isolated from the periplasm is not correctly folded due to the 
formation of intermolecular and incorrect intramolecular disulfide bridges. Claims that IGF-I with the same 
specific activity as the native protein can be recovered after affinity chromatography and cleavage of the 
protein A fusion protein (34,35) have later been disproved (52,53). 
It seems that the mismatching of disulfide bridges is a problem inherent to the E. coli system. 
Reshuffling of disulfide bridges by reduction and reoxidation as described for example by Winkler et al. 
(10), is a possibility but not an attractive option, in particular when many mutated forms with unknown 
specific activity have to be renatured. For each protein the optimal conditions have to be determined, 
which is very time consuming. We have been able to reach only moderate gains in biological activity, 
despite testing various protocols, and have therefore abandoned this strategy. 
A further reduction of the proteolytic breakdown could be achieved in several ways. The proteolytic 
enzyme responsible for the residual proteolytic degradation could be determined and the gene 
responsible knocked out in the KS474 strain. Candidate genes are Ion and hptR (54). Alternatively, the 
target site of the proteolytic enzyme involved can be determined and changed by site-directed 
mutagenesis. The use of an alternative inducible promoter that allows growth and production at 30 °C 
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might be another possibility (15). In addition production levels of active growth factor can be doubled by 
the purification of fusion protein from the periplasmic space and the medium. Attempts can be made to 
secrete all of the fusion protein to the medium by using other E.coli strains, changing the temperature or 
by altering the signal sequence to e.g. ST-II (23), but the result will not be predictable. 
The proteolytic enzymes used to cleave the fusion proteins recognize a tetrapeptide target sequence 
and are therefore highly specific. They are relatively insensitive to residues following the cleavage site 
(38,39) and therefore widely applicable, in contrast to for example thrombin. Factor Xa has been used in 
different fusion proteins (38) but has the disadvantage of being very sensitive to the reaction conditions 
used, while highly pure preparations are very expensive. Isolation of milligram amounts per liter blood is, 
however, relatively simple (38). Coupled to Sepharose and used with highly pure fusion protein in 
combination with degassed buffers, it can be used for months. Genenase I is less sensitive to the reaction 
conditions used and can be obtained as a recombinant protein in pure form. A fusion between a synthetic 
protein A IgG-binding domain and alkaline phosphatase separated by the target sequence of Genenase I 
was cleaved efficiently and specifically (39). We found, however, that protein A possesses a site in its 
so-called C-domain, a few kilo-Daltons from the Factor X, target sequence, that is attacked by 
Genenase I. The potential cleavage site He-Leu-His-Leu-Pro-Asn-Leu is found at 29 and at 87 amino 
acids from the Factor Xa cleavage site. Although this sequence contains the His residue that is considered 
to be indispensible for Genenase I activity, this sequence is not believed to be favourable for digestion 
with Genenase I. The residue following the His residue should be a tyrosine or phenylalanine, while a 
proline residue at the next position is supposed to impede cleavage. It also seems that both sequences 
lie too far from the Factor Xa target sequence to be the cleavage sequence as far as can be judged from 
the protein sizes on the gels. We have not determined where the actual cleavage site is located exactly. 
In the present study Genenase I has not been used for the production of these growth factors but in 
cases where the desired protein contains a Factor Xa target site, Genenase I may be used as an alter-
native. Although chemical cleavage by cyanogen bromide, formic acid or hydroxylamine seems cheaper 
and easier to perform, the specificity of these proteolytic enzymes is a distinct advantage because of their 
more general applicability. Also the fact that physiological conditions can be used may be of great 
importance for use with sensitive proteins. 
After isolation of the periplasmic proteins, the fusion proteins were recovered in a highly pure form by 
IgG-Sepharose affinity chromatography. Some protein bands shorter and several longer than the size of 
the fusion protein running at about 38 kDa could be observed on immunoblots. The shorter protein bands 
are clearly degradation products of the fusion protein. They are recognized by rabbit-anti-goat antibodies 
coupled to peroxidase. The longer protein bands disappear after cleavage by Factor X, or after reduction, 
using dithiothreitol or ß-mercaptoethanol, indicating that these are interchain-disulfide linked fusion 
proteins. As protein A does not contain cysteine residues, these are all formed between the growth factor 
moieties. After cleavage by Factor Xa and separation from protein A by affinity chromatography, it can be 
shown that the multimene growth factor forms are recognized by anti-growth factor antibodies, as 
indicated by the various bands (multiples of 6 kDa) on immunoblots (not shown). As it is known that these 
forms are biologically inactive they have to be removed by gel filtration chromatography. Running of the 
sample on a CB RP-HPLC column alone did not separate the multimene forms from the monomeric forms 
(not shown). Biologically active monomeric forms were separated by CB RP-HPLC to a large extent from 
inactive monomeric forms containing mismatched disulfide bridges. We can, however, not exclude that 
the preparations obtained by the present protocol still contain a considerable percentage of inactive 
growth factor protein. We have not quantified the specific activity of the purified growth factor proteins on 
a weight basis, but calibrated their biological activity relative to that of mEGF from a natural source, using 
the inhibition of binding assay on HER-7 cells (described in chapter 3) 
This protein A fusion expression system offers several advantages. Other genes can be easily adapted 
to be expressed in this system. No site-directed mutagenesis in the gene sequence is necessary to permit 
cleavage of the desired protein from the protein A fusion. Purification and cleavage conditions will not 
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affect the activity of most proteins. We have used this system succesfully to produce highly pure hEGF 
and hTGF-cc and will use it to produce EGF/TGF-cc hybrids. 
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CHAPTER 3 
EGFfTGF-α HYBRIDS: EXPRESSION, PURIFICATION AND 
PHYSICOCHEMICAL PROPERTIES 
SUMMARY 
Hybrid genes have been constructed from synthetic genes coding for hEGF and hTGF-a and have 
been expressed in an E. coli expression system. The resulting EGF/TGF-α chimeras, having domains 
exchanged at or between the third, fourth and sixth cysteine residue, were purified using IgG-
Sepharose affinity chromatography, BioGel P10 filtration chromatography and reverse-phase HPLC. 
The proteins showed remarkable differences in elution behaviour on the last two columns, but we 
have not been able to correlate these differences to the physicochemical properties of the proteins 
INTRODUCTION 
Despite their limited homology, human epidermal growth factor (hEGF) and human transforming 
growth factor-α (hTGF-a) bind to the hEGF-receptor with comparable affinity and exert the same 
biological effects in vitro (1). In the biological assays used initially to identify EGF-hke activity it was 
therefore not possible to discriminate between these growth factors, but both activities could be 
separated on the basis of differences in physicochemical properties (2) Later, however, quantitative 
differences in the biological activity of hEGF and hTGF-a have been reported For example, TGF-a is 
much more potent in stimulating 3H-thymidine incorporation in chicken adipocyte precursor cells than 
EGF (3) This is the consequence of the higher affinity of TGF-a for the chicken EGF-receptor in 
comparison with EGF (4) TGF-a has also been reported, however, to be more potent than EGF in 
several mammalian in vivo and in vitro systems including the stimulation of bone resorption in fetal rat 
lung bones (5), the inhibition of alkaline phosphatase activity in cultured rat osteosarcoma cells with 
an osteoblast phenotype (UMR-106 cells, 5), inhibition of parathyroid hormone-responsive adenylate 
cyclase activity in UMR-106 cells (6), the stimulation of anchorage-independent growth in pancreatic 
carcinoma cells (PANC-1, ASPC-1 and T3M4 cells, 7), the stimulation of the healing of second degree 
burns on pig skin (8), angiogenesis in the hamster cheek pouch assay (9), cell migration of keratmo-
cytes (10) and prostacyclin production by cultured human vascular endothelial cells (11, see also refs 
cited in 12) It has been suggested that this results from different routing and processing of 
internalized hgand/receptor complexes due to a difference in isoelectric point (pi) between EGF and 
TGF-a (12) 
Differences, both with respect to binding and activation of the chicken EGF-receptor as well as with 
respect to biological activity resulting from different physicochemical properties, can be used to study 
the structure-function relationship of EGF and TGF-a To address the question which parts of the 
growth factor molecules are responsible for these differences in activity, we have constructed hybrid 
genes of EGF and TGF-a and expressed them in Escherichia coli (E coli) The hybrids, consisting of 
a small domain of the one protein showing high activity, inserted into the background of the other 
protein showing low activity, can then be tested in assays that can discriminate the two proteins with 
respect to receptor binding or activation Those domains that have to be inserted to induce high 
activity of specific hybrids, may be involved in the processes of receptor binding and/or activation 
This strategy has been applied succesfully to determine binding domains of several cytokines making 
use of cross-species differences in receptor affinity (13-15) as well as to identify active domains of 
41 
cytokines and growth factors by an exchange approach between different, but related proteins 
(16-18). 
For the construction of EGF/TGF-a chimeras, we have chosen to use the conserved cysteine 
residues as domain boundaries. These cysteine residues are linked by disulfide bridges and since 
EGF and TGF-a have a comparable three-dimensional structure in which proper formation of disulfide 
bridges is essential, the loops formed in this way may possibly correspond to specific functions. A 
hybrid between TGF-a and the EGF-like vaccinia virus growth factor (VGF), constructed by making an 
exchange at the fourth cysteine residue, showed full biological activity (19), indicating that EGF/TGF-a 
hybrid growth factors can fold to the right conformation. 
The approach chosen here has several advantages over site-directed mutagenesis, the most widely 
used method to study structure-function relationships. In studies using site-directed mutagenesis to 
locate biologically active domains, residues to be changed are often chosen on the basis of homology 
between related proteins. This carries the risk that structurally important residues are mutated, since 
these are usually conserved. It is therefore imperative to check the mutant proteins for structural 
integrity by physical techniques. Hybrids in contrast, are derived from proteins which have an identical 
three-dimensional structure and biological function, showing only known differences in their biological 
properties, and can therefore be expected to have a comparable structure. The differences in 
biological function are most likely based on the presence of non-homologous residues of no structural 
importance. Changes in activity measured after site-directed mutagenesis generally correspond to a 
reduction in activity. This complicates the interpretation, since losses in activity may not only result 
from the mutation of a specific amino acid necessary for biological activity, but also from changes in 
overall structure essential for biological activity (20). In addition, inactive mutants may be difficult to 
purify in the absence of a suitable antibody or affinity column. In the case of chimeric proteins, the 
property of interest can be tested by measuring an increase in activity of the hybrids with respect to 
the least active of the two native proteins. Moreover, in site-directed mutagenesis experiments the 
choice of the replacing residue is rather arbitrary, which necessitates the replacement of one residue 
by several others, while on the other hand a relatively small number of hybrids is generally sufficient 
to locate a domain of interest fairly accurately. Subsequently, site-directed mutagenesis can be used 
to trace the exact residue(s) involved. 
In this study we have used EGF/TGF-a hybrids to locate the domains in these growth factors that 
are responsible for the high affinity binding of TGF-a to the chicken EGF-receptor (chapter 5) and for 
studying the differential down-regulation and processing of the ligand-receptor complex after binding 
of EGF or TGF-a (chapter 7). The biological activity of the hybrids will be described in chapter 6. If 
separate domains can be identified which are responsible for binding and activation of the EGF-
receptor, a rational strategy can be developed to construct a so called EGF-receptor antagonist, a 
protein that is able to bind but unable to activate the receptor. This antagonist would be clinically 
interesting, since it could be used to interrupt both the autocrine and paracrine growth stimulation of 
TGF-a found in many solid tumors. 
In this chapter the construction, expression and purification of EGF/TGF-a chimeras will be 
described. Their physicochemical properties, studied with respect to differences in pi, hydropathicity 
and behaviour on BioGel P10 gel filtration chromatography columns will be discussed. 
EXPERIMENTAL PROCEDURES 
Gene constructs 
Figure 3.1 shows the restriction sites in the plasmids pFX-EGF and pFX-TGF-a (see chapter 2) 
used for the construction of the EGF/TGF-a chimeric proteins. For the construction of the hybrids 
FX-E3T and FX-T3E, pFX-EGF and pFX-TGFa were digested with Nsi l/Xho I and Pst l/Xho I 
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Figure 3.1. Scheme showing part of the plasmids pFX-EGF and pFX-TGF-a. including the restriction sites used tor the construction 
of the EGF/TGF-a chimeras. Restriction sites of the cloning vector (pBS SK-) and the 1Θ3 bp FX-EGF and 179 bp FX-TGF-a inserts 
are numbered separately for clarity. The nucleotide sequence of the inserts are presented in figure 2.3. 
respectively. Nsi I and Pst I cut the third cysteine codon of EGF and TGF-oc respectively, and have 
compatible cohesive ends. The Nsi l/Xho I and Pst l/Xho I fragments were exchanged and ligated 
back into the vectors giving rise to the vectors pFX-ЕЗТ and pFX-T3E. 
The vectors pFX-E4T and pFX-T4E were constructed using the Sph I (Nsp I) site that cuts the fourth 
cysteine codon of EGF and the Nsp I site that cuts the fourth cysteine codon of TGF-a. FX-E4T was 
constructed by ligating the synthetic 32 bp Nsp l/Dra III fragments of the TGF-a gene and the 485 bp 
Dra III fragment of pFX-TGFa, together containing the З'-end of the TGF-a gene into the Sph l/Dra III 
site of pFX-EGF. FX-T4E was constructed by ligating the 141 bp Bst Xl/Nsp I fragment of pFX-TGF-a 
containing the 5'-end of the TGF-a gene into the Bst Xl/Sph I site of pFX-EGF containing the 3'-end 
of the EGF gene. 
For the construction of the vectors pFX-E6T and pFX-T6E use was made of the restriction 
endonuclease Dra III which cuts the sixth cysteine codon of TGF-a. The hybrid gene FX-E6T was 
constructed by inserting a synthetic Sph I/ Dra III EGF fragment, coding for the domain between the 
fourth and sixth cysteine codon, and the 490 bp Dra III fragment of pFX-TGFa in the Sph l/Dra III site 
of pFX-EGF. FX-T6E was constructed by ligating a synthetic Dra Ill/Sac I EGF fragment coding for 
the area between the sixth cysteine codon and the Sac I site and the Sac l/Dra III fragment of 
pFX-EGF into the Dra III site of pFX-TGFa. 
The hybrid genes FX-E3T4E, FX-T3E4T, FX-E4T6E and FX-T4E6T were constructed using the 
same restriction sites, materials and strategy. 
Expression and Purification 
The hybrid genes were introduced by Bam Hi/Sal I digestion and ligation into the pHEMA 153 
protein A fusion expression vector as described for the FX-EGF and FX-TGF-a genes (see 
chapter 2). The expression and purification by IgG-Sepharose affinity chromatography, Factor Xa 
digestion, Biogel P10 gel filtration chromatography and reverse-phase high performance liquid 
chromatography were performed as described in chapter 2. 
Calculations of molecular weights, pi and hydropathicity 
The molecular weights, pi and hydropathicity of the growth factor proteins were calculated using the 
computer program IntelliGenetics Suite, release 5.4 (IntelliGenetics, Mountain View, CA, USA). 
Different models have been proposed to calculate the hydropathicity of a protein, expressed in either 
hydrophilicity or hydrophobicity values. The hydrophobicity plot according to Kyte and Doolittle was 
devised to predict the exterior and interior domains of proteins, based on various experimental 
observations (see ref. 21). For the calculation the following values were used: A, 1.8; E, -3.5; I, 4.5; 
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M, 1.9; Q, -3.5; Y, -1.3; F, 2.8; N, -3.5; R, -4.5; V.4.2; C, 2.5; G, -0.4; K, -3.9; S, -0.8; W, -0.9; D, -3.5; 
H, -3.2; L, 3.8, P, 1.6; T, -0.7. In this method the hydrophobic residues have positive values. 
For the calculation of the hydrophihcity according to Hopp and Woods (22) the following values 
were used. A, -0.5; E, 3.0; I, -1 8; M, -1.3; Q, 0.2; Y, -2.3; F, -2.5; N, 0 2; R, 3.0; V, -1.5; C, -1 0; 
G, 0.0; K, 3.0; S, 0.3; W, -3 4, D, 3.0; H, -0.5, L, -1.8; P, 0.0; T, -0.4. This method was devised to 
locate the protein sequences that show the greatest local average hydrophihcity in order to predict 
antigenic sites. For this reason the hydrophilic residues have positive values. 
RESULTS AND DISCUSSION 
EGF/TGF-a chimeric proteins 
Figure 3 1 shows the restriction sites in the synthetic FX-EGF and FX-TGF-oc genes and the 
cloning vector that were used for the construction by cassette mutagenesis of the ЕСРЯ6Р-а hybrid 
genes. Further details about their construction have been presented in the experimental procedures 
section. 
Figure 3 2 shows schematically the hybrid 
proteins that were produced in E.coli and the 
nomenclature used to address them. The numbers 
in the names of the hybrids denote the cysteine 
residues at which the two proteins are linked. 
E3T4E for example, denotes a hybrid in which the 
domains N-terminal of the third and C-terminal of 
the fourth cysteine residue consist of EGF 
sequences, while the domain between the third and 
fourth residue consists of TGF-a sequences As 
can be seen from this figure, we have chosen to 
exchange domains at or between the third, fourth 
and Sixth Cysteine residue The third and fourth Figure 3 2 Chimeric hEGF/hTGF-oe polypeptides White boxes 
denote EGF sequences black boxes denote TGF-a 
cysteine residues were chosen while exchanges sequences Domains are indicated by Roman numerals 
made at these residues give a rough indication if 
an activity lies N-terminal or C-termmal in the 
molecule An additional argument is, that the 
domains N-termmal and C-terminal of the fourth 
residue lie on different exons in EGF (23) and 
TGF-a (24) and appear to fold separately (25) This 
could be an indication that these two domains fulfill 
different functions. An exchange at this residue has 
been made before between TGF-a and vaccinia 
virus growth factor (VGF) and the resulting hybrid 
showed full biological activity on NRK 49F cells 
(19). Finally, studies using synthetic peptides, Figure 3 3 Relationship between the molecular mass of the 
although inconclusive, have indicated that the 9™rth factor proteins and their еіиіюп from me BioGei PIO 
gel filtration column The fraction number of Ine fraction 
region C-terminal of the third cysteine is important showing maximal EGF-hke activity is plotted as a function of 
for both receptor b.ndmg and activation (reviewed the molecular mass of ^protein Gro^h factor numbering
 ß 
r a
 ' a s follows 1 hEGF, 2 hTGF-a 3 E3T, 4 E4T, 5 E6T, 6 T3E. 
in ref i ) . Exchanges at the sixth cysteine residue 7T4E тбЕ ЭЕЗТ4Е, ІОЕ4Т6Е И тзЕ4Т, І2Т4Е6Т Χ 
have been made to locate the high affinity bbindmg І и І ю п Р а к °' , h f m a r k e r ?'°[em,(insu"" 6 k D a ) M° l e=u l a r 
size seems to determine the eluüon behaviour of these 
domain of TGF-a to the chicken EGF-receptor proteins only toa moderate extent (corr coeff = 0551) 
more precisely (see chapter 5) 
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Purification by BloGel P10 gel filtration chromatography 
The chimeric genes were expressed in E. coli as fusion proteins with protein A. The growth factor 
sequences were recovered after purification by IgG affinity column chromatography, cleavage by 
Factor Xa and a second run on an IgG Sepharose column as described in chapter 2 for EGF and 
TGF-o. To separate monomeric forms of the growth factor from multimene forms resulting from 
interchain disulfide bridge formation, the samples were run on a BioGel P10 gel filtration column in 
1M HAc (see also chapter 2). The biotin-mEGF binding competition assay on A431 cells and the 
A431 growth inhibition assay were used to screen the column fractions for EGF-like activity. The 
activity peaks of EGF, TGF-ct and the hybrids are expected to elute at approximately the same 
position from this column for their molecular weights are all close to 6 kDa. EGF has a slightly larger 
molecular size (6222 Da) than TGF-a (5552 Da), while the molecular sizes of the hybrids vary 
between 5322 and 6453 Da. This wider range of molecular sizes of the hybrids is caused by the 
different position of the cysteine residues in EGF and TGF-a. While EGF has a longer C-terminal tail 
than TGF-a, this protein has a longer N-terminal extention than EGF. Table 3.1 shows, however, that 
the activity peaks of the growth factors and the hybrid molecules elute very differently than predicted 
merely on basis of their molecular size: TGF-a elutes somewhat earlier, while most notably E3T4E, 
T3E, T4E and hEGF elute much later than predicted. Figure 3.3 shows the relationship between the 
molecular size and the peak fraction in their elution profile. This figure confirms that apparently other 
factors than molecular size alone determine the elution pattern of this type of growth factor proteins. It 
is known from the literature that EGF elutes much later than expected on the basis of its molecular 
size from a BioGel P10 column run under acidic conditions (2,26) used to stabilize the protein, while 
TGF-a elutes at a slightly higher molecular weight than expected (2,27). mEGF(1-51) lacking the 
C-terminal dipeptide (Leu-Arg) is even slightly more retarded than mEGF (26). At higher pH (5.6-5.9) 
EGF elutes from the BioGel P10 column according to its proper molecular weight (28,29). When using 
Sephadex G-75 gel at this pH, however, mEGF is retarded due to interaction with the column matrix 
and elutes at an apparent molecular size of 3.8 kDa (28), while hEGF at pH 7.0 elutes at an apparent 
GF 
hEGF 
hTGF-a 
E3T 
E4T 
E6T 
T3E 
T4E 
T6E 
E3T4E 
E4T6E 
T3E4T 
T4E6T 
MW 
(Da) 
6222 
5552 
5322 
5336 
5397 
6452 
643Θ 
6377 
620Θ 
6161 
5567 
5613 
P10 
Peak fraction 
110 
73 
92 
Θ2 
98 
116 
110 
82 
126 
88 
96 
90 
Pi 
4.50 
5.84 
4.70 
4.37 
4.02 
5.77 
6.29 
7.08 
4.81 
5.21 
5.48 
5.13 
RP-HPLC 
Peak traction 
125 
89 
SO 
52 
126 
119 
84 
115' 
109 
n.d. 
114 
112 
Hydrophoblcity 
36.7 
25.2 
22.1 
25.8 
27.6 
39.8 
36.1 
34.3 
33.0 
34.9 
28.9 
27.0 
Table 3.1. Molecular mass and isoelectric point of the growth factors were calculated by the computer program obtained from 
Intelligenetics. The hydrophobicity values were calculated as described in the text. Fractions eluting from the BioGel P10 and 
C, RP-HPLC columns that showed highest EGF-like activity, determined as described in the expérimental procedures 
section, are indicated. 
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molecular weight of about 7.5-Θ kDa (30). 
Sephadex G-75, consisting of cross-linked 
dextran beads is known to bind positively 1 0 
charged and aromatic substances, while BioGel 
P10 is a Polyacrylamide matrix containing free 
amide groups (31) It is therefore likely that the 
elution at a much lower apparent molecular 
weight observed for some growth factor hybrids 
on the BioGel P10 column can be explained by 
P· с с c c 
θ -
8 -
7 -
β -
5 -
4 -
II III IV VI 
EG F 
hTGFûi 
electrostatic interactions of the proteins with the Figure 3 4 The figure shows the isoelectric pants of the 
column matrix Elution at a higher apparent doma,ns be tween m e ^steme res,dues °' EGF 'ndlca,ed bv 
grey line and TGF-a indicated by a black line The pis were 
molecular weight, observed for some Other calculated from the published pK values of the side chains of 
hybrids, is generally explained by the deviation of me indlv,dual amino acids and the term,nal N h V and -COOH 
groups when present 
the protein from the ideal globular form 
If charge interactions of the growth factors with the column material plays a role, it can be 
anticipated that the elution behaviour might be a function of the pi of the proteins Table 3 1 shows 
the calculated pi values of the growth factor proteins The values calculated for hEGF and hTGF-a 
correlate closely with the values reported in the literature (12,30,32). From the large spread in the pi 
values of the hybrids it becomes clear that there is not only a charge difference between EGF and 
TGF-a, but also a difference in charge distribution The calculated values for the pis of the domains 
between the various cysteine residues that are linked in the molecule by disulfide bridges are shown 
in figure 3.4 to illustrate this. Although hEGF is more acidic than hTGF-a, its C-terminal domain is 
very basic, while the more basic TGF-a has a very acidic C-terminal domain The figure shows that 
large charge differences also exist between the loops formed between the cysteine residues, although 
it is realised that these calculations do not take into account the possible charge effects resulting from 
the three-dimensional structure of these proteins 
Figure 3 5 shows the relationship between the pi and the elution behaviour of the growth factor 
proteins From this graph no clearcut relationship between pi and elution behaviour can be inferred 
Also, there seems to be no correlation between the number of negative or positive charges and the 
elution behaviour (not shown) Egmond et al (33) have shown in an extensive study of charge 
variants of subtihsin that the adsorption of proteins to surfaces is very complex when the process is 
dominated by electrostatic forces Binding to a cation-exchange column and also electrophoretic 
Figure 3 5 Relationship between the isoelectric point of the 
growth factor proteins and their elution from the BioGel P10 gel 
filtration column The fraction number showing maximal EGF like 
activity is plotted as a function of the isoelectric point of the 
protein Growth (actors numbering is according to figure 3 3 The 
correlation coefficient calculated for these variables is -0 15 
Figure 3 6 Relationship between the hydrophobicity of the 
growth factor proteins and their elution from the C„ RP-HPLC 
column Hydrophobicity was calculated by adding the 
hydrophobicity values according to Hopp and Woods of the 
hydrophobic residues in the protein with a value smaller than -1 
The fraction number showing maximal EGF-like activity is 
indicated on the Y axis Growth factors are numbered as in figure 
3 3 The correlation coefficient calculated for these venables is 
0 57 
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mobility is strongly dependent on the type of buffer salt used and not only on the net charge of the 
protein but also on the amount of charged residues. The elution profile of the growth factor proteins 
and hybrids seems to be influenced by electrostatic interactions but these data do not allow 
conclusions about the involvement of specific residues. The aberrant behaviour of some growth factor 
proteins on the gel filtration columns may be used to separate them from other proteins but if binding 
to the matrix is an important determinant of the elution behaviour, this may interfere with the 
separation of monomers from dimers and higher order multimers. 
Purification by C, RP-HPLC 
The active fractions eluting from the BioGel P10 column were pooled and separated on a C„ RP-
HPLC column. The A431 growth inhibition assay and biotin-mEGF binding competition assays were 
again used to screen the fractions for EGF-like activity. The activity peak of the elution profile of each 
chimera is given in Table 3.1. hEGF is a more hydrophobic protein than hTGF-a which elutes 
relatively early from RP-HPLC columns (2). No hybrid elutes significantly later than EGF but some 
mutants (E3T and E4T) elute much earlier than TGF-a. Therefore, the distribution of surface exposed 
apolar residues seems to differ between the two proteins. In order to be able to explain the elution 
behaviour of these chimeras, the overall hydrophobicity of each protein was calculated in several 
ways in an effort to obtain a good fit with the elution behaviour on the column, but a satisfactory fit 
could not be produced. The values given in table 3.1, calculated by adding the hydrophobicity values 
of the strong apolar residues with a value smaller than -1 as used by Hopp and Woods, predict the 
column elution behaviour of the proteins only to a certain extent. When the relationship between these 
values and the elution profile is plotted (fig.3.6), the graph suggests only a weak correlation between 
these hydropathicity values and the elution behaviour on the Ce RP-HPLC column. 
Hydropathy profiles obtained according to Kyte and Doolittle (21) or Hopp and Woods (22) both 
predict differences in the hydropathy of the different domains of EGF and TGF-a (fig. 3.7 and 3.8). In 
contrast to Hopp and Woods who use hydrophobicity values, Kyte and Doolittle use hydrophilicity 
values to calculate the hydropathy profiles. Hydrophobic areas shown as positive values in the graphs 
obtained according to the method according to Kyte and Doolittle (fig. 3.7) are therefore shown as 
negative values in the graphs according to Hopp and Woods (fig. 3.Θ). In both models the two (main) 
hydrophobic areas of EGF are also present in TGF-a, but less distinct. The profile according to Kyte 
and Doolittle shows EGF as a very hydrophilic protein except for two areas (D17-E24 and C31-Y37) 
that are strongly hydrophobic (fig. 3.7). Both areas include cysteine residues, which are linked in the 
a b 
Figure 3.7 Hydropathy profiles of TGF-a (a) and EGF (b) according to Kyte and Doolittle. Hydrophobic residues are shown as 
positive values. 
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a b 
Figure 3.8. Hydropathy profiles of TGF-a (a) and EGF (b) according to Hopp and Woods. Hydrophobic residues are shown as 
negative values. 
molecule by disulfide bridges, but this is not taken into account in these models. TGF-a is 
represented with three distinct hydrophilic domains, apolar N- and C-terminal sequences and some 
minor apolar domains. The plot according to Hopp and Woods (fig. 3.8) shows EGF having three 
hydrophobic domains (D11-E24, C31-Y37 and W49-L52) and suggests a less hydrophilic character 
than according to Kyte and Doolittle. These authors suggest very large polar domains at the termini 
(N1-L15 and I38-R53), areas that are less polar according to Hopp and Woods. 
These theoretical models do not give information on the exposure of the apolar residues at the 
surface. In larger proteins they are mostly shielded from the solvent and contribute to the structure 
and stability of the protein. Probably only a few of the apolar residues in mEGF are shielded from the 
solvent (34). NMR-studies have given some information on the position of the apolar side chains in 
EGF and TGF-a (25,35-37) and in combination with site-directed mutagenesis data it has been 
suggested that several apolar residues are involved in receptor recognition (20,38-40). 
It seems remarkable that the elution profile of the hybrids divides them into EGF-like and TGF-a 
like chimeras. This is most clear for the hybrids made by exchanges at the third and fourth cysteine 
residue. T3E and T4E elute late from the P10 column like EGF, while E3T and E4T elute early like 
TGF-a (fig. 3.3 & table 3.1). E3T and E4T elute early from the RP-HPLC like TGF-a, while T3E and 
T4E elute late like EGF (fig. 3.6 & table 3.1). It will be shown, that the same distinction can be made 
in their binding affinity to the chicken EGF-receptor (see chapter 5). Charges and polarity of domains 
at the surface of a ligand molecule can be important features in receptor recognition. The influence of 
charge on the binding to the EGF-receptor has been clearly demonstrated (12, chapter 7). It is 
remarkable that EGF and TGF-a have a very different charge distribution and, to a lesser extent, a 
different hydropathy profile while showing the same affinity for the EGF-receptor. Therefore we have 
tried in this study to correlate the elution behaviour of their chimeras with the presence of specific 
domains which could be exposed to the protein surface. It is realised, however, that the binding to 
surfaces is a very complex process and the present data do not allow direct conclusions about the 
involvement of distinct groups from the column elution profile obtained. 
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CHAPTER 4 
QUANTIFICATION OF EGF-LIKE GROWTH FACTOR HYBRIDS 
PRODUCED IN THE PROTEIN A FUSION EXPRESSION SYSTEM 
SUMMARY 
Biotin-mEGF and biotin-protein A competitive ELISAs have been developed and were used to 
measure the amount of EGFHOF-hybrids fused to protein A produced in a bacterial expression 
system. Using these assays the fraction of fusion protein showing EGF-Іік activity could also be 
established and these two variables have been used to optimize the culture conditions of the 
expression system. During the purification of the growth factor proteins by Factor X„ digestion, IgG-
Sepharose affinity chromatography, BioGel P10 gel filtration chromatography and Ce RP-HPLC the 
biotin-mEGF ELISA and an A431 growth inhibition assay have been used to screen the column 
fractions for biological activity. The amount of growth factor obtained was calibrated using an 
125l-mEGF binding competition assay on HER-7 cells and was expressed in ng equivalents of mEGF. 
Equal amounts of the hybrid growth factors produced overlapping displacement curves in the HER-7 
125l-mEGF binding competition assay. When tested in the 125l-mEGF binding competition assay on 
A431 cells or in the A431 growth inhibition assay, the curves obtained showed only slight deviations. 
The results obtained in the biotin-mEGF binding competition assay on A431 cells were seriously at 
variance with these findings. Possible explanations for these differences are discussed. 
INTRODUCTION 
Epidermal growth factor (EGF)-like activity was described for the first time by Cohen (1). He 
discovered that EGF isolated from the submaxillary glands of mice stimulated the premature opening 
of the eyelids and incisor eruption in newborn mice. Human EGF was first isolated from urine, but is 
present in all secretory fluids of the human body and is produced by many tissues (2). Transforming 
growth factor alpha (TGF-a), like EGF interacting with the EGF-receptor, was first isolated from 
retrovirally transformed rodent fibroblasts (3). Human tumors, embryonic tissues and normal tissues 
have later been shown to express TGF-a (2). Both growth factors show comparable affinity for the 
human EGF-receptor and have the same biological activity in several in vitro assays (4). However, the 
two proteins show only limited sequence homology and can be readily separated by biochemical or 
immunological means (5). In contrast to their comparable affinity for the hEGF-receptor, hEGF shows 
a 100-fold lower affinity for the chicken EGF-receptor than hTGF-ct (6). In order to locate the domain 
in TGF-a that determines the high affinity binding to the chicken EGF-receptor by a domain exchange 
strategy, we have produced EGF/TGF-a chimeras as fusion proteins with protein A in Escherichia coli 
ÍE.coli). The fusion proteins were isolated from the periplasmic space and purified by IgG-Sepharose 
affinity chromatography. The protein A and growth factor moieties were separated by Factor Xa 
digestion and a second IgG affinity column. The biologically active growth factors were further purified 
by gel filtration chromatography and reverse-phase high performance liquid chromatography (chapters 
2 and 3). 
An 125l-mEGF receptor binding competition assay on HER-7 cells, which are NIH-3T3 cells trans-
fected with the human EGF-receptor, was chosen for the final quantification of growth factor activity. 
Based on this assay, the activity of the growth factor hybrids was expressed in ng equivalents of 
mEGF. This assay is, however, too laborious, expensive and time consuming to be used for the 
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screening of all the column fractions during purification of the hybrids produced We have therefore 
developed binding competition assays using biotin-labeled tracers in an ELISA format and an A431 
growth inhibition assay (4) for large scale screenings of protein A and EGF-like activity. 
The growth factors produced by the presently used expression system are a mixture of biologically 
active and inactive isoforms due to differences in disulfide bond formation (chapter 2) The amount of 
protein A fusion protein and the specific activity (in terms of percentage of correctly folded, active 
protein) of the growth factors produced are dependent on the culture conditions used In order to 
obtain an optimal balance between the amount of active protein and its specific activity, we have 
tested these characteristics under different culture conditions A biotin-protem A competitive ELISA 
developed by us (7) was used to measure the amount of fusion protein produced, while the EGF-like 
activity was measured using the competitive biotin-mEGF ELISA The specific activity could be 
calculated assuming that equimolar amounts of protein A and EGF are produced 
Here we descnbe the use of these assays for the calculation of the specific activity of the fusion 
proteins produced, the detection of active protein during the purification procedure and the final 
quantification of the purified proteins Anomahties were found when quantitatmg EGF-receptor binding 
using biotin-labeled hgands in the binding competition assays when compared with the radiolabeled 
binding competition Possible explanations for these discrepancies are discussed 
EXPERIMENTAL PROCEDURES 
Materials 
Purified mEGF (culture grade) purchased from Collaborative Research Ine was used as a standard 
in all assays Other growth factors and growth factor hybrids were expressed in Escherichia coll and 
purified as described (chapters 2 and 3) 125l-mEGF, a generous gift from Dr Th J Benraad and Mr 
J J Τ M Heuvel (Department of Experimental and Chemical Endocrinology, University Hospital 
St Radboud, Nijmegen, The Netherlands), and 125l-hTGF-a were prepared as described (8) Biotin-
labeled mEGF was purchased from Boehrmger Mannheim while biotm-protein A, unlabeled protein A, 
avidin-peroxidase and N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfomc acid (BES) were obtained from 
Sigma Chemical Corporation 125l-streptavidin and 3H-thymidine were purchased from Amersham 
Biotin-protein A binding competition assay 
The biotin-protein A competition assay was performed as previously described by us (7, see 
chapter 8) In brief, 96 wells plates were coated overnight with purified rabbit immunoglobulins 
(200 ng/well) dissolved in phosphate-buffered saline (PBS), washed three times with PBS/0 05 % 
Tween 20 and incubated with Dulbecco's modified Eagle's medium (DMEM) containing 1 % bovine 
serum albumin for 1 h at 37 °C to block non-specific binding Subsequently biotin-protein A (50 ng/ml) 
was added in the presence of variable concentrations of unlabeled protein A to a final volume of 
100 μΙ and incubated for 1 h at 37 °C After four washes with PBS/Tween 20 the wells were 
incubated with avidin-peroxidase (0 25 цд/ті in DMEM/1 % BSA) for 1 hour and washed again four 
times with PBS/Tween 20 Peroxidase activity was detected as described previously (9) 
Biotin-mEGF binding competition assay 
The biotin-mEGF binding competition assay was performed according to King and Catino (10) with 
slight modifications A431 cells were seeded into 96 wells plates (1 5x104 cells/well) and grown for two 
days in bicarbonate buffered DMEM (DMEM/Bic) supplemented with 10 % fetal calf serum (FCS) 
Cells were then washed twice with phosphate buffered saline (PBS) and fixed with formaldehyde (1 % 
in PBS) for 60 mm at room temperature After four washes with PBS, non-specific binding places 
were blocked by incubation with DMEM/Bic supplemented with 10 % normal calf serum (NCS) for 
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60 min at 37 °C. This medium was replaced by 50 μΙ DMEM/Bic/10 % NCS containing 1.25 ng biotin-
mEGF and the growth factors to be tested, added in the presence of 0.1 % BSA, and the cells were 
incubated for 60 min at 37 °C in the C0 2 incubator. After this incubation period, cells were washed 
four times with PBS/0.05 % Tween 20, incubated with 100 μΙ avidin-peroxidase (0.25 μg/ml in 
DMEM/Bic/10 % NCS) and washed again four times with PBS/0.05 % Tween 20. Ortho-phenyl-
diamine was added for the detection of peroxidase activity as described (9). 
The specific activity of the growth factor moiety of the fusion proteins was calculated as follows. 
The total amount of growth factor protein was based on the molar amount of protein A in the fusion 
protein as determined by the biotin-protein A binding competition assay, assuming that equal molar 
amounts of protein A and growth factor protein are present in the fusion protein. The EGF-like activity 
was determined by the biotin-EGF binding competition assay and expressed in ng equivalents of 
mEGF activity. It is known that hEGF and hTGF-ce have a comparable binding affinity to the hEGF-
receptor as mEGF and have therefore the same specific activity. This specific activity was sub­
sequently expressed as ng equivalents mEGF activity/ng growth factor protein. 
A431 growth inhibition assay 
The A431 growth inhibition assay was performed as described elsewhere (4). A431 cells were 
seeded into 24-well dishes at 5.0x103 cells/well in 1 ml of DMEM/Bic/10 % FCS. After 6 hours of 
incubation, growth factors to be tested were added in 100 μΙ DMEM containing 0.1 % of bovine serum 
albumine (BSA) and buffered at pH 6.8 with BES. Two days later 0.5 μΟ\ 3H-thymidine (43 Ci/mmol) 
was added in 100 μΙ Ham's F-12/Bic medium and the cells were incubated for another 16 hours. The 
incorporation of 3H-thymidine in the cells was determined as described. 
125l-mEGF binding competition assay 
A431 cells or HER-7 cells (NIH-3T3 cells transfected with the human EGF-receptor, described in 
ref. 11, a generous gift from Dr. J. Schlessinger, New York University) were seeded into 24-well 
dishes coated with 0.1 % gelatin at a density of 5.5x104 cells per well and grown for 72 hours in 
DMEM/Bic/10 % FCS. 125l-mEGF (500 Ci/mmole) was added (0.1 ng in 100 μΙ of DMEM buffered at 
pH 7.7) in addition to serial dilutions of unlabeled growth factors. After incubation for two hours at 
room temperature on a rotating platform, cells were put on ice, washed twice with icecold 
PBS/0.1 % BSA and once with icecold PBS. Subsequently, the cells were incubated in 1 % 
Triton X-100 at room temperature on a rotating platform, transferred to tubes and bound radioactivity 
was determined. 
RESULTS 
Quantification of the fusion proteins 
Competitive inhibition of binding assays using biotin-labeled protein A and biotin-labeled mEGF as 
tracers were developed to measure the specific activity of the growth factors produced, and for the 
screening of column fractions. The use of biotin-labeled tracers allows the use of the ELISA format 
and therefore greatly facilitates the testing of many samples. In the case of the protein A assay, the 
binding competition has been performed using a coating of purified rabbit immunoglobulins, while 
fixed A431 cells were used in the case of the EGF assay. Avidin-peroxidase and ortho-phenyldiamine 
were used in both assays for the detection of labeled ligand bound . 
Knowing that part of the growth factor protein produced is inactive due to incorrect formation of 
disulfide bridges, we have determined the specific activity of the growth factor moiety of the fusion 
proteins after IgG-column purification. The amount of growth factor protein produced has been 
calculated on the basis of the production of protein A, assuming that equimolar amounts of protein A 
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EGF 
TGF-o 
E3T 
E4T 
T3E4T 
E6T 
T4E6T 
T3E 
T4E 
E3T4E 
T6E 
E4T6E 
(A) 
prot A 
(nM) 
38 
75 
138 
103 
100 
294 
75 
288 
250 
44 
66 
206 
(В) 
GF 
(nM) 
4 0 
2 2 
0 3 
0 2 
0 3 
5 6 
0 4 
9 9 
12 3 
5 4 
6 8 
3 5 
(С) 
rabo 
А/В 
9 4 1 
3 4 1 
4581 
519 1 
333 1 
531 
188 1 
2 9 1 
2 0 1 
8 1 1 
9 6 1 
59 1 
Table 4 1 Production of protein A fusion proteins and growth factors The 
amount of protein A/FX/GF fusion protein that is recovered from 1 liter of 
bacterial culture is shown in columns A and В The fusion proteins are 
measured, after purification by IgG-affmity chromatography, in binding 
competition assays using biotm-labeled tracers Column A shows the 
amount of protein A per liter bacterial culture column В the amount of 
growth factor activity per liter bacterial culture Column С shows the molar 
ratio of protein A to biologically active growth factor 
and growth factor are present in the fusion proteins. The fact that a small fraction of the fusion protein 
was partly degraded (chapter 2 and 3) was hereby neglected. The biotm-mEGF competitive inhibition 
of binding assay determines the amount of protein capable of competition for binding to the EGF-
receptor and is therefore indicative for the amount of biologically active EGF-hke protein, assuming 
that the growth factor proteins fused to protein A have a similar binding affinity for the receptor as the 
authentic growth factor Culture conditions influence the amount of fusion protein produced as well as 
the percentage of correctly folded and therefore biologically active growth factor protein The two 
competitive ELISAs have been used to optimize culture conditions characterized by a sufficient 
production of biologically active growth factor protein with a high enough specific activity (not shown) 
These conditions, as described in chapter 2, have been used throughout all experiments 
Table 41 shows the production levels of the different fusion proteins as measured by the 
competitive ELISAs The amount of protein A produced per liter culture medium varies considerably, 
not only between cultures of different fusion proteins but also between different cultures of the same 
protein (not shown) The amount of biologically active growth factor produced vanes even more and 
as a consequence the fraction of active growth factor. Under conditions that hEGF and hTGF-ot fused 
to protein A would have the same specific activity as purified mEGF, a molar ratio of protein A to 
active growth factor protein of 1 to 1 would be anticipated. Table 4 1 shows, however, that under the 
experimental conditions used the ratios are varying between 8.1 and 519 to 1. This may indicate that 
only 0 2-12 3 % of the growth factor protein produced is biologically active This low specific activity is 
mainly due to incorrect formation of disulfide bridges resulting in inactive polymeric and monomenc 
forms and to partial degradation of the growth factor moiety of the fusion protein (chapter 2 and 3) 
Despite vanations between cultures a trend can be discovered in the results. Hybrids with TGF-a in 
their carboxy-termmal domain show a significantly lower specific activity than hybrids 
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Figure 4.1. Determination of the concentration of the purified growth factor proteins. This figure shows the differences in growth factor 
concentration as determined in four assays. For all four assays concentrations are used that give equal binding competition in the 
'"1-mEGF binding competition assay on HER-7 cells (A). 125l-mEGF binding competition assay on HER-7 (A) and A431 cells (B), 
A431 growth inhibition assay (C) and biotin-mEGF binding competition assay on A431 cells (D). Growth factors shown are: mEGF 
( » - . ) , hEGF (A—A), hTGF-a (A A), E3T ( • • ) , E4T ( • T ) , T3E (•—•), T4E ( • — • ) , E3T4E (+—+) and T3E4T (+ +). 
with EGF at this position. Notable exception to this rule is E4T6E. This phenomenon will be discussed 
later in this chapter. 
The fusion proteins were digested by Factor Xa and the protein A affinity handle was removed by 
IgG-Sepharose affinity chromatography. The resulting growth factor preparation had a low specific 
activity, due to the presence of inactive growth factor isoforms and had to be further purified. During 
this purification procedure in which the biologically active growth factors were largely purified from the 
inactive polymers and incorrectly folded monomers (chapters 2 and 3), the biotin-mEGF binding 
competition assay was used for the screening of column fractions while this assay is easy to perform 
and best suited for large scale screening. For the purification of those cultures that produced very little 
growth factor activity, the growth inhibition assay on A431 cells, also developed during this project, 
was used instead. It is based on the fact that, in contrast to most mammalian cell lines, the 
proliferation of A431 tumor cells is inhibited by EGF-like growth factors. This assay is more laborious 
to perform than the ELISA, but it is much more sensitive, and highly specific for EGF-like biological 
activity. 
Quantification of purified growth factor proteins 
Knowing that after the completion of the purification procedure the growth factor preparation still 
contains an unknown percentage of inactive isoforms, the growth factor activity was calibrated by 
performing a binding competition assay on HER-7 cells using 125l-mEGF as a tracer and purified 
mEGF as a standard. Based on this assay, growth factor activity was expressed in ng equivalents of 
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purified mEGF This is an operational measure and represents equimolar amounts of growth factor 
only, if the hybrid proteins have the same affinity for the hEGF-receptor on HER-7 cells as mouse and 
human EGF and human TGF-a. This assay and cell line were chosen for the calibration while 
CER-109, the same NIH-3T3 cell line transfected with the chicken EGF-receptor, will be used to 
determine the domain responsible for the high affinity binding of TGF-a to the chicken receptor (see 
chapter 5) There is no indication found by us or in the literature that the incorrectly folded isoforms 
show binding activity to the receptor and could interfere in this assay. After calibration, equal amounts 
of each hybrid expressed in ng equivalents of mEGF, show parallel curves and an equal displacement 
of the tracer when tested in this assay (figure 4 1a) 
Equal amounts of the calibrated growth factor proteins have also been tested in the biotin-mEGF 
and 125l-mEGF binding competition assays on A431 cells and in the A431 growth inhibition assay (fig 
4 1b-d) In these assays the growth factor proteins do not show exactly the same activity as mEGF 
that was used as a standard Adding to this, the slope of the displacement curves of E3T and E4T 
deviate from the others, indicating a different affinity of these proteins for the EGF receptor on A431 
cells (fig 4 1b-d) The curves in each experiment can be divided into three groups one group 
showing less, one showing more competition than mEGF, while the TGF-a curve runs with the mEGF 
curve in most experiments. The groups seem to be arranged according to the origin of the C-terminal 
domain hEGF, T3E and T4E form one group, E3T and E4T the other In the binding competition 
assay using radiolabeled mEGF (fig 4 1b) and the growth inhibition assay (fig 4 1c) the curves of the 
hybrid proteins show only slight deviations from that of mEGF In these assays, E3T and E4T show 
somewhat more, while hEGF, T3E and T4E show somewhat less activity than mEGF In most 
experiments TGF-a does not deviate much from the mEGF curve These two experiments show 
comparable activities for each protein relative to mEGF and largely confirm the results from the 
calibration on HER-7 cells The biotin-labeled mEGF receptor binding competition assay in contrast, 
shows a much larger spread between the curves In addition, this assay indicates that E3T and E4T 
show less and T3E and T4E show more activity than mEGF (fig 4 1d) This experiment is therefore 
seriously at variance with the three previous experiments (see below) 
The amount of growth factors produced per liter purified bacterial culture was calculated based on 
each of these four assays (Table 4 2) The concentrations measured by the 125l-mEGF assay on A431 
cells and the growth inhibition assay show differences to a maximum of about a factor two with the 
concentrations measured on HER cells, and these assays are therefore in good agreement with each 
other The correct concentrations of E3T and E4T are, however, difficult to determine in assays on 
A431 cells due to their deviating affinity towards this cell line The concentrations measured in the 
biotin-mEGF binding competition assay in contrast, show over sixfold differences with the values 
measured in the other assays It is striking that the concentration of the growth factors with a TGF-a 
domain at their carboxy-termmus tend to be underestimated in this assay These growth factors 
showed a very low specific activity (table 4 1 ) and their activity seemed to have increased enormously 
after purification (table 4 2) The growth factors having EGF-residues at their C-terminus, over-
estimated in this assay, also show some increase in activity after purification This is probably the 
result of an increase in affinity of the growth factors after the removal of the stenc hindrance caused 
by the protein A moiety 
Of these four assays, three were performed on A431 cells These cells are charactenzed by an 
abnormally high EGF-receptor density at their surface and are known to bind EGF-like proteins 
differently from other cells (12) Of these three assayson A431 cells, two concentrations measured 
show slight differences with the values measured by the binding competition assay on HER-7 cells 
We think that these differences and the deviating displacement curves of E3T and E4T can be 
attributed to the abnormal binding behaviour of the EGF-receptor on A431 cells The results of the 
biotin-mEGF binding competition assay, however, are also at variance with the other two assays on 
A431 cells 
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EGF 
TGF-α 
ЕЗТ 
E4T 
ТЗЕ 
Т4Е 
(А) 
GF cone 
,Ml-mEGF 
on HER-7 
(nM) 
1 6 
4 3 
3 1 
1 3 
107 
17 3 
(В) 
GF cone 
,25l-mEGF 
on A431 
(nM) 
0 9 
2 6 
4 2 
2 0 
6 6 
8 0 
(С) 
GF cone 
growth inhibition 
on A431 
(nM) 
1 7 
7 5 
3 8 
2 1 
128 
142 
(D) 
GF cone 
Ыо-mEGF 
on A431 
(nM) 
3 4 
2 0 
0 7 
0 5 
27 2 
53 1 
Table 4 2 Growth factor concentration as determined by four assays The table shows the biological activity of 
several growth factor proteins expressed in nmol mEGF equivalents obtained per liter bacterial culture, as determined 
in four assays measuring EGF-like activity These values are based on the EDW of the fully punfied growth factors 
measured in the ,25l-mEGF binding competition assay on HER-7 (A) and A431 (B) cells, on the ЕС
Ю
 measured in the 
A431 growth inhibition assay (C) and the EDM as measured In the biotin-mEGF binding competition assay (D) also on 
A431 cells 
This finding can probably be explained from the use of a different tracer, the use of an ELISA or the 
use of fixed cells. 
We conclude that the use of the biotin-mEGF binding competition assay for the determination of the 
biological activity of EGF-like growth factors results in most cases in an erroneous estimation of the 
activity while also the protein A fusion protein probably shows a lower biological activity than the 
purified growth factor The assay is well suited as a first screening for the presence of EGF-like 
growth factors and for the measurement of relative amounts of the same growth factor e g. the 
production level of growth factors by an expression system under different culture conditions, but not 
for proper quantification. The specific activities of the fusion proteins measured in this assay showed 
extreme differences (see table 4 1 ) However, if they are recalculated taking into account the deviation 
of the biotin-mEGF assay towards the HER-7 assay (taken from table 4 2), the values lie closer 
together. According to this calculation, the actual ratio of protein A to EGF is about 20:1, while the 
protein A to E4T ratio is about 200 1 (compare table 4.1). This indicates that the percentage of active 
protein in the growth factors shown in table 4 1, before separation from protein A and further 
purification, varies between 0 5 and 5% 
As stated before, a difference in binding behaviour of EGF-like growth factors towards A431- and 
HER-7 cells can be explained from results in the literature, but the difference between the biotin-
mEGF and 125l-mEGF binding competition assay on A431 cells is hard to explain Apart from the use 
of different tracers, the biotin-mEGF and 125l-mEGF binding competition assays differ in more 
respects The first assay is performed on mildly fixed cells and a second incubation with avidm-
peroxidase is necessary before substrate is added to the intact cells As a consequence no recycing 
occurs and only ligand/receptor complexes bound at the cell surface are measured. The second 
assay is performed on unfixed cells and the cells are washed and lysed before measurement. Some 
recycling probably occurs at room temperature and surface bound as well as internalized hgand/ 
receptor complexes are measured. We have concentrated on these three aspects in an effort to 
explain the difference in concentration measured by the two assays 
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Tracers 
Biotin is coupled to the alpha amino group of the mEGF molecule while 125lodine is coupled to 
tyrosine residues, of which five are present in mEGF The lodinated tracer was routinely tested for 
equivalence in binding to ascertain the identical affinity of labeled and unlabeled mEGF to the 
receptor. According to the literature (13) and to the supplier, biotin-mEGF shows the same affinity to 
the EGF-receptor and the same biological activity as unlabeled mEGF. We have tested the inhibition 
of binding of biotin-mEGF using lodinated mEGF or -hTGF-cc as tracers and the binding curves show 
indeed identical slopes indicating a similar affinity for the EGF-receptor (not shown). Also in the A431 
growth inhibition assay the curves of biotin-mEGF and mEGF parallel each other (not shown). This is 
consistent with the finding that mEGF and hTGF-a compete in the same way with biotin-mEGF and 
125l-mEGF We have used hEGF and hTGF-a fused to protein A as a tracer instead of biotin-mEGF 
No difference in competition with the growth factor hybnds was observed between the two or in 
comparison with biotin-mEGF (not shown) 
Fixation 
We have tested the influence of the fixation procedure in different experiments In binding 
competition experiments using 125l-mEGF as a tracer, all growth factor mutants tested showed 
identical relative competition on fixed and unfixed A431 cells (not shown) This experiment shows a 
better competition and a different binding behaviour of the growth factors on fixed cells as compared 
to unfixed cells Fixed cells seem to bind a lower percentage of tracer added than unfixed cells E3T 
and E4T show a different slope of the binding curve on fixed as well as unfixed cells, as was 
observed in other experiments on A431 cells When the biotin-mEGF binding competition assay is 
performed on unfixed A431 cells, a lower percentage of the tracer added is bound than in the 
standard procedure Several experiments comparing binding competition on fixed and unfixed cells 
did not show a consistent picture Some experiments seemed to indicate an effect of fixation on 
binding competition of different mutants, others excluded any effect 
Assay type 
The influence of the assay type on the results was tested in two ways When the biotin-mEGF 
binding competition assay was performed as the 125l-mEGF binding competition assay on unfixed 
cells, using 125l-streptavidm to label the bound biotin-mEGF, the results were comparable to the 
standard biotin-mEGF assay on fixed cells (not shown) Secondly, we compared the standard binding 
competition assay using lodinated tracer with the results after a mock incubation with labeled strept-
avidm, to exclude the possibility that the extra incubation with labeled streptavidm influenced the 
results by disturbing the binding equilibnum The two protocols showed identical binding competition 
curves (not shown). 
These experiments have not shown unequivocally the cause of the discrepancy between the 
competitive ELISA and the other assays These results will be evaluated further in the discussion 
DISCUSSION 
Three assays have been developed to evaluate the production of EGF/TGF-a chimeras in an E coli 
protein A fusion expression system and to detect EGF-like activity during purification Two of these 
assays, ELISAs based on competitive binding, use biotin-labeled tracers in conjunction with 
peroxidase labeled avidm for the detection of protein A and EGF-like growth factors. Although not 
very sensitive, they are very well suited to compare different culture conditions and for large scale 
screenings The biotin-mEGF ELISA is, however, unsuitable to measure the correct biological activity, 
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for data obtained with this assay were at variance with the values obtained by other methods The 
growth inhibition assay on A431 cells is more sensitive than the mitogenic stimulation assay on 
normal rat kidney (NRK) cells, is highly selective for EGF-like proteins and can be performed in 
serum-containing medium This assay was used primanly for the screening of column fractions in 
those cases in which the size of the samples needed for the biotm mEGF-assay represented too high 
a percentage of the growth factor produced 
The protein A and EGF-like growth factor ELISAs were used initially to evaluate the production 
levels and specific activity of the growth factor proteins under different culture conditions The molar 
amount of protein A in the fusion protein was used to quantify the amount of growth factor protein 
produced and the binding competition to EGF-receptors on the surface of A431 cells as a measure for 
the activity of the growth factors The specific activity of the growth factors measured in this way will 
be slightly underestimated because of the fact that a certain percentage of the growth factor moiety of 
the fusion protein has been degraded (chapter 2) In addition, this method only gives an actual 
measure of the specific activity of the growth factor proteins if the affinity of binding of the growth 
factor is not influenced by the protein A moiety or the reverse The production of fusion protein based 
on the amount of protein A showed a large variation This was not unexpected as other groups have 
reported large differences in production levels of mutants (14,15) We have no reason to believe that 
the small growth factor moiety disturbs the binding of protein A to IgG The extremely low production 
and specific activity of some chimeras was initially blamed exclusively on stenc hindrance by the 
protein A moiety and folding problems of these hybrids This seemed to be confirmed by the fact that 
measurement of the fully punfied proteins by the 125l-mEGF binding competition assay showed in 
several cases an increase of the amount of growth factor produced Earlier studies have seldomly 
shown, however, that N-terminal extensions of EGF caused effects on binding to the receptor (2,16) 
Other growth factors showed a significant decrease in activity after purification The identity of the 
carboxy-terminal domain seemed to predict the difference in activity EGF sequences in this domain 
causes a decrease, TGF-a residues an increase in activity after purification This effect can be 
attributed to a large extent to the deviating values obtained by the biotm-EGF competition assay (see 
below) 
The amount of fully purified biologically active growth factor was determined using a standard 
125l-mEGF binding competition assay on HER-7 cells This cell line expresses too little EGF-receptors 
to be used in assays using biotin-labeled tracers As a control, the activity of some purified growth 
factor proteins was also measured in the binding competition experiments using radiolabeled- and 
biotm labeled tracers and the growth inhibition experiment on A431 cells The activity of hTGF-a is 
almost identical to mEGF used as a standard in all four experiments, but the activity of other growth 
factors measured on A431 cells showed differences with the values obtained on HER-7 cells The fact 
that A431 cells bind EGF-like proteins differently from other human cell lines (12) may explain small 
differences between the concentrations measured on HER-7 and A431 In contrast, the concentrations 
measured in the competitive ELISA were seriously at variance with the values obtained in the three 
other assays This deviation explains to a large extent the extreme variations in the specific activities 
measured Specific activities calculated on the basis of the HER-7 binding competition show that the 
percentage of active growth factor when fused to protein A varies between 0 5-5% instead of between 
0 2 12 3% as calculated on the basis of the biotin-mEGF receptor binding competition assay The 
identical results found in the receptor binding competition assay and growth inhibition assay on A431 
cells show that the competitive binding assay can indeed be used as a measure for the biological 
activity of these chimeras 
Looking at the receptor binding activities measured by the competitive ELISA, there seems to be a 
relationship between the identity of the sixth domain and the activity of the growth factor Although the 
fact that TGF-a behaves like mEGF seems to indicate that hEGF sequences account for these 
differences, this seems very unlikely The amino acid sequence of mEGF is in only one position more 
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homologous to hTGF-ot than to hEGF: hTGF-o and mEGF have an aromatic residue at position 5 
resp. 3 whereas hEGF has a negative charge here. Unfortunately not all purified growth factors were 
measured in both binding competition assays. The comparison of the amount of activity of the 
chimeras measured in both assays does therefore not give conclusive evidence as to what growth 
factor domains are causing the deviating results in the competitive ELISA . 
The large spread in the specific activities of the different chimeras may, however, not be fully 
accounted for by the differences between the binding competition assays. Part of the low specific 
activity of some hybrids may be caused by folding problems of these proteins or by other reasons. 
Moreover, steric hindrance by protein A may not be identical in all fusion proteins measured. 
Looking at the differences between the competitive ELISA and the standard 1Z5l-mEGF binding 
competition assay, the most obvious differences are, that the ELISA is performed on fixed cells and 
only ligand receptor complexes residing at the cell surface are measured, while the radioreceptor 
assay is performed on unfixed cells and all cell bound activity is measured. Two effects could be 
imagined. First of all, a difference in affinity of the hybrids for the fixed and unfixed receptors. 
Secondly, differential processing and recyling of the hybrids in unfixed cells. An additional 
complication might be the production of TGF-a by live A431 cells (17). Experiments using iodinated 
tracer on fixed and unfixed cells excluded the differential binding of the hybrids to the fixed receptors. 
Effects of differential recycling have no influence on the results of these experiments as both the 
external and internal pools of ligand/receptor complexes are measured. The ELISAs performed on 
fixed and unfixed cells did not give a clearcut answer. This assay is more difficult to reproduce and 
different experiments are not always easy to compare due to differences in the enzyme reaction. If 
unfixed cells were used, the maximum value of the enzyme reaction on fixed cells was not reached, 
most likely due to the downregulation of the receptor. Experiments using 125l-labeled streptavidin on 
unfixed cells seemed to indicate clearly that a difference in affinity of binding to fixed and unfixed 
receptors was not the cause. The extra incubation with (strept)avidin also proved to be of no influence 
on the binding competition. 
The results we have presented, show that great care should be taken in using assays for the 
determination of EGF-like growth factor concentrations. A431 cells are known to differ in binding 
behaviour as well as in other respects from most cell lines, but the large discrepancies found using 
the biotin-mEGF assay were not predictable. We will use the ,25l-mEGF binding competition assay on 
HER-7 cells to calibrate the binding of chimeric proteins to the hEGF-receptor using purified mEGF as 
a standard. The growth factor proteins produced may even after purification by RP-HPLC contain 
some contamination by incorrectly folded and therefore inactive forms, but there is no indication that 
these will influence the biological activity measured. The activity of each hybrid and its counterpart will 
be tested for binding on the chicken-EGF receptor, known to bind EGF with much lower affinity 
(chapter 5). In the same way differences in biological activity will be tested, using systems 
discriminating the biological activity of two proteins. 
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CHAPTER 5 
IDENTIFICATION OF THE HIGH AFFINITY BINDING SITE OF 
TRANSFORMING GROWTH FACTOR-a (TGF-a) FOR THE CHICKEN 
EPIDERMAL GROWTH FACTOR RECEPTOR USING EGF/TGF-a 
CHIMERAS 
SUMMARY 
Human epidermal growth factor (hEGF) and human transforming growth factor-α (hTGF-a) are 
structurally related growth factors that share relatively little sequence homology They both exert their 
biological action by binding to the cell-surface EGF receptor. hEGF and hTGF-a bind with similar 
affinity to the hEGF receptor, but hEGF binds with an -100-fold lower affinity to the chicken EGF 
receptor compared with hTGF-a. To map the region in hTGF-a that confers its ability to bind with 
high affinity to the chicken EGF receptor, 10 hybrids of hEGF and hTGF-a were constructed by 
exchanging domains bordered by the thirth, fourth, and sixth conserved cysteine residues. The activity 
of the expressed chimeric proteins was determined by their ability to compete with 125l-mEGF for 
binding to NIH-3T3 cells transfected with the hEGF receptor. Subsequent binding competition studies 
of NIH-3T3 cells transfected with the chicken EGF receptor showed that chimeras carrying TGF-a 
sequences COOH-termmal from the sixth cysteine have a high affinity for this receptor, similar to 
hTGF-a. In contrast, chimeras with EGF sequences in this COOH-termmal domain have only low 
binding affinity, similar to hEGF. We conclude that the COOH-termmal linear region of hTGF-a is 
important for its high affinity interaction with the chicken EGF receptor. 
INTRODUCTION 
Epidermal growth factor (EGF) and transforming growth factor-α (TGF-a) belong to a family of 
growth factors that exert their action by binding to the EGF receptor (1,2) Members of this family are 
characterized by the presence of 6 almost identically spaced cysteine residues, and the correct 
disulfide bond formation of these cysteines has been shown to be essential for receptor binding and 
biological activity (1-3). Based on the cysteine spacing, EGF and TGF-a can be considered to be 
composed of six domains. Due to the formation of disulfide bridges, three loops are formed, linked to 
a linear NH2- and COOH-termmal stretch (1-3) EGF is particularly expressed in adult tissues and is 
found in high concentrations in saliva and urine (1,4) TGF-a is predominantly expressed in 
embryonic tissue and solid tumors, where it may play an important role in both paracrine and 
autocrine growth control (5). 
Many studies have been performed on the structure-function relationship of EGF and TGF-a based 
on site-directed mutagenesis and two-dimensional nuclear magnetic resonance (NMR) studies (1,6). 
Although individual amino acids relevant to biological activity have been identified in this way, 
relatively little information is available about domains in these molecules specifically involved in 
receptor binding, or in receptor activation (1,7,8) Studies using synthetic peptides corresponding to 
partial sequences of these growth factors (1,9), and approaches using specific antibodies against 
these proteins (10,12) have also not given conclusive evidence in this respect 
Recent studies by Lax et al. (13) have shown that the human EGF receptor binds EGF and TGF-a 
with similar affinity, but that the chicken EGF receptor binds EGF with much lower affinity than TGF-a 
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These authors have used this observation to identify the high affinity binding site for EGF/TGF-ct on 
the human EGF receptor by the use of chimeric human-chicken EGF receptors In this study, we have 
investigated which domains in hTGF-a are responsible for the high affinity interaction with the chicken 
EGF receptor Using a domain exchange strategy, we have constructed chimenc molecules of human 
EGF and TGF-ct that are bordered by the conserved cysteine residues. Here, we show that the linear 
COOH-terminal domain of TGF-oc is responsible for the high affinity interaction with the chicken EGF 
receptor, which indicates that this region of the growth factor plays a direct role in high affinity 
receptor binding 
EXPERIMENTAL PROCEDURES 
Preparation of constructs 
The gene coding for the mature 50-amino acid sequence of human TGF-cc (human codon use) was 
made using synthetic oligonucleotides and was linked to the sequence coding for the recognition 
sequence of the proteolytic enzyme Factor X (lle-Glu-Gly-Arg) at the 5'-end (14) Using the Bam HI 
site at the 5'-end and the Sal I site at the З'-end, the construct was cloned into the pHEMA 153 
expression vector (15) containing the heat inducible λΡ
Η
 promoter and the coding sequence of 
Staphylococcus aureus protein A including its signal sequence (a generous gift from Drs Η Engel 
and W Keck, University of Groningen, The Netherlands) The synthetic gene for human EGF 
(bacterial codon use) was obtained from British Biotechnology (Oxford, UK) and was coupled to the 
Factor X (FX) sequence in a similar way 
For chimeric constructs linked at the third cysteine, EGF was cleaved at this cysteine codon by 
Nsi I, and TGF-a by Pst I For chimeric constructs linked at the fourth cysteine, use was made of the 
common restriction site for Nsp I in EGF and TGF-a in this codon For chimeric constructs linked at 
the sixth cysteine, EGF was cleaved by Sph I at the fourth cysteine and TGF-a by Dra III at the sixth 
cysteine codon, filling in the gaps using synthetic oligonucleotides 
Expression and purification 
Growth factors and chimeric constructs were expressed as protein A/FX/growth factor fusion 
proteins in Escherichia coli KS474, a degP-protease deficient mutant (a generous gift from 
Drs К L Strauch and J Beckwith, Harvard University, see ref 16) Bacteria were grown in 2YTE 
(16 g bactotrypton, 10 g yeast extract, 8 g NaCI/liter) at 28 °C (16) The heat-shock procedure and 
isolation of penplasmic protein were performed as described (17) After purification on IgG-Sepharose 
(Pharmacia, Uppsala, Sweden), the amount of fusion protein recovered was measured by a 
competitive enzyme-linked immunosorbent assay using biotin-labeled protein A (18) The fusion 
proteins were digested by Factor Xa coupled to CNBr-activated Sepharose, and growth factors were 
purified by an additional run on IgG-Sepharose Multimene forms of the growth factors were removed 
by gel-permeation chromatography on a Bio-Gel P10 column (BioRad Laboratories, Richmond, CA) in 
1 M HAc, while correctly folded protein was largely purified from inactive disulfide bridge mismatches 
by reverse-phase chromatography on a 3 0 χ 0 21 cm RP-300 Aquapore Octyl column (Brownlee 
Laboratories, Santa Clara, CA) Biological activity in the column fractions was assayed using an A431 
cell growth inhibition assay (19) or a biotm-EGF binding competition assay using this cell line (20) 
1251-EGF binding assay 
NIH-3T3 cells transfected with the human EGF receptor (HER-7 cells) or the chicken EGF receptor 
(CER-109 cells) were a generous gift from Dr J Schlessinger (New York University) Mouse EGF 
(Bioproducts for Science Ine , Indianapolis) was lodinated using Enzymobeads (BioRad) to a specific 
activity of - 500 Ci/mmole (21) For EGF binding assays, HER-7 cells were grown to confluency in 
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gelatinized 24-well dishes (1.8 cm2) and CER-109 cells in 6-well dishes (9.8 cm2). 1iSl-mEGF was 
added to HER cells (0.1 ng/100 μΙ) and CER cells (10 ng/250 μΙ) in serum-containing Dulbecco's 
modified Eagle's medium buffered at pH 7.7 in addition to serial dilutions of unlabeled growth factors. 
After incubation for 2 h at room temperature, cells were washed twice with icecold phosphate-buffered 
saline (PBS), 0.1 % bovine serum albumin, once with icecold PBS and were incubated subsequently 
in 1 % Triton X-100 for 1 h at room temperature prior to gamma counting. 
RESULTS 
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Figure 5.1. Chimeric hEGF/hTGF-a polypeptides. White boxes 
denote EGF sequences and black boxes indicate TGF-a 
sequences. Domains are denoted by Roman numerals. 
A total of ten chimeric growth factors of 
hEGF and hTGF-a were constructed by 
exchanging domains bordered by the third 
fourth and sixth cysteine residue. A survey of 
these chimeras is shown in Fig. 5.1. According 
to the nomenclature used, E3T designates a 
protein with EGF sequences NH2-terminal and 
TGF-a sequences COOH-terminal of the third 
cysteine. The other mutants were named 
accordingly. Based on this cysteine spacing, 
EGF, TGF-a and derived mutants can be 
considered to be composed of six domains. 
These domains are indicated by Roman 
numerals in Fig. 5.1. 
It is well established that hEGF and hTGF-a 
bind with similar affinity to the hEGF receptor 
present in HER cells (13). It cannot be 
excluded that the recombinant growth factor 
preparations obtained still contain inactive mis­
matches. We have therefore calibrated the 
activity of the various chimeric growth factors 
based on their ability to give 50% competition 
of 125l-mEGF binding to HER cells. Assuming 
that the various mutants have similar binding 
affinity for these cells, their activity was 
subsequently expressed in nanogram equi­
valents of mEGF. 
It is well established from studies based on 
site-directed mutagenesis (1,6) and on the use 
of synthetic peptides (9) that the loop 
structures corresponding to domains IV and V 
of EGF and TGF-a are particularly important 
for biological activity. We therefore first 
concentrated on mutants that were obtained by 
exchanging domains at the third and fourth 
cysteines, as listed in the upper part of Fig. 5.1. 
It is shown in Fig. 5.2 that after calibration of the active growth factor concentrations for this set of 
chimeras, their dose-response curves for binding competition with 1Ml-mEGF on HER cells nearly 
coincide with half-maximal displacement at 7.5 ng/ml. 
grow» t»ctof concenfcXion (ng/ml) 
Figure 5.2. Inhibition of binding of , Kl-mEGF to HER-7 celts fay 
mEGF, hEGF. hTGF-a, and hEGF/hTGF-a hybrids. The 
concentrations of the unlabeled growth factors mEGF (>—•), 
hEGF (A A), hTGF-a ( • A), E3T ( • • ) , T3E (•—•), 
E4T ( • • ) , T4E ( • T), T3E4T (+ +), and E3T4E (+-+) 
are expressed in nanogram equivalents of mEGF/milliliter. 
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Figure 5.3. Inhibition of binding of 125l-mEGF to CER-109 cells ЩЧ№ 5.4. Inhibition of binding of 125l-mEGF to CER-109 cells 
by mEGF, hEGF, hTGF-a, and hEGF/hTGF-a hybrids. The by mEGF (·—·), hEGF (A—A), hTGF-a (A A), E6T 
concentrations of the growth factors and symbols are as ( · · ) . T6E ( · — · ) , T4E6T (• '•), and E4T6E (•"•). 
described for fig. 5.2. 
Fig. 5.3 shows dose-response curves of these various mutants for binding competition with 
,25l-mEGF to the chicken EGF receptor present on CER-109 cells. It is shown that hTGF-a competes 
for binding to the chicken EGF receptor with an affinity near to that observed for the human EGF 
receptor, in agreement with the data of Lax et al. (13). mEGF binds the chicken EGF receptor with 
low affinity showing half maximal inhibition of binding at -500 ng/ml unlabeled ligand. This is in 
agreement with the binding data of Lax et al. (13) and with studies on mitogenic stimulation of chicken 
cells by mEGF (22). Interestingly, our data show that hEGF is a better competitor of 125l-mEGF for 
binding to the chicken EGF receptor than mEGF, although the affinity is still significantly lower than 
that observed for TGF-ot. No such difference between mEGF and hEGF was reported previously by 
Avivi et al. (23). 
The data of Fig. 5.3 also show that those mutants that have TGF-a sequences COOH-terminal of 
the fourth cysteine (E3T, E4T, and T3E4T) have a high affinity for the chicken EGF receptor, similar 
to TGF-a. In contrast, the mutants with EGF sequences COOH-terminal of the fourth cysteine (T3E, 
T4E, and E3T4E) have a low affinity for the chicken EGF receptor, similar to EGF. It can therefore be 
concluded that the difference in binding affinity for the chicken EGF receptor between EGF and 
TGF-a resides in the domains V and VI of these molecules and that the nature of the loop structure 
that contains domain IV is not relevant for this process. 
To assess in more detail which domains in EGF and TGF-a are involved in this difference in 
binding affinity, additional chimeric mutants were made by exchanging domains at the sixth cysteine. 
The structure of the chimeras obtained is listed in the lower part of Fig. 5.1. Their activity was 
calibrated again based on the ability to give 50% competition of 125l-mEGF binding to HER cells, 
resulting in dose-response curves for binding to the hEGF receptor similar to those shown for the 
mutants in Fig. 5.2. The data presented in Fig. 5.4 show that mutants with a TGF-a sequence COOH-
terminal of the sixth cysteine (E6T and T4E6T) have a high binding affinity for the chicken EGF 
receptor, similar to TGF-a. In contrast, the mutants with an EGF sequence COOH-terminal of the 
sixth cysteine (T6E and E4T6E) have a low binding affinity for this receptor, similar to hEGF. It can 
therefore be concluded that the linear COOH-terminal region of EGF and TGF-a (domain VI) 
determines their difference in binding affinity for the chicken EGF receptor and that the loop structure 
corresponding to domain V is not relevant for this process. 
66 
DISCUSSION 
In this study, we have shown by a domain exchange strategy that the COOH-termmal linear region 
of EGF and TGF-oc determines their relative binding affinity for the chicken EGF receptor It is well 
established from NMR studies that the three-dimensional structures of EGF and TGF-a in solution are 
very similar (6) Moreover, studies on the human and chicken EGF receptors have shown that their 
presumed ligand-bindmg domains are highly homologous (23) Therefore it is very likely that similar 
domains of EGF and TGF-a interact with corresponding regions in these receptor molecules Our 
results therefore strongly suggest that the linear COOH-termmal region of TGF-a and EGF contains 
ammo acids which are directly involved in receptor binding 
Interestingly, domain VI of TGF-a has a net negative charge under physiological conditions, while 
that of EGF has a net positive charge A neutral amino acid is present at position 359 (which is well 
within the ligand binding domain) in the human and mouse EGF receptors, while a lysine is present in 
the chicken EGF receptor (23) This may therefore result in charge repulsion of domain VI of hEGF 
and mEGF without affecting the affinity for TGF-a Recent NMR experiments have indicated that the 
conformation of the COOH-termmal linear domain of EGF is particularly pH-sensitive Most likely as a 
result of deprotonation of Asp46, this region shows less flexibility in solution at neutral pH than at low 
pH (24) Since this amino acid is conserved in TGF-a it does not seem likely that conformational 
differences between EGF en TGF-a are responsible for the difference in affinity for the chicken EGF 
receptor 
Site-directed mutagenesis studies have indicated that Tyr38 and Leu48 are part of the receptor-
binding domain of TGF-a and that, in addition to Asp46, also Arg42 is essential for biological activity 
(7) The homologous residues in EGF have been shown to have similar importance (8) Other amino 
acids in this COOH-termmal region are relatively indifferent toward mutation, at least when judged for 
binding affinity for human and rodent EGF receptors (1,7,8) No such studies have as yet been 
performed for the chicken EGF receptor Present investigations are aimed at exchanging individual 
amino acids in domain VI between EGF and TGF-a to analyze their role in binding affinity for the 
chicken EGF receptor It has been established that the amino acids COOH-termmal of Leu47 in EGF 
are dispensable for biological activity (25) It is therefore tempting to speculate that the relevant ammo 
acids are located in domain VI, NH2-terminal of Leu47 
The approach of exchanging domains between homologous ligands with different biological 
activities to map receptor-binding domains has been used before in the case of interleukm-5 (26), 
platelet-denved growth factor (27), and various other cytokines (28) It is expected that chimeras of 
closely related molecules will fold to an active conformation similar to that of the wild type proteins, 
which is illustrated by the fact that a chimera of vaccinia growth factor and TGF-a is biologically active 
(29) Domain exchange approaches particularly focus on variant residues in the proteins under 
investigation, which are generally of minor importance for the overall structure Moreover, the 
introduction of relevant ammo acids is detected by an increase in biological activity, which contrasts 
with the reduction in biological activity generally observed in site-directed mutagenesis studies 
Furthermore, such mutation studies are mainly focussed on conserved residues, risking an impact on 
protein conformation 
Site-directed mutagenesis studies of Walker et al (30) have shown that EGF mutants with low 
receptor binding affinity can still induce a complete mitogenic response, similar to non-mutated EGF 
This might indicate that distinct domains within these growth factor molecules can be responsible for 
receptor binding and receptor activation Preliminary results show that the chimeras presented in this 
study may bind HER cells with similar affinity, but induce growth stimulation of these cells to different 
extents, ranging from weakly agonistic to superagonistic (data not shown) We are currently 
investigating how the various domains in these chimeric proteins are involved in the mitogenesis 
process Such identification of receptor-binding and receptor-activating domains is a prerequisite for 
the further development of EGF receptor antagonists 
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CHAPTER 6 
SUPERAGONISTIC ACTIVITY OF EGF/TGF-a CHIMERIC PROTEINS 
ON CELLS EXPRESSING THE HUMAN, BUT NOT THE CHICKEN 
EGF-RECEPTOR 
SUMMARY 
The biological activity of mouse and human EGF, hTGF-a and ten hEGF/hTGF-a chimeras was 
tested by measuring their stimulation of 3H-thymidine incorporation in cells expressing the human or 
chicken EGF-receptor All growth factor proteins were calibrated to give equal displacement of 
radiolabeled mEGF on the cell lines expressing the human EGF-receptor. Three chimeras, E3T, E4T 
and T3E4T, showed an Θ- to 20-fold higher biological activity than purified mEGF and the other 
growth factor proteins on cells transfected with the human EGF-receptor (HER cells) as well as on 
human keratinocytes (HaCaT cells) normally expressing this receptor. On chicken adipocyte precursor 
cells, the large differences in affinity of the EGF/TGF-a chimeric proteins for the chicken EGF-
receptor were reflected in their mitogenic activity, without signs of superagonistic activity of any of the 
growth factor proteins. On CER-109 cells, however, most chimeras showed higher biological activity 
than expected on the basis of their affinity, most notably those with a very low binding affinity. This is 
probably due to the presence of low levels of endogenous mouse EGF-receptors in this cell line 
These results indicate that binding affinity and biological activity of EGF-like molecules can be 
separated and that the chicken and human EGF-receptor differ in their ability to transmit growth 
stimulatory signals into the cell 
INTRODUCTION 
EGF and TGF-a bind the mammalian EGF-receptor with equal affinity (1). Binding of these ligands 
triggers a conformational change of the receptor followed by homologous or heterologous 
dimenzation, activation of its cytoplasmic tyrosine kinase actvity and the propagation of a mitogenic 
signal to the cell nucleus by a cascade of cytoplasmic signals, among which many phosphor-
ylation/dephosphorylation events (1-3) The proliferation of mammalian cells expressing the EGF-
receptor is stimulated by EGF and TGF-a to an equal extent, as measured under in vitro assay 
conditions (1) Differences in mitogenic activity between EGF and TGF-a have, however, been 
observed on cells expressing the chicken EGF-receptor EGF binds with about 100-fold lower affinity 
to the chicken EGF-receptor than TGF-a and shows a concomitant 100-fold lower mitogenic 
stimulation on cells expressing this receptor (4,5). In studies on the structure-function relationship of 
EGF-like molecules a close correlation has generally been observed between binding affinity and 
mitogenic activity (1,6). 
We have used Е6РЯСР-а chimeras to locate the domain of TGF-a responsible for the high-affinity 
binding to the chicken EGF receptor by performing binding competition assays on NIH-3T3 cells 
transfected with the chicken EGF-receptor (CER-109) cells (chapter 5). The concentration of the 
chimeras used in these assays was calibrated in binding competition assays on the HER-7 cell line, 
using purified mouse EGF as a standard (chapter 4) These chimeras show therefore identical affinity 
for the human EGF-receptor, but show large differences in affinity for the chicken EGF-receptor We 
have now tested the mitogenic activity of these chimeras in 3H-thymidme incorporation assays on cells 
transfected with, and cells normally expressing the human and chicken EGF-receptors, in order to 
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establish if a correlation exists between their biological activity and binding affinity for the two 
receptors. We have found that the large differences in affinity of the growth factor proteins for the 
chicken receptor are well reflected in their mitogenic stimulation of chicken adipocyte cells. On cells 
expressing the human EGF-receptor in contrast, we found that three chimeras show an 
approximately tenfold enhanced mitogenic stimulation, despite their equal apparent affinity for the 
human receptor. The mitogenic stimulation measured in CER-109 cells does not reflect affinity 
differences and seems to be partly mediated by the low level of endogenous mEGF-receptors, 
probably showing equal (high) affinity for all chimeras. 
EXPERIMENTAL PROCEDURES 
Materials 
hEGF, hTGF-cc and the EGF^GF-oc chimenc proteins were constructed, expressed in Escherichia 
coli (E coli) and purified as described in chapters 2 and 3 Quantification was performed by 
calibration for binding competition with 125l-mEGF to HER-7 cells as described in chapter 4. Purified 
mEGF was purchased from Collaborative Research Inc. NIH-3T3 cells (clone 2.2) transfected with the 
human EGF-receptor (HER cells), or with the chicken EGF-receptor (CER-109 cells) were a generous 
gift from Dr. J Schlessmger (New York University). HER-7 cells express 6.0 χ 10s, HER-14 3.0 χ 105 
and CER-109 5.5 χ 104 receptors/cell (7) The human keratinocyte cell line HaCaT expressing the 
human EGF receptor (8) was a generous gift from Dr Ν E Fusenig (Deutsches Krebsforschungs 
Zentrum, Heidelberg). 
Binding competition assays 
Binding competition assays were performed as described (chapter 4). 
3H-Thymidine incorporation 
HER-7, HER-14 or CER-109 cells were seeded in gelatinized 24-well dishes (1.8 cm2) at a density 
of 6 0 χ 10" cells/well and grown for 24 hours in bicarbonate-buffered Dulbecco's modified Eagle's 
medium (DMEM/Bic) supplemented with 10 % newborn calf serum (NCS), after which the medium 
was replaced by 0 9 ml of Ham's F12/DMEM (1Ί) supplemented with 30 nM Na2Se03, 10 цд/ті 
human transferrin and 0.5 % bovine serum albumin (BSA). After an additional 48 hours of incubation, 
serial dilutions of recombinant growth factors were added in 100 μΙ DMEM containing 0.1 % of BSA 
and buffered at pH 6.8 with 50 mM BES (N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid; Sigma 
Chemical Corporation) Eight hours later 0.5 цСі 3H-thymidine (43 Ci/mmol) was added in 100 μ I 
Ham's F-12 medium Incorporation of the tracer into the cellular DNA was determined 24 hours after 
growth factor addition, as described (9). 
HaCaT cells were seeded at a density of 3.0 χ 10" cells/well and reached 50 % confluency after 
3 days of growth in DMEM/Bic supplemented with 10% NCS. The medium was replaced by 0.9 ml 
bicarbonate buffered DMEM/Ham's F-12 (1:1) medium supplemented with 30 nM Na2Se03, 10 μΙ/ml 
human transferrin and 0.5% BSA, and cells were incubated for 24 hours. At this time the medium was 
replaced by fresh medium and serial dilutions of growth factors were added in 100 μΙ of DMEM/BES 
(pH 6.8). 3H-Thymidme incorporation was determined 24 hours after growth factor addition as 
described (9). 
3H-Thymidme incorporation studies on chicken adipocyte precursor cells were performed by 
Dr. S С. Butterwith and co-workers at the AFRC Institute of Animal Physiology and Genetics 
Research, Edinburgh Research Station, Roslm, UK, as described (5). 
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Figure 6.1. Mitogenic stimulation of HER-14 cells by hEGF, Figure 6.2. Stimulation ot 3H-thymidine incorporation by hEGF, 
hTGF-a and ten EGF/TGF-α chimeric proteins as measured hTGF-a and EGF/TGF-a chimeric proteins in a human 
by the incorporation of 3H-thymidine into the nuclear DNA. keratinocyte cell line (HaCat cells). Data are expressed relative 
Growth factor concentration was determined in binding to stimulation by 9 % FCS. Growth factors are indicated as 
competition assays on HER-7 cells using purified mEGF as a described in the legend of figure 6.1. 
standard, and are therefore ng equivalents of mEGF. Data are 
expressed relative to stimulation by 9 % fetal calf serum 
(FCS). Growth factors shown are: hEGF A A), hTGF-a (A 
A), E3T ( • • ) , T3E ( • • ) , E4T ( • T) , T4E ( • • ) , 
E6T ( · · ) , T6E ( · · ) , E3T4E ( + - + ) , T3E4T (+ +), 
E4T6E p — • ) and T4E6T ( • Ш). 
RESULTS 
hEGF, hTGF-a and ten EGF/TGF-α chimeric proteins were produced, and their concentration 
calibrated in binding competition assays on HER-7 cells, using purified mEGF as a standard 
(chapter 4). In order to establish if all of these growth factor proteins show identical biological activity, 
corresponding to their equal binding affinity, mitogenic stimulation assays were performed on HER-14 
cells. This cell line was preferred above the HER-7 cell line, while it showed a lower basal 
3H-thymidine incorporation than HER-7 cells (not shown, see also ref, 7). From binding competition 
assays it was concluded that the growth factor proteins also show equal binding affinity on HER-14 
cells (not shown). Figure 6.1 shows dose-response curves of a 3H-thymidine incorporation assay on 
HER-14 cells, indicating that most growth factor chimeras show an identical mitogenic activity as the 
wild-type growth factors. There were, however, three exceptions: the ЕС
Ю
 of E3T, E4T, and T3E4T is 
about 8-20 times lower than that of the other growth factors. Comparable results were obtained with 
HER-7 cells (not shown). To exclude the possibility that this result was artifactual due to the use of 
transfected cells, the experiment was repeated on the human keratinocyte cell line HaCaT. After 
having established that the growth factor proteins showed identical affinity on this cell line, it was 
demonstrated that E3T, E4T and T3E4T also show superagonistic activity on this cell type, whereas 
the other chimeras show identical activity as the wild type recombinant growth factors and purified 
mEGF (fig. 6.2). From these experiments it can be concluded, that E3T, E4T, and T3E4T have a 
higher biological activity than the wild type growth factors and the other chimeras at a similar receptor 
occupation. 
EGF, TGF-a and the chimeras show over 100-fold differences in binding affinity for the chicken 
EGF-receptor (table 6.1), see also chapter 5). We have therefore also tested if these affinity 
differences are reflected in the mitogenic stimulation of cells expressing the chicken EGF-receptor. As 
shown in figure 6.3 and table 6.1, hEGF and TGF-a stimulate 3H-thymidine incorporation to 
approximately the same level in CER-109 cells (EC50 of 2.5 and 2 ng/ml respectively), despite their 
large difference in affinity for this receptor (IC50 of 100 and 8 ng/ml respectively), whereas mEGF is 
less active. In table 6.1 the binding affinity and mitogenic activity of the growth factor proteins are also 
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mEGF 
hEGF 
hTGF-α 
E3T 
E4T 
E6T 
T3E 
T4E 
T6E 
ЕЭТ4Е 
T3E4T 
E4T6E 
T4E6T 
CER-109 CELLS 
ІС
Ю
 (ng/ml) relative EC M (ng/ml) relative 
binding affinity mitogerucity 
(%) (%) 
500 2 22 9 
100 8 2 5 80 
8 100 2 100 
2 400 0 2 1000 
4 200 0 07 3000 
9 90 1 2 170 
100 β 2 5 80 
50 16 1 3 150 
70 11 ND ND 
250 3 1 3 150 
2 400 0 2 1000 
70 11 ND ND 
8 100 1 2 170 
CHICKEN ADIPOCYTE 
PRECURSOR CELLS 
ЕСя, (ng/ml) relative mito-
genicity 
(%) 
> 10 < 3 
> 10 < 3 
0 3 100 
0 07 400 
0 2 150 
0 3 100 
> 10 < 3 
> 10 < 3 
4 8 
ND ND 
ND ND 
> 10 < 3 
0 3 100 
Table 6 1 The concentration of the different growth factor proteins giving half-maximum inhibition of binding (IC^J of ,25l-mEGF 
on CER-109 cells is shown, and concentrations giving half maximum mitogenic simulation (ECM) on CER-109 and chicken 
adipocyte precursor cells, as measured by °H-thymidine incorporation into the nuclear DNA The relative binding affinity (cq 
mitogenicity) is expressed as the І С
Я
 (ЕС
Ю
) of TGF-α divided by the IC M (ЕС») of the growth factor protein χ 100 % The 
concentrations of the growth factors were based on their \С
Ж
 on HER-7 cells and are therefore ng equivalents of mEGF 
binding/ml rather than protein mass concentrations 
shown relative to TGF-oc, which has an equal binding affinity for the human and chicken receptor 
E3T, E4T and T3E4T, which showed superagonistic activity on HER cells, also show higher activity 
on CER-109 cells than expected on basis of their affinity for the chicken EGF-receptor, but so do EGF 
and the chimeras with EGF sequences in their C-terminal tail which show low affinity for the receptor 
The unexpectedly high mitogenic activity of chimeras showing low affinity for the chicken EGF-
receptor might be explained by the presence of low levels of endogenous mouse EGF-receptors (3-10 
χ 103 receptors/cell) in the parental NIH-3T3 cell line, which is not mitogenically stimulated by EGF. 
To exclude that our results were influenced by the presence of these endogenous mouse EGF-
receptors, which have the same affinity for EGF and TGF-α as the human receptor, the experiment 
was repeated on pnmary chicken adipocyte precursor cells expressing the EGF-receptor. In this 
experiment all growth factor proteins show an ECS0 in a mitogenic assay, that is proportional to their 
binding affinity for CER-109 cells, using TGF-α as a standard (table 61). No superagonistic activity of 
E3T, E4T, and E3T4T was observed on this cell line. The affinity of the chimeras for the chicken 
adipocytes has not been tested directly, but is expected not to deviate significantly from the results 
obtained on CER-109 cells It can therefore be concluded that after binding of E3T, E4T or T3E4T an 
enhanced mitogenic activity signal is mediated by the human-, but not by the chicken EGF-receptor. 
DISCUSSION 
In this study we have tested the correlation between mitogenic activity and binding affinity of mEGF, 
hEGF, hTGF-a and ten EGF/TGF-a chimeras on cells expressing the human or chicken EGF-
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Figure 6 3 Stimulation of 3H-thymidine incorporation by hEGF, Figure 6 4 Stimulation of 3H-thymidine incorporation by EGF 
hTGF-a and EGF/TGF-o chimeric proteins in CER 109 cells TGF-o and EGF/TGF-a chimeric proteins in chicken adipocyte 
Data are expressed relative to stimulation by 9 % FCS Growth precursor cells in culture Data are expressed relative to 
factors are indicated as described in the legend of figure 6 1 stimulation by 4 % Ultroser (Life Technologies UK) Growth 
factors are indicated as described in the legend of figure 6 1 
receptor On HER- and HaCaT cells, expressing the human EGF-receptor, three of the chimeras 
(E3T, E4T, and T3E4T) showed mitogenic activities that were about 8 to 20 times higher than 
expected on the basis of their binding affinity, while the other chimeras and growth factors showed a 
good correlation between binding and activity In these experiments the binding affinity was calibrated 
in binding competition experiments using mEGF as a standard, and the amount of growth factor 
protein expressed in ng equivalents of mEGF per ml Recent expenments have shown, that the 
concentration determined by binding competition of one of these proteins (E4T) corresponds with its 
protein concentration as represented by the area of its HPLC-peak measuring the absorption at 
229 nm (M van de Poll, pers comm) It may therefore be expectated, that also the mitogenic activity 
of these chimeras measured per weight unit of protein, is higher than that of EGF and TGF-a Also 
the fact that the mitogenic activity of the chimeras on chicken adipocyte precursor cells reflects their 
binding affinity for the chicken EGF-receptor, indicates that the enhanced mitogenic activity on human 
cells of some chimeras is not just the consequence of an error in the quantification Further evidence 
for true superagonistic activity comes from preliminary experiments which showed that the 
superagonistic activity of E3T and E4T is reflected in a more rapid phosphorylation of the intracellular 
substrate MAP kinase in HER cells (M van der Poll, pers comm ) The biological activity of E3T, 
E4T, their complements and the wild type growth factors has also been tested in the growth inhibition 
assay on A431 cells, but no discrepancy was observed between binding affinity and activity on this 
cell line (chapter 4) On A431 cell line the displacement curves of E3T and E4T showed, however, a 
deviating behaviour (see chapter 4) 
Little correlation between binding affinity and biological activity was found on CER-109 cells, mouse 
fibroblasts transfected with the chicken EGF-receptor Most notably hEGF and all chimeras showing 
low affinity on the chicken EGF-receptor showed a much higher biological activity than expected The 
high biological activity of these growth factors can well be explained by the presence of a low level of 
endogenous mouse EGF-receptors (3-10 χ 103 receptors per cell) These receptors show, like the 
human EGF-receptor, an approximately 100-fold higher affinity for EGF than the chicken EGF-
receptor Although no phosporylation of the endogenous receptors or mitogenic stimulation can be 
measured in the parental cell line, their tyrosine kinase activity is most likely able to cross-
phosphorylate the approximately 5 5 χ 10" transfected chicken EGF-receptors in CER-109 cells, 
resulting in a significant amplification of the signal of the mouse receptors This mechanism has also 
been proposed to occur after the transfection of kmase-negative EGF-receptors in the same parental 
cell line (10) The observation that the mitogenic activities of the chimeras and growth factors are 
comparable on CER-109 cells and mouse fibroblasts (M van de Poll, pers comm ), indicates that the 
mitogenic signal measured in CER-109 cells originates from the mouse EGF-receptor 
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In contrast to the results on the human cell lines, none of the chimeras showed enhanced 
stimulation of the chicken adipocyte precursor cells This indicates that a difference exists between 
the chicken and human receptor not only in binding affinity for EGF, but also in the efficiency of signal 
transduction afetr binding of the three superagonists 
The finding that binding affinity and biological activity can be separated is important for the 
construction of a receptor-antagonist This can only be performed successfully, if the domains 
responsible for receptor binding and receptor activation are located in different areas of the growth 
factor molecule Walker et al (11) have reported earlier an EGF-mutant (L47V) with a large difference 
between binding affinity and biological activity This mutant showed a 100-fold lower affinity than 
mEGF, but identical mitogenic activity on Balb/c 3T3 cells (11) 
In chapter 10 a working-model for the mechanism of superagonist activity will be presented, 
explaining the superagonistic activity of the three chimeras on human cells and their lack of 
superagonistic activity on the chicken adipocyte precursor cells The elucidation of the mechanism 
resulting in superagonistic activity could provide leads for the design of other superagonists and 
antagonists 
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CHAPTER 7 
pH-DEPENDENT RECEPTOR BINDING AFFINITY OF EGF/TGF-cc 
CHIMERAS DETERMINES THE INTRACELLULAR FATE OF THE 
EGF-RECEPTOR AFTER LIGAND-INDUCED INTERNALIZATION 
The Involvement of Histidlne Residues in Receptor Recycling 
SUMMARY 
EGF induces an almost complete downregulation of the EGF-receptor, while a high percentage of 
the EGF-receptor population is recycled after TGF-a binding. This phenomenon was attributed to the 
difference in pi between EGF and TGF-ot by Ebner and Derynck (18) and hypothesized to be the 
explanation for a quantitative difference in biological activity between these growth factors in some 
assay systems We have measured the pH sensitivity of binding of ЕвРЯСЕ-а chimeras, having 
widely varying pis, relative to 125l-mEGF in order to test this hypothesis The chimeras showed a large 
variation in affinity of binding at low pH, but no correlation was found with their pis Their receptor 
affinity at low pH could rather be correlated with the presence of specific histidine residues within the 
domains derived from the TGF-a sequence These histidine residues are found in the hypothetical 
binding domain and may affect binding after protonation at low pH by charge repulsion or disruption of 
the binding domain The fraction of receptors that recycles after ligand binding was tested in binding 
assays in the presence or absence of monensin, an inhibitor of recycling This assay and the rate of 
receptor recovery after incubation with the different ligands showed a clear correlation with the 
receptor affinity at low pH Despite high levels of recycling the large majority of the EGF-receptor 
population is degraded after long incubations with ligand, irrespective of the ligand tested 
INTRODUCTION 
Epidermal growth factor (EGF) and transforming growth factor-α (TGF-a), two 6 kDa polypeptides, 
bind with equal affinity to the human EGF-receptor and show comparable mitogenic stimulation in in 
vitro assays on human cell lines expressing EGF-receptors (1) Studies using site-directed 
mutagenesis (1,2), synthetic peptides representing partial sequences of these growth factors (3,4 and 
references therein), monoclonal antibodies directed against various domains of these proteins (5-7) 
and EGF/TGF-a chimeras (chapter 5) have been performed to locate the domains responsible for 
binding to and activation of the receptor Domains and residues that are involved in biological activity 
have been located, but these experiments have not been able to distinguish between domains 
involved in binding and in receptor activation The observation that mutants can be designed which 
show low affinity, but normal activation of the receptor seems to indicate that binding and activation 
reside in separate domains (8,9) 
Although EGF and TGF-a show the same biological activity in most in vitro assays, evidence has 
been presented that the biological activity of TGF-a differs from that of EGF in some in vivo and in 
vitro assays on mammalian cells TGF-a shows a ten- to one hundred fold higher activity in the 
stimulation of bone resorption in fetal rat lung bones (10), the inhibition of alkaline phosphatase 
activity in cultured rat osteosarcoma cells with an osteoblast phenotype (UMR-106 cells,10), the 
inhibition of parathyroid hormone-responsive adenylate cyclase activity (11) in UMR-106 cells, the 
stimulation of anchorage-independent growth in pancreatic carcinoma cells (PANC-1, ASPC-1 and 
T3M4 cells,12), the healing of second degree burns on pig skin (13), angiogenesis in the hamster 
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cheek pouch assay (14), cell migration of keratmocytes (15) and prostacyclin production by cultured 
human vascular endothelial cells (16) It has been suggested that the difference in biological activity of 
EGF and TGF-a in the above assay systems is not caused by a difference between the activation 
domains of the growth factors leading to different activated states of the receptor, but by a difference 
in processing of the hgand-receptor complex after hgand-induced internalization (17). Binding of EGF 
to the receptor causes complete receptor down-regulation: the hgand-receptor complex is internalized 
and degraded in the lysosomes, resulting in the (almost) complete disappearance of the receptors 
from the cell surface and a net loss of receptors from the cell. TGF-a on the other hand induces 
recycling of a large proportion of receptor and ligand after internalization of the hgand-receptor 
complex This has been attributed to the relatively high isoelectric point (pi) of TGF-a, causing a low 
affinity of binding to the receptor at acidic pH (17). This would cause the release of the ligand from 
the receptor in a mildly acidic intracellular compartment shortly after internalization, and result in 
recycling of the majority of the intact ligand and receptor to the cell surface. EGF on the contrary, 
having a lower pi, would not be released from the receptor even in the more acidic compartments on 
the route to the lysosome, resulting in the degradation of the majority of ligand and receptor in this 
compartment The complete degradation of the EGF-receptor after binding of EGF but partial 
resistance to degradation after binding of TGF-a, has indeed been observed by several authors 
(17-19) 
In this study, we have used EGF/TGF-a chimeras to verify this model The assumption that the 
general pi of the growth factor determines the affinity for the receptor at low pH was based on 
experiments with only two proteins. We have tested the receptor binding affinity of ten chimeras 
having widely varying pis ranging between 5 5 and 7 7. Our data indicate that not the overall pi but 
the presence of certain domains seems to determine the binding affinity at low pH The down-
regulation, recycling and degradation of the EGF-receptor after binding of the chimeras was tested 
and the results were related to the binding at low pH The chimeras could be distinguished in clearly 
EGF-hke, TGF-a-like and intermediate groups. The involvement of specific His residues in the 
biological activity of TGF-a will be discussed 
EXPERIMENTAL PROCEDURES 
Materials 
Purified mEGF (culture grade) purchased from Collaborative Research Ine was used as a standard 
in all assays Other growth factors and growth factor hybrids were expressed in Escherichia coli and 
purified as described (chapters 2 and 3). ,25l-mEGF, a generous gift from Dr. ThJ Benraad and 
mr J J Τ M Heuvel was prepared as described (20). The polyclonal anti-peptide antibody 281 -7, 
directed against an internal domain of the human EGF-receptor (21), was a generous gift from 
Dr L Η К. Defize, Hubrecht Laboratory, Utrecht L-35S-methionme, in vivo cell labelling grade, was 
obtained from Amersham Monensin was purchased from Fluka Protein A-Sepharose was obtained 
from Pharmacia 
Binding assays 
125l-mEGF binding competition assays on NIH-3T3 cells transfected with the human EGF-receptor 
(HER-7 cells) were performed as described in chapter 4 The binding buffer (DMEM/Bic/HEPES/ 
10%FCS, pH 7 7) was adjusted with HCl to lower pH values in the pH-dependent binding 
experiments when indicated 
Receptor downregulation experiments were performed on HER-7 cells plated to a density of 
1 1x105 cells per well in gelatinized 24-well dishes (1.8 cm2) After one day the bicarbonate-buffered 
Dulbecco's modified Eagle's medium (DMEM/Bic) containing 10 % fetal calf serum (FCS) was 
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replaced by SATO medium (DMEM/HAM's F12 medium 1:1, supplemented with 30 nM Na2Se03 and 
10 цд/rnl transferrin) and cells were cultured for another day. Subsequently, the medium was replaced 
by 150 μΙ DMEM/Bic/10 % FCS containing 15 ng growth factor protein per well, with or without 
monensm to a final concentration of 0.3 mM, and the incubation was prolonged for variable periods of 
time at 37 °C. The bound growth factors were removed by two acid washes (5 mM acetic acid, 
135 mM NaCI, 2.5 mM KCl, pH 4.0) and two washes with binding buffer (pH 7.7). The cells were sub­
sequently incubated for 30 mm with 0 1 ng ,25l-mEGF in 100 μΙ DMEM/Bic/HEPES/FCS, pH 7 7 at 
room temperature, and washed as described above for the binding competition assay, after which the 
radioactivity bound was determined in a gamma counter. 
Receptor recovery experiments were performed on HER-7 cells plated and grown as described for 
the downregulation experiment. The SATO medium was replaced by 100 μ I DMEM/Bic/10 % FCS 
containing 25 ng growth factor protein per well and after incubating for two hours at 37 °C the bound 
growth factors were removed by two acid washes and two washes with binding buffer (see above). 
After incubation of the cells with 150 μΙ binding buffer for various periods of time at 37 °C, 0.1 ng 
125l-mEGF was added in 100 μΙ binding buffer and the cells were incubated for 30 mm at room 
temperature The cells were washed and bound radioactivity determined as described above. 
Receptor degradation 
After growing HER-7 cells to near confluency in 6-well plates (9.8 cm2) coated with 0.1 % gelatin in 
DMEM/Bic/10 % FCS, the medium was replaced by methiomne-free SATO medium. After an 
incubation period of 9 hours, 25 μΟ\ 35S-methionine was added and the incubation was continued for 
another 15 hours. After the replacement of the medium by 1 ml SATO medium containing 10 % 
growth factor-inactivated FCS (22), 0.1 % BSA and 60 ng of growth factor, the cells were incubated 
for 8 hours, washed with icecold phosphate-buffered saline (Mg2+- and Ca2+-free), lysed on ice in 
500 μΙ lysis buffer (60 mM NaCI, 30 mM Tris pH 7.4, 0.2 % NP-40, 0.5 % sodium deoxycholate, 
0.1 % sodium dodecyl sulfate (SDS), 0.05 mg/ml aprotmin), sonified, and centnfuged at 12000xg for 
15 mm Proteins binding non-specifically to rabbit antibodies were removed from the supernatant by 
two immune precipitations using non-immune rabbit serum (11000) The EGF-receptor was 
precipitated by an overnight incubation at 4 °C with 2 μΙ 281-7 polyclonal anti-peptide antibody 
recognizing the cytoplasmic domain of the receptor (20), followed by an incubation for 1 hour at 4 °C, 
in the presence of 40 μΙ of protein A-Sepharose, and centrifugaron at 12000xg for 10 mm. The 
precipitated proteins were washed twice with high-salt buffer (10 mM Tris-HCI pH 7.4, 0 2 % Nonidet 
NP-40, 1 M NaCI), twice with low-salt wash buffer (10 mM Tris-HCI pH 7.4, 0.2 % Nonidet NP-40, 
0 1 M NaCI), separated on 7 5 % SDS-PAGE and visualised using KODAK X-Omat film 
RESULTS 
pH dependent binding 
TGF-a has a much sharper pH optimum for binding to the EGF-receptor than EGF TGF-a 
dissociates from the hEGF-receptor at much higher pH values than EGF upon lowering the pH below 
physiological level (half-maximal dissociation values of pH 6.9 for TGF-a and pH 5 6 for EGF), while 
TGF-a binding is also more sensitive to alkaline conditions than EGF binding (17). This difference in 
pH sensitivity of binding is thought to be caused by the lower pi of EGF (pi 4.50) than of TGF-a 
(pi 5 84) and to result in a difference in intracellular routing of the ligand-receptor complex which may 
cause differences in biological activity of the two growth factors (17). We have tested the influence of 
the overall pi of the proteins on the pH sensitivity of binding by performing competitive binding 
experiments with EGF, TGF-a and EGF/TGF-a chimeras showing widely varying pis (table 7 1) at 
neutral and acidic pH values. Most chimeras have a pi in between those of EGF and TGF-a, but 
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GF Pi GF Pi 
hEGF 
ЕЗТ 
E4T 
E6T 
E3T4E 
E4T6E 
4.50 
4.70 
4.37 
4.02 
4.81 
5.21 
hTGF-CE 
ТЗЕ 
T4E 
T6E 
T3E4T 
T4E6T 
5.84 
5.77 
6.29 
7.08 
5.48 
5.13 
Table 7.1. Isoelectric points of EGF/TGF-a chimeras, pi values of 
the chimeras were calculated using the computer program 
IntelliGenetics Suite, Release 5.4 (IntelliGenetics, Inc., Mountain 
View, Ca.). 
some growth factor hybrids have a pi higher than TGF-a (T4E and T6E) and some a pi lower than 
EGF (E4T and E6T) indicating that the native growth factors have a different charge distribution. Most 
noticable is the large charge difference of domain VI that has a very low pi in TGF-a, but has a 
slightly basic pi in EGF (see also chapter 3, fig. 3.4). 
Figure 7.1 shows the receptor binding competition with 1Z5l-mEGF of these chimeras on HER-7 cells 
at pH values between 5.5 and 7.7 as a percentage of the binding at pH 7.7. The binding competition 
at pH 7.7 cells was used to calibrate growth factor activity (chapters 2 and 3) and was set at 100 %. 
The binding of hEGF and E3T4E to the receptor is least sensitive to a lowering of pH, while T3E4T, 
TGF-a, E3T and E4T dissociate already at relatively high pH. The chimeras with the most extreme 
pis (T6E and E6T) show an intermediate sensitivity of binding to a lowering of pH, indicating that in 
contrast to earlier conclusions based on EGF and TGF-a only (17), the overall pi of the growth factors 
is not an important determinant of sensitivity of binding to low pH. It is therefore more likely that the 
pH sensitivity of binding is determined by the pi of certain domains or specific residues (see 
discussion). The sensitivity of binding of the chimeras can, somewhat arbitrarily, be divided into three 
groups: EGF-like (EGF, E3T4E), TGF-a-like (TGF-a, T3E4T, ЕЗТ, E4T) and an intermediate one 
(T3E, T4E, T6E, E4T6E, E6T, T4E6T). The model of Ebner and Derynck (17) predicts a correlation 
between the affinity of binding to the receptor at low pH and the induction of recycling of the receptor 
and therefore the rate of recovery of the binding capacity of the cell after internalization. To test the 
correlation between pH sensitivity of binding and intracellular routing of the receptor we have tested 
the chimeras in receptor downregulation and 
recovery assays. In the receptor down-
regulation experiment, cells are incubated with 
growth factor for variable periods of time in the 
absence or additional presence of monensin 
(17), a substance that prevents the recycling of 
the receptor. Subsequently, the growth factors 
bound at the cell surface are removed by acid 
washes, and the cells are incubated with tracer 
for 30 minutes to measure the loss of 
receptors from the cell surface. In the receptor 
recovery experiment, cells are incubated with 
growth factor for two hours after which the 
growth factors bound at the cell surface are 
removed by acid washes, the medium is 
replaced by growth factor-free medium and the 
recovery of binding capacity is measured over 
time by 30 minutes incubations with tracer. 
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Figure 7.1. pH dependent receptor binding competition. EGF-
receptor binding competition assays on HER-7 cells, performed 
with ЕСРЯСР-а chimeras (100 ng/ml) at various pH values 
using ,Hl-mEGF (1 ng/ml) as a tracer. The binding competition of 
the chimeras at each pH value was expressed as a percentage 
ot the binding competition measured at pH 7.7. The chimeras 
tested are hEGF (A A), hTGF-α (A A), E3T ( • • ) , E4T 
( • • ) , E6T ( · · ) , T3E (•—•), T4E ( • - • ) , T6E ( · ~ · ) , 
E3T4E (+ +), T3E4T {+ +), E4T6E ( • - • ) and T4E6T ( • • ) . 
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Receptor downregulation 
Previous studies have shown that an 
incubation with EGF induces the almost 
complete disappearance of the EGF-receptor 
from the cell surface, while after an incubation 
with TGF-a a high percentage of the binding 
capacity of the cell is retained (17). This 
difference can be explained by the more 
efficient recycling of the receptor after the 
binding of TGF-a than after the binding of 
EGF, for suppression of recycling after binding 
of TGF-a by the presence of monensin (23) 
results in an equal level of downregulation as 
observed after EGF-binding, both in the 
absence as in the additional presence of 
monensin (17). We have tested the effect of 
preincubation with ЕСРЯСР-а chimeras on the 
EGF-binding capacity of the cell. 
HER-7 cells were incubated with 100 ng of the different growth factor chimeras per milliliter in the 
absence or presence of monensin, and after an acid wash to remove all bound growth factors, cells 
were incubated with ,?sl-mEGF to determine the amount of EGF-receptors at the cell surface (Fig.7.2). 
When receptor recycling is largely inhibited by the presence of monensin, all proteins tested induce a 
comparable reduction (about 55-65%) of EGF-binding places at the cell surface, indicating that the 
receptors internalize at the same rate after binding of the different growth factor proteins. In the 
absence of monensin, the amount of available binding places is reduced by 30 to 50 % only, and 
comparing the amount of binding places available in the absence and presence of monensin for each 
chimera, very different levels of receptor recycling become apparent. The chimeras can be divided 
into three groups on the basis of their receptor recycling ability. After binding of TGF-a, E3T, E4T, 
T3E4T and T4E6T, growth factors which show low receptor binding affinity at acidic pH, a large 
proportion of the surface receptors seems to recycle, while after binding of EGF and E3T4E, growth 
factors which have been shown to retain a high level of receptor binding capacity at low pH, very little 
recycling seems to occur. The other chimeras take an intermediate position. This classification in 
groups corresponds quite well with that composed on basis of pH sensitivity of binding. This indicates 
a clear correlation between pH-sensitivity of binding and the induction of receptor recycling, in 
agreement with the results of Ebner and Derynck (17). 
Receptor recovery 
After incubation with EGF it takes 5 hours before cells have regained their capacity to bind EGF-
like growth factors (17). This recovery of binding capacity is dependent on de novo synthesis of the 
receptor, since it can be inhibited by cycloheximide (17). In contrast, after preincubation with TGF-a, 
this refractory period is much shorter and its length is largely insensitive to cycloheximide indicating a 
mechanism independent of protein synthesis (17). We have tested the effect of the EGF/TGF-a 
chimeras on the recovery of the binding capacity following growth factor induced internalization. Cells 
were incubated for two hours with the growth factor proteins, acid washed to remove all bound and 
unbound growth factors and after varying periods of time the binding capacity was tested by an 
incubation with 125l-mEGF (fig. 7.3). Preincubation with TGF-a, E3T, E4T and T4E6T reduces the 
binding capacity to about 45% (E4T to about 37 %) and shows a recovery of the binding capacity to 
60-70 % within 30 minutes (fig.7.3). This recovery is most likely due to recycling of the EGF-receptor, 
since these growth factors have been shown to induce recycling of the EGF-receptor in the previous 
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Figure 7.2. Ligand induced downregulation and recycling of the 
EGF-receptor on HER-7 cells. 'Ml-mEGF binding capacity of 
HER-7 cells was tested after a preincubation with 100 ng 
ligand/ml for 1 hour and expressed as a percentage of tracer 
bound in the absence of growth factor during preincubation. The 
shaded areas indicate the percentage of tracer binding in the 
presence of 300 μΜ monensin during preincubation. 
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Figure 7.3 Time dependent EGF-receptor recovery after ligand induced internalization. After preincubation with growth factor 
proteins. HER-7 cells were acid washed (time=0) and tracer binding capacity was tested at various time points thereafter. For 
clarity the chimeras are shown divided into groups inducing fast (A) and slow (B) receptor recovery. EGF and TGF-a are shown 
in both figures as a reference. Growth facors are indicated as in fig. 7.1. 
experiment. After 60 minutes a further, very slow recovery can be noticed. The other chimeras do not 
induce the very fast recovery in the first 30 minutes. Particularly after incubation with EGF, reducing 
the binding capacity by 70%, no significant recovery is observed during the first thirty minutes, 
followed by a very slow recovery. Slight differences can be noticed between the other chimeras. T3E, 
E6T and T6E reduce the binding capacity to about 30 % while the recovery of the binding capacity to 
60 % takes 2 hours or longer (fig 7.3). In contrast, T4E and E4T6E reduce the binding capacity by 
only about 60 % and the latter shows recovery to almost 60 % within one hour. T3E4T and E3T4E 
have not been tested in this experiment and for this reason it is difficult to divide the chimeras in 
groups similar as in the previous experiments. If E3T4E should induce the same extremely slow 
recovery as EGF, these two chimeras could again be seen as a seperate group, TGF-a, E3T, E4T 
and T4E6T as a second group and the other chimeras tested as the third group, in full agreement 
with the previous experiment. 
Receptor degradation 
EGF-receptors that are not recycled back to the 
cell surface after ligand-induced internalization, are 
routed into the degradative pathway resulting in their 
proteolysis in the lysosomes. Immunoprecipitation 
with an anti-EGF-receptor antibody showed that 
cells preincubated with TGF-a do contain a large 
amount of intact receptor, in contrast to cells 
preincubated with EGF (17-19). This finding is in 
agreement with the results from the downregulation 
and recovery experiments which show that TGF-a 
induces much more recycling than EGF. In 
preliminary experiments we have tested if the extent 
of degradation of the receptor caused by the 
chimeras corresponds with their ability to induce its 
recycling as measured in the two previous 
experiments. We have incubated HER-7 cells for 8 
hours with a saturating amount of the chimeras and 
performed immunoprecipitations on the lysed cells, 
using the 281-7 polyclonal antibody directed against 
a cytoplasmic sequence of the EGF-receptor. After 
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Figure 7.4. Ligand induced degradation of the EGF-recep-
tor. HER-7 cells prelabelled with 3Ss-methionine were 
incubated for 8 hours with growth factor (60 ng/ml) and 
lysed, after which EGF-receptors were precipitated using 
the 281-7 anti-peptide polyclonal antibody, recognizing a 
cytoplasmic receptor domain. Growth factors used are: In 1: 
hEGF; In 2: hTGF-a; In 3: no growth factor added; In 4. 
E3T; In 5: E4T; In 6: E6T; In 7: T3E; In 8: T4E; In 9: T6E. 
Size markers are shown on the left. 
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this incubation period with the growth factor proteins, very little intact receptor protein (170 kDa) can 
be precipitated from the cells incubated with EGF or the chimeras, in contrast to the control cells or 
cells incubated with TGF-oc (fig. 7.4). An additional weaker band of about 150 kDa can be observed in 
all lanes in some experiments. Scanning of one of the autoradiograms shows that after this incubation 
period 75 % of the receptors bound to TGF-a, but over 90 % of the receptors preincubated with EGF 
or the chimeras were degraded (not shown). T4E seems to be an exception. Incubation with this 
hybrid induces the degradation of about 85 % of the EGF receptors. These preliminary data show 
that, despite the recycling of the receptor that occurs after incubation with some chimeras, the 
receptor becomes degraded after long incubation times. Although T4E does not induce a high level of 
recycling, it may not cause degradation of the receptor to the same extent as EGF and the other 
chimeras. This finding should, however, be confirmed by additional experiments. A more detailed 
study should also be performed to test if a direct correlation exists between the rate of recycling after 
incubation with a ligand and the half-life of the receptor. 
DISCUSSION 
Generally, receptors involved in the transport of substances from the extracellular space into the 
cell are recycled after internalization, while receptors involved in the transduction of extracellular 
signals into the cell are degraded in the lysosomes. This process, the ligand-induced internalization 
and degradation of cell surface receptors, resulting in a net loss of receptor from the cell, is called 
downregulation. It causes a diminished sensitivity of the cell to the extracellular signal and is 
considered to be one of the mechanisms that regulates the duration of the transduced signal. In the 
case of the EGF-receptor it has been shown that the rate of downregulation is dependent on the 
ligand bound to the receptor. EGF binding causes degradation of most of the ligand and receptor, and 
protein synthesis is necessary to reestablish EGF-binding capacity, while after TGF-a binding on the 
other hand, a large percentage of both receptor and ligand is recycled, and most of the binding 
capacity is therefore restored within a short period of time (17). 
It has been suggested (17) that this difference in processing of the ligand-receptor complex is due 
to the difference in pi between EGF and TGF-a. The relatively high pi of TGF-a would cause 
dissociation of ligand and receptor in a moderately acidic compartment shortly after internalization, 
thereby preventing the trafficking of the ligand-receptor complex to the lysosomes, and resulting in 
recycling of the receptor. The almost continuous availability of the receptor on the cell surface after 
TGF-a binding, in contrast to the disappearance of the receptor from the cell surface after EGF-
binding, would explain the higher sensitivity of cells for TGF-a than for EGF in some assay systems 
(17). 
We have tested this model by performing binding competition assays at different pH values using 
EGFH"GF-a chimeras of varying pis and measuring the extent of recycling of the receptor induced by 
these chimeras. The chimeras showed large differences in pH sensitivity of binding, but no correlation 
has been found with the overall pi of the proteins. Most notably the chimeras with the most extreme 
pis (E6T and T6E) showed only a moderate difference in pH sensitivity of binding. From these results 
it can be concluded that the overall pi of the protein is not the main determinant of the binding affinity 
at low pi, as suggested by Ebner and Derynck (17). The high pH sensitivity of binding of TGF-a 
seems rather to be determined by three domains. Exchange of either domain V (T4E6T) or VI (T6E) 
of TGF-a, or both combined (T4E) reduces the pH sensitivity of binding drastically, all to 
approximately the same level. Chimeras containing both domain V and VI of TGF-a, but not domain 
Mil (E3T and E4T), are significantly less pH sensitive than TGF-a and T3E4T, indicating that domain 
Mil has also some effect on the pH sensitivity. This seems to indicate that mainly domain V and VI 
determine the pH-sensitivity of binding, while in addition domain l-lll has a small but significant 
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influence Probably only one of these three ammo-terminal domains will determine the pH sensitivity, 
but we have not made additional exchange mutants within these domains Exchange of domain IV 
(T3E4T and E3T4E) only has no significant effect on the pH sensitivity of binding of either EGF or 
TGF-tx 
Looking at the EGF and TGF-a sequences (see figure 1 1 ), we can speculate about the residues 
involved in this pH sensitivity From the differential binding to the chicken EGF-receptor it has already 
been concluded that non-conserved residues in the carboxy-terminal domain VI of TGF-a are 
involved in the binding to the receptor (chapter 5) Of the seven residues in this domain two are 
strictly conserved (D47, L48) and four uncharged (A46, L48, L49 and A50) Of the two charged 
residues (E44 and H45), His45 with a pKa of 6 3 (24) becomes protonated within the pH traject 
(pH 7 7-5 2) we have used for our binding studies, and is situated within the domain that is 
responsible for the high affinity binding of TGF-a to the chicken EGF-receptor (chapter 5) TGF-a 
contains other His residues at position 4, 12, 18, and 35, two of which (His12 and 18) are found at 
homologous positions in the hEGF sequence, that contains only these two His residues The other 
two His residues of TGF-a are found in the first and fifth domain, both of which seem to influence the 
affinity of binding at low pH In domain V, only four residues are not conserved between EGF and 
TGF-a of which only His35 is charged and has a pKa of 5 4 (24) In the first N-termmal domain the 
His residue at position four is reported to have a pKa of 6 5 (24) Most of these His residues (His12, 
18, 35 and 45) lie within the hypothetical receptor binding domain of TGF-a (25), which underlines 
their possible role in pH-dependent binding 
The finding that the conformation of TGF-a is more sensitive to pH than that of EGF has also been 
partly attributed to the presence of histidine residues at position 18, 35 and 45 (25) The receptor 
binding domain of TGF-a is most likely formed by residues from the N-terminal as well as the 
C-termmal domain, that lie close together in the interdomain cleft (see introduction) In TGF-a the 
relative orientation of these domains may be largely determined by the hydrogen bonding between the 
conserved His18 and His35 which is not conserved in EGF (25) where this role is performed by other 
residues (25) We suggest that the release of TGF-a from the receptor at acidic pH is caused by the 
protonation of residues His35, 45 and to a lesser extent also of His4 or 18, either directly via charge 
repulsion between hgand and receptor or indirectly via small conformational changes in the ligand 
These pH dependent changes may of course be accompanied and reinforced by pH-induced changes 
in the receptor protein 
The down regulation and recovery of the receptor after binding of the chimeras were studied to test 
if these phenomena were coupled to the pH dependent binding of the chimeras The receptor 
downregulation experiment shows that monensm, an lonophore that disrupts intracellular traffic and 
the recycling of many receptors, has a large effect on the availability of receptor binding sites at the 
cell surface after preincubation with TGF-a, E3T, E4T, T3E4T, and T4E6T, but only little effect after 
preincubation with EGF and E3T4E The rate of downregulation induced by the chimeras, as judged 
from the effect of monensm, does not exactly match the sensitivity of binding at low pH E3T, E4T and 
T4E6T show somewhat more recycling than predicted from the binding expenment, but the same 
groups can be distinguished as in the previous experiment with only T4E6T as an exception This 
chimera belongs to the group showing intermediate pH-sensitivity of binding, but clearly induces 
recycling of the receptor The absolute rate of receptor recycling may have been underestimated in 
this experiment, since monensm, depending on the concentration used, may not fully inhibit receptor 
recycling (23) In the present experiments, however, no indication was found for this since EGF and 
TGF-a induced the same extent of downregulation in the presence of monensm 
The rate of receptor recovery after internalization correlates well with the extent of recycling 
measured in the receptor downregulation experiment TGF-a, E3T, E4T and T4E6T regain over 60 % 
of their original binding capacity within 30 minutes, EGF shows no significant recovery during this 
time, while the other chimeras show an intermediate level of recovery The first time point (5 mm ) 
84 
shows that there is an initial difference in receptor availability at the cell surface This should reflect 
the level of downregulation induced by the saturating amounts of growth factors A change in this 
equilibnum may, however, have been brought about during the incubation with tracer, since the 
incubation for 30 minutes at room temperature may have caused some additional downregulation and 
some recovery 
The receptor degradation experiment seemed to indicate that after long incubation times almost 
complete degradation of the receptor population takes place despite the occurrence of significant 
recycling after preincubation with some chimeras Only after preincubation with TGF-a, one of the 
most efficient recyclers, a significant proportion of the receptors is not degraded under these 
conditions In contrast to the binding competition assay, immunoprecipitation does not distinguish 
between internal receptors and surface-bound receptors We have not established what percentage of 
the remaining receptors after long incubations was surface-bound From the fact that the cells were 
prelabelled with 35S-methionme it is at least clear that none of this intact receptor protein was recently 
synthesized 
The present experiments indicate that the model of Ebner and Derynck is partly correct The 
binding affinity of a ligand for the EGF-receptor at low pH is indeed a measure for the availability of 
the receptor at the cell surface and the level of receptor degradation after relatively short incubation 
times This is, in contrast to their model, not a function of the general pi of the ligand, but rather of the 
presence of His residues in domains V, VI and l-lll of the ligand The dissociation of the ligand in an 
early endocytic compartment causes most likely the loss of tyrosine kinase activity of the receptor and 
this is probably the signal for the recycling of the receptor to the cell surface, since it has been shown 
that tyrosine kmase-negative receptors are recycled (26) after sorting in the multi-vesicular bodies 
(27) 
Ebner and Derynck assume that the constant recycling of the EGF-receptor after TGF-a binding 
explains its higher biological activity in some assay systems, but they do not address the question 
why, despite this fact EGF and TGF-a do show identical activity in most mitogenic stimulation 
assays Their suggestion that EGF causes growth inhibition of A431 cells while the strong 
downregulation of the EGF-receptor induced by this growth factor interrupts the autocrine TGF-a loop 
which causes constitutive mitogenic stimulation, does not take into account that TGF-a shows 
identical biological activity as EGF in the growth inhibition assay on these cells (see chapter 4) EGF 
and TGF-a also show identical mitogenic activity on HER-7 cells despite the high level of recycling of 
the receptor induced by TGF-a Three chimeric proteins in contrast, which show, like TGF-a, high pH-
sensitivity of binding (E3T, E4T and T3E4T) and induce a high level of recycling of the receptor, do 
show superagonistic activity A possible explanation for this difference between TGF-a and the 
chimeras will be discussed in chapter 10 The elucidation of the mechanisms which influence the 
routing of the ligand-receptor complex after internalization, and therefore the biological response of 
the cell on ligand binding, may open new routes for the design of EGF-receptor antagonists 
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CHAPTER θ 
AN EXACT GENERAL ANALYSIS OF LIGAND BINDING 
DISPLACEMENT AND SATURATION CURVES 
SUMMARY 
Quantitative analysis of ligand-protein interaction relates binding to the free concentration of ligand 
molecules in solution. A theoretical analysis is presented herein, by which intermolecular interactions 
can be described as a function of the added concentrations of ligand molecules. Following this 
analysis, ligand binding displacement and saturation curves can be converted directly into a linear 
form, even when nonradioactive^ labeled hgands are used to detect ligand-protein interaction From 
the linearities obtained, relevant binding parameters, including the binding dissociation constant, can 
be calculated On the basis of this analysis, binding parameters have been characterized for the 
interaction between biotin-protein A and immunoglobulins, using an ELISA-type of detection, and for 
the interaction of a fluorescently labeled fatty acid with a specific fatty acid binding protein 
INTRODUCTION 
Many analytical methods for identification and quantification of biologically relevant molecules rely 
on the ability of these compounds to interact with specific binding proteins, such as receptor 
molecules and antibodies. These types of molecular interaction form the basis of such important 
analytical techniques as radio-receptor assays (RRA), enzyme-linked immunosorbent assays (ELISA), 
and radio-immuno assays (RIA) In many cases, use is made of a labeled derivative of the compound 
of interest by introduction of a radioactive atom or by attachment of a fluorescent or chemical label, 
such as a dansyl or a biotm group (1) The amount of the compound ol interest present in biological 
samples is then quantified by studying the extent of displacement of binding of this labeled ligand to 
its specific binding protein, which can be monitored from the characteristics of the introduced label 
Within the existing models of reversible interaction between a ligand and its binding protein, the extent 
of ligand binding can be related to the concentration of ligand molecules remaining free in solution 
after reaching equilibrium (2). The exact concentration of free ligand required for this type of analysis 
can be determined experimentally only if a radiolabeled ligand molecule is used. In the case of 
fluorescently or chemically labeled hgands, however, no straightforward expenmental method is 
available for direct quantification of the concentrations of free ligand. 
In the present study, a theoretical analysis of ligand binding displacement curves is presented, 
which relates the extent of labeled ligand binding to the added, instead of the free, concentrations of 
labeled and unlabeled hgands. The present analysis is therefore generally applicable, that is, it applies 
not only to radiolabeled hgands, but also to fluorescently or chemically labeled hgands, as long as the 
parameter measured to detect ligand binding is proportional to the amount of labeled, bound ligand 
Using this method, both ligand binding displacement and saturation curves can be expressed directly 
in a linear form, which is of great statistical importance for measurement of a large number of 
samples in routine analysis (3,4) From the linearity obtained, not only the ligand binding dissociation 
constant but also values for the free concentrations of ligand molecules can be derived, even for non­
radioactive^ labeled hgands. Expressions are also presented for analyzing this type of displacement 
curve in the additional presence of a nonspecific binding component. The examples presented here 
for analysis are the binding of biotm-labeled protein A to substrate-attached immunoglobulins, as 
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detected by an avidin-coupled peroxidase reaction, and the interaction of a fluorescently labeled fatty 
acid to a specific fatty acid binding protein 
EXPERIMENTAL PROCEDURES 
Binding of protein A to immobilized immunoglobulins 
Immunoglobulins (IgGs) were purified from normal rabbit serum by chromatography on protein A-
Sepharose, and stored in phosphate-buffered saline (PBS) at a concentration of 2 μα/ml From this 
solution 100 μΙ was added per well (0 33 cm2), followed by overnight incubation at 4 °C Plates 
(96 wells) were subsequently washed three times with PBS/0 05 % Tween 20, and nonspecific 
binding was blocked by incubation for 1 h at 37 ° С in a serum-free culture medium containing 1 % 
bovine serum albumin Subsequently biotin-protein A (Sigma) was added at a concentration of 
50 ng/ml in the presence of additional variable concentrations of unlabeled protein A, to a final volume 
of 100 μΙ After incubation for 1 h at 37 °C, the wells were washed four times with PBS/Tween and 
subsequently incubated in the above albumin-containing medium now containing avidm-peroxidase 
(Sigma) for 1 h at a final concentration of 0 25 μρ/ητιΙ After four washes with PBS/Tween, peroxidase 
activity was detected by addition of o-phenyldiamine as a substrate, and color development was 
analysed as descnbed previously (5) 
Interaction of fatty acids with fatty acid binding proteins 
Binding of 11-(dansylamino)undecanoic acid (DAUA) to purified porcine liver fatty acid binding 
protein was determined as described before (6) Expenments were carried out with 0 2 μΜ binding 
protein in 10 mM Tns-HCI pH θ 0 containing a final concentration of 0 1 % ethanol Fluorescence was 
measured at 345 nm (excitation) and 505 nm (emission), a condition under which no fluorescence is 
observed in the absence of protein 
THEORY 
The reversible binding of labeled ligand to a homogeneous class of noncooperating binding sites, in 
the additional presence of unlabeled ligand molecules under equilibrium is given by (7,8) 
В'-—У£—+К
Л
Г [1] 
KjF +FU 
in which F is the free concentration of labeled and Fu that of unlabeled ligand molecules after 
reaching binding equilibrium, and В the amount of labeled bound ligand under these conditions N 
stands for the number of specific binding sites available and KD for the binding dissociation constant, 
while KA is a constant for non-specific binding which is only of relevance in the case when additional 
ligand binding takes place to low affinity binding domains in a nonspecific manner It will be assumed 
that this potential nonspecific binding component is nonsaturable within the range of ligand 
concentrations used When a constant concentration of labeled ligand (L0') is added with varying 
concentrations of unlabeled ligand (Lu), eq 1 provides a theoretical description of ligand binding 
displacement curves 
The use of eq 1 requires that labeled and unlabeled ligands behave chemically identical This can 
also be expressed as 
88 
pu f 
— = — [2] 
<-" Li 
indicating that within any given experiment the free fraction of both ligands must be similar. The 
concentration of free ligand (F) will differ from the added concentration (L) according to 
F=L-pB [3] 
in which В is the amount of bound ligand at equilibrium, and ρ is a dimension-converting parameter. If 
F, L, and В are all expressed in the same units, ρ will equal unity. Otherwise 1/p will equal the 
specific activity expressed in radioactivity per concentration unit (e.g. cpm/nM) in the case of a radio­
labeled ligand, while for a fluorescently or chemically labeled ligand, 1/p will generally be expressed 
in absorption units per nM. The concomitant use of eq. 1 and 3 implies that В and N are expressed in 
the same units. 
In the absence of nonspecific binding (KA=0), the binding of labeled ligand can be fully displaced by 
addition of an excess of unlabeled ligand, following eq. 1. B„' will now be defined under these 
conditions as the amount of labeled bound ligand in the absence of unlabeled ligand (Lu=0), making 
B0'= NF07(KD+F0'), in which F0* is the free concentration of labeled ligand under conditions without 
displacement. The reduction in labeled bound ligand upon addition of a particular concentration of 
unlabeled ligand (Lu) will now be expressed as ф=В7В0'. 
Because of the general validity of eq. 3, it follows that in the absence of unlabeled ligand F0'=L0'-
pB„°, while upon addition of a certain concentration of unlabeled ligand, the free concentration of 
labeled ligand is given by F'=L0'-pB'. Under conditions that L0' is a constant, it therefore follows upon 
elimination of p, and by using the definition of φ, that 
F-=(1-0)¿>0FO [4] 
Since φ and L0" are experimentally known, it follows that if F0' can be determined, all values of F' 
following addition of unlabeled ligand can be calculated. Furthermore, it follows from the definition of 
φ, combined with eq. 1 under conditions KA=0 that 
Κ^Γ-φΡ0)^-φ)Γ^φρ·ρ" [5] 
and in combination with eq. 4 that 
JL.F^r+KpbÍ [6] 
From this equation together with eq. 2, it follows upon elimination of F' that 
1-ф
 Lu Fg 
and since from combination of eqs. 2 and 4 it follows FU=LU(1^(1-F07L0')), elimination of F" results in 
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φ-φ) F* F" F* 
'О ° (A 0\ 
ίψ-ί.'0φ[\-φ) Φ KD KD L, 
[8] 
This final equation describes a linear relationship between the experimentally derived dimensionless 
parameter on the left-hand side and 1/φ, while based on the values of the slope and the intercept of 
this linearity, the system parameters F0' and KD can be determined. Intriguingly, eq. 8 does not 
contain the specific activity parameter p, and is therefore valid for any type of binding assay in which 
the signal for binding obtained is proportional to the amount of labeled bound ligand. 
In cases where additional ligand binding takes place to nonspecific domains (KA>0), labeled bound 
ligand according to eq. 1 cannot be completely displaced by the addition of excess unlabeled ligand. 
If the fraction of bound non-displaceable labeled ligand is defined as φ., it follows from the 
considerations presented in the Appendix that 
φ-φ) 
¿W-0J-¿>d-d» 
F\ 
W - * . ( 1 - W » 
Ф-^О 
Ktf-iJfl-FyQ)) 
[9] 
which is the equivalent expression of eq. 8 for ф„>0. Again, there is a linear relationship between the 
experimentally derived, dimensionless parameter on the left-hand side and 1/φ. Since φ. can be 
obtained directly from the competition experiment, the parameter F0* is again obtained from the ratio 
of intercept and slope; once this value is known, KD can be derived from the slope. 
RESULTS 
Data simulation 
Figure 8.1 A shows simulated ligand binding 
displacement curves, both in the absence 
(φ„=ο) and presence (φ„>ο) of a nonspecific 
binding component. The parameters used for 
data simulation are presented in the Figure 8.1 
legend, using the condition that the free ligand 
concentrations are significantly lower than the 
added concentrations (F<L). Linearization of 
the displacement curve in the absence of non­
specific binding following eq. 8 results in fig. 
8.1 B, while in the presence of non-specific 
binding, fig. 8.1 С is obtained following eq. 9. 
The value for ф„ used in fig. 8.1 С was derived 
f ram the value of KA according to eq. 14. In 
both cases linearity was exact, giving an inter­
cept with its abscissa between 0 and 1. It fol­
lows from eq. 8 and 9 that both in the presence 
and absence of non-specific binding the abso­
lute ratio of intercept and slope equals 
(1-F07L0'), therefore an intercept with the 
abscissa equal to 0 denotes binding characteri­
stics in which the fraction of labeled ligand 
Figure 8.1: Linearization of ligand binding displacement curves in 
the absence ( · ) and presence (o) of a non-specific binding 
component. (A): Simulated displacement curves for competition 
of labeled ligand binding upon addition of unlabeled ligand. 
Binding data were simulated by iterative computer analysis 
based on eq. [1] using the concentrations of ligand initially added 
(L) instead of free concentrations (F). After calculation of B-
values, corresponding F-values were calculated according to eq. 
[3], which were again used in eq. [1] in an iterative way. The 
following values were used for simulation: N = 10,000; K0 = 10; 
ρ · 0.0005; L„' = 1 and KA = 0 ( · ) or 300 (o). Binding of labeled 
ligand represented by φ = 1 corresponds to non-displaced 
conditions (L" = 0). (B): Linearized displacement curve in the 
absence of non-specific binding, according to eq. [8]. Data points 
corresponding to a value of 1/φ > 14 have not been included. 
(C): Linearized displacement curve in the presence of non­
specific binding, according to eq. [9]. A value of φ = 0.3405 has 
been used, obtained following eq. [14]. 
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bound following interaction with the binding protein is negligible (F^L,,*). By contrast, an intercept with 
its abscissa equal to 1 indicates binding in which, under non-dispiaced conditions, nearly all added 
ligand molecules become bound as a result of the interaction with the binding protein (Fo'=0). 
Statistics of data analysis 
Analysis of the simulated binding data of fig.
 Т
аЫе h EFFECT OF RANDOM ERRORS ON PARAMETER 
8.1A.B (Lo'=1, KD=10, KA=0; see legend) ESTIMATION FROM LINEARIZED DISPLACEMENT 
according to eq. 8, resulted in generated values 
0 
1 
2 
4 
0.681 
0.684 ι 0.047 
0.678 ± 0.097 
0.712 ± 0.195 
10.00 
10.05 ι 0.69 
9.96 i 1.43 
10.41 ± 2.87 
for F0' and KD as shown in table 8.1 (0 % relative relative random F„· * SSD к0 ± SSD 
random error). In order to investigate how errors U 
in experimental data points propagate when using 
the present linear expressions, relative random 
error levels of 1,2 and 4 % were superimposed 
on the simulated B' values, and the effects on the . . . „ 
Binding data were simulated using the parameters given in the 
system parameters F0* and KD determined. Table legend of fig. 1 (Кд=0). Subsequently for each data point a 
8.1 shows that, although the sample standard ™mai d i s t r i b u t o n w a s generated with mean value в and 
standard error p.B. in which ρ is the relative random error level. 
deviation in the parameters F0' and KD gradually Binding data were then generated from these normal 
increases with increasing error level, the mean distributions, and plotted in a linear fashion according to eq. [8] 
to obtain values for F„' and «¡,, using unweighted linear 
values of these parameters remain Close to the regression analysis. For each relative random error level tested 
values generated in the absence of statistical mean va lues and samP|e s tandard ^ 3 « 0 " 3 ,or ^ese *"° 
parameters are indicated, based on 1000 repeated calculations, 
error. Only in the case Of a 4 % error level are Under all conditions tested the values of F,- and Ко thus 
the mean values of the two parameters within a obtained, appeared to obey a normal distribution. 90 % confidence interval (Fo=0.700 - 0.724, Ko=10.23 
undisturbed values. 
10.59) significantly ifferent from the 
Binding of biotin-protein A to immobilized immunoglobulins 
Binding of biotin-labeled protein A to rabbit 
immunoglobulins can be detected by incubating 
the complex with avidin-peroxidase and a suitable 
substrate which is converted by a peroxidase 
reaction into a colored derivative. Figure 8.2A 
shows a displacement curve of biotin-protein A 
binding by unlabeled protein A, according to the 
protocol described in the legend. In the presence 
of a 200-fold excess of unlabeled over labeled 
ligand, a value of ф=0.06 was obtained which is 
indicative of near-complete binding competition. 
For linearization of these data according to eq. 9, 
the parameter ф^ is required. Using a trial-and-
error method, various values of ф„ between 0 and 
0.06 were therefore tested for the best linear fit. 
Statistics for linearity were carried out by 
minimizing studentized residuals, as described in F i 9 u r e 8 2. Analysis of protein A binding to immobilized 
α
 immunoglobulins. A: Displacement curve for biotin-protein A 
detail elsewhere (8). The best linear fit, as shown binding (50 ng/mi) to immunoglobulins (igGs), following 
in fig. 8.2B, was obtained using a value of 
φ„=0.03 (see the dashed horizontal line in fig. 
8.2A). From the intercept with the abscissa at 
1/φ=0.87, a value of FoVLo"=0.13 was obtained, 
which in combination with the slope resulted in 
addition of increasing concentrations of unlabeled protein A. 
Binding of biotin-protein A was detected by incubation with 
avidin-peroxidase and ortho-phenyldiamine as peroxidase 
substrate. Care was taken that the reaction was stopped while 
the increase in color intensity was still linear with time. 
B: Linear representation of displacement curve (A) according 
to eq. [9], using a value of φ.=0.03 (see dashed line under A) 
as non-specific contribution. 
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Ко=0.0152 μσ/ιπΙ. These data show that under non-displaced conditions only a small fraction of the 
added biotin-protein A remains free in solution and that as a consequence the KD-value obtained is 
much smaller than the concentration of unlabeled protein A required for half-maximum binding compe­
tition (approximately 0.25 μο/ιηΙ). 
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Binding of fluorescent lipids to a fatty acid 
binding protein 
Binding of 11-(dansylamino)undecanoic acid 
(DAUA) to porcine liver fatty acid binding protein 
results in strong fluorescence enhancement, 
which can be used to analyze lipid-protein inter­
actions (6). Figure 8.3A shows the enhancement 
of fluorescence when increasing concentrations of 
DAUA are incubated with a constant con­
centration of binding protein, as outlined in the PSS ' «.л».—·—· 
legend. Although binding shows saturation Figure 8.3: Binding characteristics of ii-dansylamino-
characteristics, an additional nonsaturable compo- undecanoic acid (DAUA) to purified porcine liver fatty acid-
nent appears to be present which may result from b i n d i n 9 p r o , e i n· A : S a , u r a , i o n b i n d i n g c u r v e o b t a i n e d b y 
incubation of increasing concentrations of DAUA with 0.2 μΜ 
nonspecific interaction. This type of saturation „ _ , . . . _ . . .. . .. 
r , H
 binding protein. Fluorescence increase is indicated in arbitrary 
binding curve, which relates the extent of ligand
 mits ( a u . ) . B : Transformation of saturation binding curve (A) 
binding (B) to the added concentration of labeled into a displacement-type of curve, using the method outlined in 
ligand (L), can be readily converted into a ^ 8 , e x t· T n e d a t a P0"1' corresponding to 0.15
 μΜ DAUA was 
„,:„„, „ „ „ „ » » _ . „ u.. _ι_<;_· ι u _ chosen as a reference value. C: Linear representation of 
displacement-type curve by defining for a chosen r 
displacement curve (B) according to eq. [9], using a value of 
data point, the added ligand concentation as L¿
 φ = 0 0 2 5 ( s e 8 d a s n e d ш u n d e r B ) a s ^ . ^ ^ M 
and the corresponding binding as B0\ By taking bution. D: Scatchard plot for specific interaction of DAUA with 
this selected data point as a reference, B'-values fatty acid-binding protein. Knowing the values of F„" and φ 
are now defined for all other data points from № β "nearity under C, data from A were corrected for their 
according to B=B(L;/L), and L" values according n°^Pecific component, and specific binding (BJ was expres-
sed as a function of free ligand concentration. 
to LU=L-L0". A plot of ф(=В /B0') versus Lu now has 
all of the characteristics of a ligand binding dis-placement curve. This conversion strategy requires 
only that labeled and unlabeled ligand behave in a chemically identical manner. 
Figure 8.3B shows the displacement curve derived from fig. 8.3A, using the data point at 0.15 μΜ 
DAUA as a reference value. Using the same trial-and-error strategy as described for fig. 8.2, a value 
of φ,=0.025 (see the dashed horizontal line in fig. 8.3B) was obtained to give the best linear fit of 
these data when expressed according to eq. 9. From this linearity (see fig. 8.3C), values for 
F07L0'=0.727 and KD=0.19 μΜ were determined. Furthermore, from the value of φ„ the parameter KA 
for nonspecific binding could be determined according to eq. 14, resulting in a value of 0.68 
absorbance units (au) per μΜ lipid. Once the concentration of free lipid in the chosen reference point 
was known, free concentrations for other data points could be calculated according to eq. 4. By 
subtracting the nonspecific binding component (KA.F) from the experimental data points of fig. 8.3A, 
the specific binding data thus obtained were plotted according the method described by Scatchard (2), 
as shown in fig. 8.3D. From this linear plot, it is shown that maximum specific ligand binding results in 
a fluorescence enhancement of 11 au; together with the known value of KD, a complete saturation 
curve for specific binding with the fatty acid binding protein can thus be obtained. 
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DISCUSSION 
In the present study, theoretical equations have been derived to express ligand binding dis­
placement and saturation curves in a linear form and to determine relevant system parameters from 
the slopes and the intercepts of the linearities obtained Because data can be expressed directly as a 
function of the total ligand concentrations added, the methof descnbed here can be used for any type 
of labeled ligand, provided that the signal measured to detect ligand binding is proportional to the 
amount of ligand-protem interaction On the basis of the results obtained, values for the free 
concentration of ligand molecules can be calculated, even for non-radioactively labeled ligands, the 
data can then be plotted conventionally in a Scatchard plot if desired. Application of the above 
equations is limited to situations where a single, non-cooperative class of binding sites is present 
which binds labeled and unlabeled ligands with the same affinity In addition it is assumed that the 
free ligand molecules are not complexed by other molecules in solution and that subsequent protocols 
to detect ligand binding, for example by incubation with avidin or a second antibody, do not 
significantly interfere with the amount of labeled bound ligand 
In previous studies, exact mathematical descriptions have been presented for ligand binding 
displacement curves, both in the case of a single (9) and in the case of multiple (10) receptor classes 
The linearities obtained by those methods can also be used in the case where labeled and unlabeled 
ligands have different receptor affinities The present method has the advantage that data from 
displacement curves can be directly converted into linear form, without separate determination of the 
available concentration of receptor molecules Moreover, the present equations take into account the 
possibility that additional ligand binding takes place to nonspecific domains in a nonsaturable manner 
After the analysis of displacement curves by a homologous unlabeled ligand according to the present 
method, the binding affinity for nonhomologous ligand molecules can be subsequently determined on 
the basis of an equivalent competition principle, as described in detail elsewhere (11) 
On the basis of the general eq 9, the system parameters for receptor-hgand interaction can be 
obtained directly from displacement curves either by computer-assisted nonlinear regression analysis 
or by expression of the data in a linear form as presented in this study The first approach is generally 
more accurate, while a linear expression is particularly sensitive for detection of significant deviations 
from a proposed theoretical model As for other equations describing ligand binding (12), alternative 
linear expressions can be derived for eqs θ and 9, for example by multiplying both sides of the 
equations by φ or by placing 1/φ on the left-hand side of the equation The present format has been 
chosen because it can be used for any range of F0 between 0 and L0', without the possibility that the 
slope may become independent of φ or that slope and intercept may reach infinite values As a result, 
the present equations generally result in a high correlation coefficient, in spite of possible data 
scattering, which is of great advantage when applying this method for linearization of binding 
calibration curves to be used for routine analysis on a large number of samples (H A Ross and E J J 
van Zoelen, unpublished) We realize, however, that this does not imply that, following the statistical 
considerations given in table 8 1, the present format of eqs 8 and 9 necessarily gives rise to the 
highest accuracy in determining binding parameters 
The present method describes an exact and direct analysis for binding of chemically and 
fluorescently labeled ligands This approach can also be useful for radiolabeled ligands, particularly 
when, as a result of high-affinity binding, very low values for the free ligand concentrations are 
obtained (F0 '«L0 ) Other methods described in the literature for binding analysis of fluorescently 
labeled ligands generally use iterative procedures based on estimated values of the various system 
parameters (13,14) In the case of ELISA reactions based on enzymatic binding detection, 
approximation methods have also been described for the mathematical analysis of displacement 
curves, particularly based on a so-called logit-log transformation (4,15,16) In contrast to these other 
strategies, however, there is no need to assume values for the free concentration of ligand molecules 
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using the present method, where experimental binding data can be directly expressed as a function of 
the hgand concentrations added 
APPENDIX 
In the case KA>0, eq 1 will describe the amount of total labeled bound ligand and will be composed 
of a specific binding component B'ep given by the first right-hand term and a nonspecific binding 
component given by KA F*. If for a constant L0', φ is now defined under these conditions as the ratio of 
total binding following displacement (<J>=B7B0'), while θ is defined as the ratio of only the specific 
binding components (6=B'sp/B0'sp), it follows that 
ф=
 в^к
А
г
 [ 1 0 ] 
Bosp*KAFo 
Equations 2-4 will still be valid under these conditions, in which В now stands for total hgand binding, 
and therefore it follows from combination of eqs 4 and 10 that 
=ф^ ф)і0 [11] 
in which Ζ is defined as KA/Bosp Equation 5 will now hold for θ instead of φ, and from elimination of θ 
by combination with eq 11, 
1 _
* F: 
[12] 
which is the equivalent expression of eq 6 in the case KA>0 
The interpretation of the term ZL0 can be seen as follows. At an infinite concentration of unlabeled 
ligand (F"=»), φ will reach an asymptotic value φ„>0 It follows from eq 1 that В =KA F., and in 
combination with eq 4 that F =(1-φ^)Ι_0+φ F0' Since by definition φ =B 7B0', it follows that 
<MB0 KA F0 )=KA L0-(1 -φJ By definition, ZL0 =KA L07B0-sp, in which Вэ sp=B0 -KA F0, and thus 
Φ 
ZL
°=-rt [13] 
1-0. 
When introduced into eq 12, and using the same strategy as above for elimination of Fu, eq 9 is 
obtained The relationship between the value of φ„ experimentally obtained and the system parameter 
for nonspecific binding KA is given by KA=B^/F *, and thus 
^ = 0 - ^ ( ( 1 - 0 J V 0 . ^ ) f14l 
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CHAPTER 9 
DETERMINATION OF RECEPTOR-LIGAND BINDING PARAMETERS 
FROM NON-HOMOLOGOUS COMPETITION CURVES 
SUMMARY 
Ligand-receptor binding analysis is frequently used to quantify receptor densities and hgand binding 
dissociation constants We have recently described an exact mathematical analysis of hgand binding 
competition curves, taking into account that free ligand concentrations may differ significantly from 
hgand concentrations added, and that additional ligand binding may take place to non-specific 
domains (Chapter 8) Based on this analysis we have derived an equation to determine the 
dissociation constant of a non-homologous competitor based on the concentration required for 50% 
competition of specific binding This equation forms an extension of the Cheng-Prusoff equation, by 
taking into account the reduction in ligand concentration both as a result of receptor binding and of 
binding to non-specific domains Based on this equation the affinity of binding of epidermal growth 
factor/transforming growth factor-α chimeras towards the chicken epidermal growth factor receptor 
has been determined 
INTRODUCTION 
The specific interaction of a ligand with a receptor molecule or a binding protein can be well 
described mathematically in terms of a model of reversible binding, characterized by a specific 
dissociation constant for equilibrium binding Ligand binding dissociation constants can readily be 
obtained from concentration-dependent ligand binding isotherms, which are frequently expressed in a 
linear fashion following the method of Scatchard (1) Interpretation of ligand binding data requires 
quantification of the concentration of ligand molecules which remain free in solution after equilibrium 
binding In the case of a radiolabeled ligand such free concentrations can readily be obtained from the 
ligand concentrations added, in combination with the amount of labeled ligand bound 
We have recently described a mathematical analysis in which hgand binding data are expressed in 
terms of the hgand concentrations added, instead of the free hgand concentrations (Chapter 8) Based 
on that analysis we have shown that ligand binding dissociation constants can also be derived when 
free ligand concentrations cannot be determined experimentally, for example in the case of biotm-
labeled or fluorescently labeled hgands 
Non-specific binding, which can be described as ligand binding to non-receptor domains which is 
not saturable within the range of hgand concentrations used, is a general problem inherent to the 
interpretation of all ligand binding data (2-4) Using the possibility to quantify non-specific binding by 
the above analysis, we have also extended our mathematical analysis by deriving an exact expression 
for the Cheng-Prusoff equation, which relates the concentration required for half-maximum competition 
of radioligand binding by an unlabeled competitor to the dissociation constant of this competitor (5) 
This analysis allows quantification of ligand binding dissociation constants in the case radiolabeled 
and unlabeled hgand have different binding affinities, also when additional ligand binding takes place 
in a non-specific manner. The present studies are illustrated on the binding characteristics of 
epidermal growth factor (EGF)-like hgands to the chicken EGF receptor 
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MATERIALS AND METHODS 
Cell Culture and Chemicals 
Murine epidermal growth factor (mEGF) was obtained from Byproducts for Science Inc. 
(Indianapolis, IN), lodinated mEGF, labeled using Enzymobeads as described (6), was a generous gift 
from Dr. Th.J. Benraad and Mr. J.J.T.M. Heuvel (Department of Experimental and Chemical 
Endocrinology, University Hospital, Nijmegen, The Netherlands). Recombinant human transforming 
growth factor (TGF)-a, as well as the chimeric growth factors E3T and E4T, were prepared and 
purified as described in chapter 5. hTGF-a was ¡odinated in a similar manner as mEGF. NIH-3T3 
cells transfected with the chicken EGF receptor (CER-109 cells; a generous gift from Dr. J. 
Schlessinger, New York University, NY) were cultured in bicarbonate-buffered Dulbecco's modified 
Eagle's medium (DMEM), supplemented with 10 % fetal calf serum (Gibco BRL, Life Technologies). 
Radioligand-Receptor Binding Studies 
CER-109 cells were plated at a density of 5.5 χ 104 cells/1.8 cm2 in 1 ml serum-containing medium. 
After three days of culturing, the medium was removed, and replaced with 0.1 ml DMEM buffered with 
15 mM HEPES and 17.6 mM NaHC03, pH 7.7. This medium also contained 0.1 ng [125l]-hTGF-a and 
the unlabeled growth factors to be tested, added in the presence of 0.1 % bovine serum albumin 
(BSA). After incubation for two hours at room temperature whilst gently shaking, cells were placed on 
ice, and subsequently washed twice with ice-cold phosphate-buffered saline with 0.1 % BSA, and 
once with this buffer without BSA. Cells were then lysed by incubation for two hours at room 
temperature in 250 μΙ of a 1 % Triton X-100 solution, which was subsequently transferred for gamma 
counting. 
RESULTS 
General Theory 
We have previously shown that competition of binding of a radiolabeled ligand by a homologous 
unlabeled ligand to a homogeneous class of binding sites can be described explicitely as a function of 
the concentration of homologous competitor added, according to (Chapter 8) 
¿ Û l - Φ ) 1 1 "* W F'0(l-Fm0/Ll) 
£scp((p-<p„)-£¿cp(l-cp) 
F0 
Ks(l-<p„(l-F'0/L'0)) \Ke{\-^(l-Fm0/L'0)) t 
[1] 
In this equation L0' stands for the constant concentration of radiolabeled ligand added, and Lsu for the 
concentration of unlabeled, homologous competitor added. By definition φ is the fraction of non-
displaced bound labeled ligand upon addition of Lsu, and φ, the fraction that cannot be displaced at 
infinite Ls
u
 as a result of non-specific binding. Ks is the ligand binding dissociation constant, while F0' 
is the free concentration of labeled ligand in the absence of unlabeled competitor. This equation 
describes a linear relationship between 1/φ and the left-hand term, from which the ligand binding 
dissociation constant Ks can be determined. This equation can also be used to determine Ks from the 
binding characteristics of non-radiolabeled ligands, as shown previously by us (Chapter 8). 
It has been well established that a direct correlation exits between the dissociation constant of a 
competitor molecule and the concentration of competitor required for half-maximum binding 
competition of labeled bound ligand (5,7). Under conditions that free ligand concentrations do not 
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differ significantly from the ligand concentrations added, it has been shown by De Blasi et al. (7) for 
homologous displacement that Ks=Ls,/4-L0", in which Ls* is the concentration of unlabeled homologous 
competitor required for half-maximum displacement. In the case of non-homologous displacement it 
has been shown by Cheng and Prusoff (5) that KpL^I+L^/Ks), in which L,* is the concentration of 
non-homologous competitor required for half-maximum competition. At a later stage corrected 
versions of these equations have been derived, by taking into account that as a result of ligand 
binding free ligand concentrations may differ significantly from the concentrations added (8,9). 
We have shown previously (10) that the concentrations of homologous (Lsu) and non-homologous 
(L,) ligand which have to be added to induce the same extent of competition of labeled ligand binding 
(same value of φ) are related according to 
L+-L:: K,.-K„
 [ 2 ] 
L^l-b/a) K
s
(l-bja) 
in which (a) is the amount of radio-activity added, (b) the amount of radio-activity bound under these 
conditions, and (b„) the non-displaceable amount of radio-activity bound as a result of non-specific 
binding. In this equation (1-b/a) is a correction term for the fact that free ligand concentrations may 
differ from the concentrations added, and (1-bJa) a correction term of the fact that additional non­
specific binding may take place (10). If B'-values are expressed in radio-activity units, then 
b=Bs*=<pB0', and b„=B„'=<p„,B0'. If B"-values are expressed in molar amounts, then Bs"=b.p.V., in which 
V is the incubation volume, and 1/p the specific activity of the labeled ligand. 
Both eq. [1], which describes the shape of a homologous competition curve, and eq. [2], which 
correlates the shape of homologous and non-homologous competition curves on the basis of a 
socalled equivalent competition principle, take into account the possibility of non-specific ligand 
binding. By combining these two equations upon elimination of Lsu, an exact equation is therefore 
obtained which relates φ to L, for a non-homologous competition curve. If now L,'A is defined as the 
concentration of unlabeled competitor at which b=,/2(b0-b )+b , it follows by definition that the value of 
φ at half-maximum competition is given by φ,4='/2(1+φ ). Using Fs'=L0"-pBs' (Chapter 8) and the 
definition a=L07p, it follows that F0'=L0'.(a-b0)/a, in which b0=B0'. Using the above definitions it can be 
shown that the dissociation constant of a non-homologous competitor is given by 
K.. 
Li 
Í a VLo[ 2a-b0-ba\ 2 a-2b. j 
- * s 
( ¿ Л 
¿ a-b0-bx [3] 
This equation takes into account both that the free ligand concentrations may be significantly smaller 
than the concentrations added, and that non-specific ligand binding may take place. If these two 
considerations are ignored (b<a), the present equation is identical to equation of Cheng and Prusoff 
(5). If only the non-specific binding is neglected (b,=0), the present equation converts to the format 
previously derived by Linden (8) and Munson and Rodbard (9). If competition takes place by a 
homologous ligand (K,=KS), eq. [3] converts to 
s. , a-bn 2a-b-bL KS-(L4S-L0)(~¡f>(—-y~) [4] 
a D~ ¿a 
which under conditions b«a gives rise to the equation of De Blasi et al. (7). The parameter І_,'л used in 
this study may be interpreted as similar to l50, IC50 or ED50 used in other literature (5,7,9). 
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Determination of dissociation constants from concentrations required for half-maximum binding 
competition 
We have recently constructed chimeric forms of epidermal growth factor (EGF) and transforming 
growth factor (TGF)-a, and compared their binding affinity for both the human and chicken EGF 
receptor (Chapter 5). It has been established that TGF-a binds with high affinity, and EGF with low 
affinity to the chicken EGF receptor (11), and therefore studies using EGF/TGF-a chimeras may give 
information on receptor binding domains in these growth factor molecules (Chapter 5). The chimeric 
growth factor E3T consists of EGF sequences N-terminal of the third cysteine residue, and of TGF-a 
sequences C-terminal of this cysteine. E4T has EGF sequences up to the fourth cysteine, and TGF-a 
sequences from this position on. We have previously shown that TGF-a, E3T and E4T have similar 
binding affinity for the human EGF receptor (Chapter 5), but as shown in fig. 1 their affinity for binding 
to the chicken EGF receptor is not the same. In this figure, competition curves are shown for binding 
of [12Sl]-TGF-a binding to CER-109 cells by unlabeled E3T, TGF-a and E4T. CER-109 cells are 
murine NIH 3T3 cells, transfected with the chicken EGF receptor. The data show that binding of 
labeled TGF-a can be displaced to a large extent, but not completely by the various competitors 
tested, although with different half-maximum concentrations. 
In order to quantify the non-specific binding component, the binding curve obtained by competition 
with the homologous TGF-a ligand was analysed for specific and non-specific binding parameters, 
according to the linear subtraction method (4). A non-specific binding constant of KA=172.3 cpm.ml/ng 
was obtained, which in combination with eq. [14] in chapter 8 results in a value of φ „=0.0252 or 
b„=171.5 cpm, as indicated in fig, 1. The specific binding component is presented in a Scatchard plot 
of the insert of fig. 1. These data show that binding of TGF-a to CER-109 cells can be well described 
on the basis of a single affinity receptor class giving rise to a linear Scatchard plot, in agreement with 
the data of Lax et al. (11). Under the present experimental conditions a value for Ks of 5.1 ng/ml and 
a binding capacity of 55,000 receptors per cell was obtained from Scatchard analysis. 
In the ligand binding competition curves presented in fig. 1 the concentrations required for half-
maximum competition of specific binding have 
been indicated using vertical dashed lines. Based 
on eq. [4] for the homologous competition curve, 
the concentration required for half-maximum 
competition by TGF-a (Ls'"=7.4 ng/ml) corres­
ponds to a value of Ks=4.7 ng/ml. Using this value 
of Ks, the non-homologous competition curve by J 
E3T (L,'/2=2.8 ng/ml) gave rise to a value of K,=1.5 8 
ng/ml according to eq. [3], while for E4T (L,'!=15.1 
ng/ml) a value of K¡=10.0 ng/ml was obtained. 
These data therefore show that ligand binding 
dissociation constants can be obtained from the 
concentrations required for half-maximum 
competition by both homologous and non- Figure 9.1: Displacement of [,25l]-TGF-a binding to CER-109 
homologous ligands, using an exact expression cells ***** ( Δ ) · T G F - « i * » a n d f f ( D ?". T h e l a b e l e d J i 9 a n d 
was added at a concentration of 1 ng/ml, corresponding to 
which takes into account ligand binding to both 35082 cpm [,25l]-TGF-a per well. The solid line (o) represents 
receptor and non-specific domains. * * n o "- s P e c i , i c b k l d i n 9 component of Ш - T G F - « , as 
determined from the homologous competition curve according 
to the linear subtraction method (4). The horizontal dashed line 
represents the half-maximum competition level of specific 
radioligand binding, while the vertical lines represent the 
DISCUSSION corresponding concentration of the three unlabeled ligands 
tested, required to induce half-maximum competition. The insert 
shows a Scatchard plot for specific TGF-a binding, obtained 
The Cheng-Prusoff equation is Widely used to from the homologous competition curve and the calculated 
determine ligand binding dissociation
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from non-homologous competition curves. Originally this equation has been derived for describing 
competitive inhibition of enzymatic reactions, and therefore does not take into account reduction in 
ligand concentration as a result of binding (5). In later modifications of this expression (8,9) reduction 
in ligand concentration as a result of specific receptor binding was taken into account. In the present 
study we have derived an exact expression which takes into account reduction in ligand 
concentrations, both as a result of specific receptor binding and as a result of non-specific ligand 
binding, assuming that labeled and unlabeled ligand have similar non-specific binding characteristics. 
It is well realized that the Cheng-Prusoff equation, including the present and previous amendments, 
provides only a first estimate of ligand binding dissociation constants, since the values obtained rely 
only on the concentration required for 50% ligand binding competition. Various methods have been 
described for complete analysis of non-homologous competition curves (2,4,12-14), although direct 
methods for linearisation of those data, e.g. in a Scatchard plot, are not yet available. In the case of 
multiple receptor classes, the correlation between concentrations required for half-maximum 
competition and dissociation constants is less straightforward, and an exact analysis of binding 
constants for non-homologous ligands requires more elaborate methods, for example those described, 
by Munson and Rodbard (2), Almagor and Levitzki (15) and Van Zoelen (10). 
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CHAPTER 10 
GENERAL DISCUSSION 
The research described in this thesis was initiated with the final aim of localizing the receptor-
binding and activation domains of TGF-a and EGF, using chimeras between EGF-receptor binding 
ligands which show clear differences in receptor affinity and/or activation This knowledge can 
eventually lead to the design of an EGF-receptor antagonist, a ligand-analogue that is able to interrupt 
the autoenne loop of TGF-a found in many solid tumor cells No such substance has been 
synthesized up till now for any of the tyrosine kinase receptors Residues and domains with functional 
significance have been localized using site-directed mutagenesis, antibodies or partial peptides, but 
these experiments have not been able to separate residues or domains involved in binding from those 
involved in activation of the receptor Strayer and Leibowitz have described the presence an EGF-
receptor antagonist in poxvirus infected cells (1), but we have not been able to confirm this report 
(unpublished results) 
The finding that EGF has a 100-fold lower binding affinity for the chicken EGF-receptor than TGF-a 
(2), while both have the same affinity for the human EGF-receptor, provided the opportunity to locate 
the domain responsible for this difference in affinity using ЕСРЯйР-а chimeric proteins and to test 
this approach for use in the localization of the functional domains of EGF and TGF-a The availability 
of at least two structurally and functionally related proteins with a large difference in binding or actvity 
characteristics is the prerequisite for the chimeric protein approach Use of chimeric proteins for this 
goal has several advantages over other methods First of all chimeras are constructed from related 
proteins of identical overall structure with known binding and activity characteristics Therefore, the 
chimeras most likely have an overall structure comparable to the parent molecules, while their activity 
levels are expected to vary between the activities of each contributing protein A significant loss of 
activity in a set of complementary chimeras would be a clear indication of incorrect protein structure 
The consequence from the use of related proteins is, that only the variant residues can be studied 
The influence of mutations made by site-directed mutagenesis on protein structure on the other hand, 
are unpredictabe This is the more important while the residues that are to be changed, are mostly 
chosen on basis of conservation among related proteins in the expectation that these residues might 
be functionally important Conservation of residues might as well serve, however, to maintain the 
correct protein structure Mutation of a stucturally important residue almost inevitably leads to a loss of 
binding affinity A further advantage is that using chimenc proteins a gain instead of a loss of function 
can be measured Loss of función can be the result of many causes, e g by a disruption of the 
correct protein structure, while an accidental gam of function is much less likely Quantification of 
proteins mutated by site-directed mutagenesis therefore involves determination of the amount of 
protein produced as well as the verification of the correct protein strucure In the case of the 
EGF/TGF-a chimeras, differences in binding affinity for the human and chicken EGF-receptor were 
studied, and therefore the amount of protein activity could easily be quantified by calibration of their 
binding affinity for the human receptor, using purified mEGF as a standard Finally, only a limited 
number of chimeras can give an accurate indication of the domain that contains the target variant 
residue, which can next be located by individual amino acid exchange The search for a functional 
domain by site-directed mutagenesis only, generally involves the construction of a large number of 
mutants, especially while each residue has to be replaced by a number of other residues before the 
effect of a replacement can be judged 
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Production of correctly folded growth factor proteins is an important prerequisite for structure-
function research The presence of three disulfide bndges, which determine to a large extent the 
proper three-dimensional structure of EGF-hke growth factors, dictates largely the features of the 
expression system to be used. Intracellular expression in bactena, in combination with reshuffling of 
the disulfide bridges by reduction and reoxidation is far too time-consuming considering that for each 
chimera to be produced, the proper refolding conditions have to be determined. Bacterial cells are 
capable of forming the correct disulfide bndges, if the proteins are secreted into the penplasmic 
space. Introduction of the growth factor genes into the pRIT 21 vector (3), containing the constitutive 
protein A promoter and protein A signal sequence, produced very low levels of growth factor activity, 
mainly due to proteolytic degradation (unpublished results). The pHEMA 153 vector (4), used in the 
experiments described in this thesis gave a better protein production, but only after use of the E. coll 
KS474 strain (5) as a host, the level of active growth factor reached an acceptable level After full 
purification the amount of active growth factor protein obtained, vaned between 1.3 and 17 nmol per 
liter of bacterial culture. Before separation from protein A and further purification, the percentage of 
active growth factor was found to be 0 5-5% of the total amount of growth factor protein produced, 
depending on the growth factor or chimeric protein expressed This value may be an underestimation 
of the actual value, due to possible stenc hindrance by the protein A moiety After separation from 
protein A and further purification, the percentage of active growth must have been much higher, but 
the samples may still have contained considerable levels of inactive growth protein We have found 
no indication that these forms compete for binding to the receptor and influence the quantification of 
active protein Recent experiments from our laboratory have shown (6) that using the pEZZ 18 
expression vector (Pharmacia), containing two optimized IgG-bmdmg regions of protein A under the 
lac UV5 and protein A promoters, introduced into E coli KS474. higher levels of biologically active 
growth factors can be obtained. After RP-HPLC purification, the amount of protein in the active peak 
as determined by measuring the absorption at 229 nm and calculating the peak area, correlated well 
with the value obtained in the binding competition assay on HER-7 cells. This indicates that the active 
protein was fully separated from the inactive forms and using these highly purified growth factors a full 
confirmation of our present results were obtained The levels of active EGF-hke growth factors using 
this system varied between 2 2 and 41 nmol per liter bacterial culture (M van de Poll, pers, comm.). 
Other expression systems have been considered and used Yeast cells are capable of high-level 
expression of correctly folded proteins containing many disulfide bridges, and this host was in fact our 
first system of choice Using the Mating Factor-α (MFot) promoter and signal sequence, about 2 mg/l 
EGF and 500 μο/Ι TGF-α were obtained in the culture medium, but purification from the culture 
medium was accompanied by considerable loss of activity (unpublished results) Introduction of the 
IgG-bmdmg domains of the protein A sequence in the yeast expression vector, to be used as an 
affinity handle, resulted in our hands in loss of transformability of the yeast cells Use of the pUR 2730 
vector, containing the inducible GAL7 promoter and SUC2 signal sequence that is able to express 
very high levels of a-galactosidase (7), was hampered by a very low transformation efficiency. Use of 
the vector pSY 16 (8), containing the same promoter and the MFot signal sequence, but with a much 
better transformation efficiency, was more succesful The <x-galactosidase/FX/E3T fusion protein was 
expressed using this vector, producing 8 mg E3T per liter culture medium, calculated on basis of 
a-galactosidase activity (unpublished results) The fusion protein can be purified from the culture 
medium by one ion-exchange column and two immobilized metal affinity column (IMAC) purification 
steps (Dr I. Bom, Unilever Research Laboratories and unpublished results). After further optimization 
of this yeast expression system, which requires additional study, it may provide the milligram amounts 
of protein that will be needed for the structural analysis of candidate EGF-receptor antagonists. The 
Pichia pastons expression system also gave promising results and may be an alternative. 
The results presented in chapter 5 clearly indicate that domain VI, (most likely the residues Glu44, 
His45 and/or Ala46 of TGF-α), determines the difference in affinity for the chicken EGF-receptor 
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between EGF and TGF-a (chapter 5) Subsequent research has shown that exchange of Arg45 of 
EGF by alanine found at the homologous position in TGF-a, is sufficient to confer high affinity for the 
chicken receptor to hEGF (6), although residues C-termmal of Leu47 also appear to be involved in 
binding. This result underlines the theory that low affinity binding of EGF to the chicken receptor may 
be caused by charge repulsion between this ligand and the chicken EGF-receptor (chapter 5, see 
also chapter 1) maybe by influencing the interaction between Leu47 and the receptor. Richter and co-
workers (9) suggested that TGF-a possesses two sets of determinants which distinguish TGF-a 
binding from mEGF binding to the chicken EGF-receptor, of which the C-terminal tail is one, and 
residues in the B-loop (probably residues Phe22 and/or Lys28) the other. They arrive at this 
conclusion on basis of their results with mEGF/hTGF-a chimeras and the higher affinity of human 
EGF than mouse EGF for the cEGF-receptor described earlier by us (chapter 5). In their view, hEGF 
contains the same B-loop determinant as hTGF-a, which explains its higher affinity for the chicken 
EGF-receptor than mEGF (9). 
After the successful use of EGF/TGF-a chimeras for the localization of the C-terminus as the 
important determinant for the difference in binding between EGF and TGF-a to the chicken EGF-
receptor, experiments are now in progress to locate the binding domains of EGF using chimeras 
between hEGF and Notch, one of the EGF-hke proteins that do not bind the receptor Preliminary 
results indicate that a residue from the B-loop is involved in binding to the receptor (M.L M van de 
Poll, pers. comm ). 
Although hEGF, hTGF-a and all of the chimeras showed identical competition with 125l-mEGF for 
binding to the hEGF-receptor as mEGF, and the growth factors and most chimeras showed the same 
mitogenic activity on HER-7, HER-14 and HaCaT cells, three chimeras (E3T, E4T and T3E4T) 
stimulated mitogenic activity at lower concentrations on these cell lines (chapter 6) On chicken 
adipocyte precursor cells, however, the mitogenicity of the chimeras and growth factors corresponded 
with their binding affinity for the chicken EGF-receptor (chapter 6) The reason for the superagonistic 
activity of the three chimeras on the human cells is not easy to explain from the present data One 
possible explanation would be differential binding of the superagonists to high- and low-affinity 
receptors We have not studied this possibility in depth, but from the available data this seems 
unlikely In A431 cells, EGF and TGF-a bind the EGF-receptor with two different affinities (10) The 
low affinity receptors can be selectively blocked by the 2E9 monoclonal antibody (11), and occupation 
of the high affinity receptor sites by EGF is sufficient for induction of full mitogenicity (11,12) On this 
cell line, the parent growth factors as well as E3T, E4T, T3E and T4E (T3E4T was not tested) showed 
a clear correlation between binding affinity and biological activity, without a sign of superagonist 
activity (chapter 4) It was, however, noticed that the displacement curves of E3T and E4T showed 
slightly different slopes than the other growth factor proteins In HER-7 cells, TGF-a binds the 
receptor with only one affinity, while EGF binds with two affinities to this cell line (2) It is not known, 
however, if these receptor populations show differences in activation of the HER-7 cell In a pilot 
binding competition experiment (unpublished results) performed in the presence of an amount of 2E9, 
that blocked almost 60 % of tracer binding in the absence of unlabeled growth factor, no differences 
in displacement of 125l-mEGF between the different growth factors have been noticed TGF-a, E3T 
and E4T are known to bind with a single activity to CER-109 cells (2, chapter 9), but no data are 
available for EGF-binding due to its low affinity for this receptor From the mitogenic stimulation data 
obtained with this cell line no conclusions can be drawn while the background of mouse EGF-
receptors seems to contribute significantly to the stimulation measured (chapter 6). A possible 
explanation for the superagonistic activity will be discussed below 
Using the chimenc protein approach, we have also tried to locate the domains of EGF and TGF-a 
that activate the receptor To this end we needed a biological assay in which the two growth factors 
show different activities The mitogenic activity of EGF and TGF-a is identical in in vitro assays, but 
differences in activity have been noted in some other assay systems (see chapter 7 for references) 
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Most of them are either experimentally not attractive when many growth factor samples are to be 
tested, or EGF and TGF-a show only little difference in activity. We have tested EGF and TGF-a in 
two of these assays Soft-agar assays have been performed on PANC-1 cells according to Smith (13), 
but no differences in activity between EGF and TGF-a have been observed (unpublished results) 
Differences in the inhibition of alkaline phosphatase activity in cultured rat osteosarcoma cells with an 
osteoblast phenotype (UMR 106-01 cells,14) between EGF and TGF-a (5 vs 35% respectively at 
0 1 ng/ml) as well as between T4E and E4T (19 vs 33 % respectively at 1 ng/ml) have been 
observed, but these differences were considered too small and the assay too laborious for the testing 
of many chimeras (unpublished results). 
The quantitative differences in biological activity between EGF and TGF-a have been explained by 
a difference in processing of the EGF-receptor after binding of each growth factor caused by a 
difference in their receptor affinity at low pH (15) The basis for this difference would be the large 
difference in pi between the two growth factors, causing the release of TGF-a from its receptor in an 
acidic compartment shortly after internalization resulting in the escape from degradation of ligand and 
receptor, but the continued association of receptor and ligand after the binding of EGF, resulting in 
their degradation (15) Using the chimeras as a tool, we have been able to show that the low affinity 
of TGF-a for the receptor at low pH and the high level of receptor recycling induced by this growth 
factor is not the result of a difference in pi as has been suggested (15), but is most likely caused by 
the protonation of specific histidme residues (His35, His45 and to a lesser extent His4) present in 
TGF-a (chapter 7) Apart from TGF-a, the three chimeras that contain these residues (E3T, E4T and 
T3E4T) showed low affinity at acidic pH, and E3T and E4T (T3E4T has not been tested) induced a 
high level of recycling of the receptor The involvement of each of these histidme residues should of 
course be confirmed by additional site-directed mutagenesis studies The affinity of the chimeras 
tested for the EGF-receptor at low pH correlated well with the extent of recycling of the receptor after 
binding of the ligand, and it is likely that the two are indeed linked by cause and effect (chapter 7) 
The relation between these findings and quantitative differences in biological effects is, however, 
complicated The high level of receptor recycling induced by TGF-a does not result in a higher 
mitogenic activity than EGF on cells expressing the human EGF-receptor, but could explain the 
quantitative differences biological activity between EGF and TGF-a reported in the literature and in 
the alkaline phosphatase inhibiting activity observed by us It is striking, that the three chimeras that 
showed superagonistic activity in the 3H-thymmine incorporation assay, also showed a low affinity at 
acidic pH and that E3T and E4T (T3E4T has not been tested) induced a high level of recycling 
TGF-a on the other hand, as noted above, inducing the same level of recycling, is not a superagonist 
in the mitogenesis assay on HER-7 cells Induction of recycling has been mentioned as the reason for 
increased mitogenic activity of an EGF-mutant Walker et al (16) found that the EGF mutant Val47, 
showing strongly decreased affinity for the receptor but increased recycling, had the same 
mitogenicity on Balb/c 3T3 cells as wild type EGF They have not studied if the recycling of the ligand 
was brought about by a resistance to proteolytic enzymes or to an early release from the receptor, 
nor have they studied the fate of the receptor These results indicate that the fate of receptor and 
ligand after internalization may have a serious effect on the biological activity of the ligand and that 
this, and not the presence of different binding pockets for EGF and TGF-a may explain differences in 
activity between EGF and TGF-a, as for example has been suggested by Winkler et al (10) The 
effect of recycling of the receptor and/or ligand may well vary dependent on cell type and biological 
effect studied Mitogenic activity is dependent on the continued presence of EGF or TGF-a for long 
periods of time and may be influenced differently by high levels of receptor recycling than other 
processes that require shorter incubation times with ligand 
The difference in mitogenic activity of TGF-a on the one hand and the superagonists on the other, 
might be explained by a difference in time that the tyrosine kinase activity is stimulated The tyrosine 
kinase is probably active as long as the ligand is bound to the receptor from the moment of binding at 
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the cell surface untili the degradation in the lysosome or the release of the ligand in a compartment 
early after internalization (17) It can be imagined that TGF-ot is internalized quickly after receptor, and 
becomes separated from the receptor in a mildly acidic compartment very soon after internalization, 
resulting in a very short period of time in which the receptor tyrosine kinase is active per round of 
internalization Due to the recycling of the receptor and the long incubation time needed for mitogenic 
activity, the sum total of mitogenic stimulation caused by TGF-a would be identical as caused by 
EGF, which stimulates tyrosine kinase activity continuously dunng the time that the ligand-receptor 
complex is routed to the lysosome, but causes downregulation of the receptor. The super-
agonist/receptor complexes on the other hand could need more time for these events than TGF-a 
They could, for example, be internalized slower and/or be released in a more acidic compartment 
than TGF-a, later after internalization, but still be almost as capable to escape degradation together 
with the receptor This would result in a longer stimulation of the cell after binding of the 
superagonists than after binding of TGF-a, but resulting in virtually the same level of recycling 
receptor and ligand, causing a higher stimulation of the cell over time than after EGF or TGF-a 
binding An indication for a difference in behaviour between E3T and E4T on the one hand and 
TGF-a on the other, would be the almost complete degradation of the receptor after long incubation 
times with the superagonists, but not after binding of TGF-a The slightly lower pH-sensitivity of 
binding of E3T and E4T than TGF-a (fig 7 1) would fit into this model, but T3E4T binding shows the 
same pH-dependancy as TGF-a T4E6T on the other hand that has an even lower pH-sensitivity of 
binding than E3T and E4T, but is still capable of efficient recycling, does not show superagonistic 
activity The slightly different displacement curves of E3T and E4T in the binding competition 
experiment on A431 cells point to different binding characteristics of the superagonists on this cell 
line The kinetics of binding are presently studied, to test if the superagonistic chimeras differ in 
binding properties, for example in their receptor dissociation rate (AEG Lenfennk, pers comm ) 
Preliminary experiments indicated that the superagonistic activity of E3T and E4T is indeed reflected 
in a more rapid phosphorylation of the intracellular substrate MAP kinase in HER cells (M van der 
Poll, pers comm ) A different sensitivity to degrading enzymes would be of course also be a possible 
explanation for the differences in biological activity 
The fact that the chimeras show identical biological activity on chicken cells is an indication that the 
enhanced activity of the three chimeras on the HER cells is not the result of an error in their 
quantification When our explanation for the superagonistic activity of the three chimeras on HER cells 
is correct, there are two plausible explanations for the lack of superagonistic activity on chicken cells 
The first is, that the time needed for internalization of the superagonist/receptor complex is shorter, or 
not different from the time needed for the internalization of the other ligand/receptor complexes The 
other would be, that the important residues in the human receptor, causing repulsion of positively 
charged ligands at low pH are not (all) present in the chicken receptor, and that therefore no (large) 
differences exist between the growth factor proteins in pH-sensitivity of binding, and therefore in the 
routing of the internalized ligand/receptor complex Such a role could be played by His334, His346, or 
His394 in the hypothetical ligand binding domain of the human receptor (18, fig 1 4) All three His 
residues are conserved among the human and mouse sequences, but replaced by uncharged 
residues (Ser, Ser, and Туг respectively) in the chicken receptor Additional experiments should clarify 
if these assumptions are correct 
It thus seems that three different domains of the EGF-like ligands influence the biological activity 
following a ligand-receptor interaction The first is the receptor binding domain which primarily 
determines the binding affinity at the cell surface and secondly the domain which activates the 
receptor The superagonistic activity of some chimeras and the results with the Val 47 mutant (16) 
seem to indicate that the receptor binding and activation domains are not identical, which is a most 
important requisite for the construction of a receptor antagonist A third domain seems to influence the 
dissociation of the ligand from the receptor in the acidic intracellular compartments and to determine 
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the routing of the receptor and ligand. Dissociation of ligand and receptor swtches off the tyrosine 
kinase activity which is apparently a signal for recycling of the receptor from the endosomal 
membrane. The combination of the time in which the tyrosine kinase is active per round of 
internalization and the amount of internalizations a receptor is able to perform could be an important 
determinant of the biological activity of a ligand. This complicates the interptetation of the binding and 
activity results, but a better insight in the processing of the chimeric proteins may also shed light on 
the signal transduction by EGF-like growth factors and open new avenues to the design of an EGF-
receptor antagonist. 
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SUMMARY 
Growth factors are polypeptides that play an important role in the regulation of proliferation and 
differentiation of mammalian cells. They are produced in cells throughout the body and act by high-
affinity binding to specialized transmembrane receptors in the plasma membrane of their target cells. 
Some solid tumors are capable of continued auto-stimulation of proliferation by coexpressing the 
epiderrmal growth factor receptor (EGF-R) and transforming growth factor alpha (TGF-a), one of its 
ligands from the EGF-like family. This autocrine stimulation presumably takes place by binding of the 
secreted ligand to the EGF-receptor at the cell-surface. The autocrine loop might be interrupted by the 
addition of a ligand analogue that binds to, but is not capable of activation of the receptor. Such a 
receptor-antagonist is presently unknown and can only be designed if binding and activation of the 
receptor are performed by two separate domains of the ligand. Despite intensive research using 
synthetic peptides, antibodies blocking the ligand/receptor interaction and site-directed mutagenesis, 
residues involved in binding and residues involved in activation of the receptor could not be 
distinguished. 
In this thesis an alternative strategy is described to locate functionally important residues within 
TGF-a, which is based on domain-exchange with the structurally related growth factors from the 
EGF-like family. Prerequisite for this approach is the availability of an assay in which the two 'parent' 
proteins show clear differences in binding or activation of the EGF-receptor. Binding competition 
assays have shown that mEGF has an approximately 100-fold lower affinity for the chicken EGF-
receptor than hTGF-oc. This offered the opportunity to locate the domain in TGF-a that is involved in 
high-affinity binding to this receptor by domain-exchange with EGF. 
To this end, ten hEGF/hTGF-a chimeric genes in which domains were exchanged at the six highly 
conserved cysteine residues (see fig. 5.1 for an overview) were constructed, expressed in an E. coli 
expression system and purified. To standarize purification of the growth factor proteins, which differ 
widely in physicochemical properties, they were expressed with a protein A affinity-tag which was 
made removable by digestion with the highly specific proteolytic enzyme Factor Xa. After secretion into 
the periplasmic space of E. coli, the fusion proteins were purified by IgG-affinity chromatography and 
digested with Factor Xa after which the protein A moiety was removed by a second IgG-affinity 
column. The growth factors were further purified by gel filtration chromatography and RP-HPLC to 
remove misfolded, biologically inactive growth factor proteins from the sample (chapters 2 and 3). 
The resulting purified growth factor proteins were calibrated in binding competition assays on 
HER-7 cells (mouse NIH-3T3 cells transfected with the human EGF-receptor) using purified mEGF as 
a standard and tested in other assays for binding to and activation of the hEGF-receptor (chapter 4). 
The chimeras showed comparable behaviour in most assays, only in the ELISA binding competition 
assay in which biotin-labeled mEGF is used as a tracer, some growth factor proteins showed aberrant 
displacement curves. A plausible explanation for this could not be found. 
From binding competition experiments with these chimeric proteins on NIH-3T3 cells transfected 
with the chicken EGF-receptor (CER-109 cells) it could be concluded that the domain C-terminal of 
the sixth cysteine residue of hTGF-a determines its higher affinity for the chicken EGF-receptor 
relative to hEGF. Three amino acids are the most likely candidates to be involved. The lower affinity 
of EGF for the chicken than for the human EGF-receptor might be explained from charge repulsion 
between the ligand and the chicken receptor (chapter 5). 
Despite their identical binding competition with mEGF for the human EGF-receptor, three of the 
chimeras (E3T, E4T and T3E4T) showed an 8-20-fold higher activity than hEGF, TGF-a and the other 
chimeras in 3H-thymidine incorporation assays on HER-7 cells and on human keratinocytes. 
Comparable experiments on chicken adipocytes showed that all chimeras show identical biological 
activity towards the chicken EGF-receptor when related to their affinity for this receptor. In mitogenic 
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Stimulation experiments on CER-109 cells, the growth factor proteins with low affinity for the chicken 
receptor showed relatively high biological activity, but this result is most likely brought about by the 
presence of low levels of endogenous mouse EGF-receptors (chapter 6). 
EGF and TGF-oe show identical biological activity in most, but not in all assay systems. It was 
hypothesized by others that differences in biological activity between these growth factors are caused 
by a different routing of the ligand-receptor complex after internalization, this as a result of the 
difference in their isoelectric points (pi). The higher pi of TGF-oc would result in dissociation of ligand 
and receptor in a slightly acidic compartment early after internalization, causing recycling of the 
receptor to the cell surface allowing its repeated use. EGF on the other hand, having a lower pi, 
would not dissociate from the receptor in acidic compartments and cause the degradation of the 
receptor in the lysosome. The chimeras have widely varying pis, but in binding competition 
experiments at different pH values, pi proved to be not an indicator of pH-sensitivity of binding. This 
seems rather to depend on the presence of histidine-residues in the domains derived from the TGF-a 
sequence, which lie in the hypothetical binding domain. Chimeras which show little affinity for the 
human EGF-receptor at low pH, do show a high level of recycling of the receptor. Strikingly, the 
chimeras which show superagonistic activity in the mitogenic stimulation assay (E3T, E4T and T3E4T) 
induce the highest level of recycling of the receptor, but not higher than TGF-a (chapter 7). 
Chapters θ and 9 deal with the quantitative analysis of ligand-protein binding. In chapter θ we show 
that ligand-protein interactions can be described as a function of added, instead of free ligand. Using 
this method, binding parameters can be obtained from displacement curves of ELISA reactions and 
other assays that do not use radioactively labeled tracer. An equation for the exact determination of 
the ligand binding dissociation constant from non-homologous binding displacement curves, such as 
obtained in the binding competition experiments with the chimeric proteins in which labeled mEGF is 
used as a tracer, is presented in chapter 9. 
In the general discussion a model is presented which explains the superagonistic activity of some 
chimeras in the mitogenic stimulation assay on the basis of their pH-dependence of binding and 
concomitant level of induction of recycling of the receptor. The chimeric protein approach has shown 
to be fruitful for the determination of the domain of EGF and TGF-a which determines the affinity of 
binding to the chicken EGF-receptor, and has given more insight into the signal-transduction of EGF-
like growth factors. 
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SAMENVATTING 
Groeifactoren zijn Polypeptiden die een belangrijke rol spelen in de regulatie van de proliferatie en 
differentiatie van zoogdiercellen Ze worden in cellen overal in het lichaam geproduceerd en werken 
via hoog-affiniteitsbindmg aan gespecialiseerde transmembraanreceptoren in de plasmamembraan 
van hun doelcellen Sommige solide tumoren zijn in staat tot continue zelfstimulatie van hun 
proliferatie door coexpressie van de epidermale groeifactor receptor (EGF-R) en transforming growth 
factor-α (TGF-α), een van zijn liganden uit de familie van EGF-achtige groeifactoren Deze autocnene 
stimulatie vindt waarschijnlijk plaats door binding van het door de cel zelf gesecreteerde ligand aan de 
EGF-receptor op het celoppervlak De autocnene loop zou doorbroken kunnen worden door het 
toevoegen van een ligand-analoog welke bindt aan de receptor maar niet in staat is deze te activeren 
Zo'n receptor antagonist is nog niet bekend en kan alleen ontworpen worden als binding en activering 
van de receptor worden uitgevoerd door twee verschillende domeinen van het ligand Ondanks 
intensief onderzoek, waarbij gebruik werd gemaakt van synthetische peptiden, ligand/receptorbinding 
blokkerende antihchamen en plaatsgenchte mutagenese kon geen onderscheid worden gemaakt 
tussen residuen die betrokken zijn bij binding aan en residuen die betrokken zijn bij activering van de 
receptor 
In dit proefschrift wordt een alternatieve strategie beschreven om functioneel belangrijke domeinen 
te locahseren binnen TGF-α Deze is gebaseerd op uitwisseling van domeinen van TGF-α met die 
van structureel verwante groeifactoren uit de EGF-achtige groeifactorfamihe Voorwaarde voor deze 
aanpak is dat een assay beschikbaar is waarin de twee "ouder" groeifactoren duidelijke verschillen 
vertonen in binding aan of activering van de EGF-receptor Bindingscompetitie assays hebben laten 
zien dat muize-EGF een ongeveer 100-maal lagere affiniteit voor de kippe-EGF receptor vertoont dan 
hTGF-a Dit bood de gelegenheid om via domein-uitwisseling met EGF het domein van TGF-α te 
locahseren dat betrokken is bij de hoog-affmiteitsbinding aan deze receptor 
Tien hEGF/hTGF-a chimere genen waarin domeinen waren uitgewisseld op de zes hoog-
geconserveerde cysteine residuen (zie fig 5 1 voor een overzicht) werden hiertoe geconstrueerd, tot 
expressie gebracht in een E coli expressie systeem en gezuiverd Om de zuivering van de 
groeifactoreiwitten, die grote verschillen vertonen in hun physicochemische eigenschappen, te 
standaardiseren werden ze tot expressie gebracht met een protein A affiniteitshandvat dat 
verwijderbaar gemaakt werd via digestie met het specifieke proteolytische enzym Factor Xa Na 
secretie naar de penplasmatische ruimte van E coli werden de fusie-eiwitten gezuiverd via IgG-
affiniteitschromatography en gedigereerd met Factor Xa, waarna protein A verwijderd werd door een 
tweede affiniteitszuivenng Verdere zuivering van de groeifactoreiwitten vond plaats door 
gelfiltratiechromatografie en RP-HPLC om niet correct gevouwen, inactief groeifactoreiwit te 
verwijderen uit het preparaat (hoofdstukken 2 en 3) 
Het gezuiverde groeifactoreiwit werd gecalibreerd in bindingscompetitieassays op HER-7 cellen 
(muize NIH-3T3 cellen getransfecteerd met de humane EGF-receptor), waarbij gezuiverd mEGF werd 
gebruikt als ijkmatenaal, en getest in andere assays op binding aan en activering van de humane 
EGF-receptor (hoofdstuk 4) De chimeren gedroegen zich vergelijkbaar in de meeste assays, alleen in 
de bindingscompetitie ELISA waarin biotme-gemerkt mEGF werd gebruikt als tracer, vertoonden 
sommige groeifactoreiwitten een afwijkende verdringingscurve Een bevredigende verklaring hiervoor 
werd met gevonden 
Uit bindingscompetitie experimenten met deze gecahbreerde eiwitten op NIH-3T3 cellen 
getransfecteerd met de kippe-EGF receptor (CER-109 cellen) kon worden geconcludeerd dat het 
domein C-terminaal van het zesde cysteine residu van TGF-α de hogere affiniteit van deze 
groeifactor voor de kippe-receptor bepaalt ten opzichte van EGF Drie aminozuren in dit domein zijn 
zeer waarschijnlijk bij dit proces betrokken De lagere affiniteit van EGF voor de kippe-receptor dan 
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voor de humane receptor zou verklaard kunnen worden uit ladingsafstoting tussen het ligand en de 
kippe-EGF receptor (hoofdstuk 5). 
Ondanks hun identieke bindingscompetitie-activiteit ten opzichte van mEGF voor de humane EGF-
receptor, vertoonden drie van de chimeren (E3T, E4T and T3E4T) een 8-20-maal hogere activiteit 
dan EGF, TGF-a en de andere chimeren in 3H-thymidine incorporatie assays op HER-7 cellen en op 
humane keratinocyten die ook de EGF-receptor tot expressie brengen. Vergelijkbare experimenten op 
kippe-adipocyten lieten zien, dat elk groeifactoreiwit een identieke activiteit vertoonde op de kippe-
receptor, wanneer die werd gerelateerd aan de affiniteit van de groeifactor voor deze receptor. In 
mitogene stimulatie experimenten op CER-109 cellen vertoonden eiwitten met een lage affiniteit voor 
de kippe-EGF receptor een relatief hoge activiteit. Dit wordt waarschijnlijk veroorzaakt door de 
aanwezigheid van een laag niveau van endogene muize-EGF receptoren (chapter 6). 
EGF en TGF-a hebben een identieke biologische activiteit in de meeste, maar niet in alle test-
systemen. Door anderen werd verondersteld dat de verschillen in biologische activiteit tussen deze 
groeifactoren worden veroorzaakt door een verschil in de wegen waarlangs de ligand-receptor 
complexen worden geleid na intemalisatie, dit ten gevolge van een verschil in isoëlektrische punt (pi). 
De hogere pi van TGF-a zou resulteren in een dissociatie van ligand en receptor in een licht zuur 
compartiment kort na intemalisatie, en het weer terugsturen van de receptor naar het celoppervlak 
waardoor deze meermalen gebruikt kan worden voor signaaltransductie. EGF daarentegen, met een 
lagere pi, zou niet dissociëren van de receptor in compartimenten met zure pH en zou de afbraak van 
de receptor veroorzaken in het lysosoom. Om deze hypothese te testen hebben wij met de chimeren, 
die sterk verschuilende pi's hebben, bindingscompetitiexperimenten uitgevoerd bij verschillende pH's. 
Uit deze experimenten bleek dat pi geen indicator is voor de pH-gevoeligheid van binding. Deze 
schijnt eerder af te hangen van de aanwezigheid van histidine residuen in domeinen afkomstig van de 
TGF-a sequentie, die liggen in het hypothetische bindingsdomein. Chimeren die een lage affiniteit 
vertonen voor de EGF-receptor bij lage pH, vertonen inderdaad een hoger niveau van recycling van 
de receptor. Opvallend is dat de chimeren die een superagonistische activiteit vertonen in de 
mitogene stimulatie assay (E3T, E4T en T3E4T) het hoogste niveau van recycling van de receptor 
induceren, maar niet hoger dan TGF-a (hoofdstuk 7). 
Hoofdstukken 8 en 9 behandelen de kwantitatieve analyse van de ligand-eiwit binding. In 
hoofdstuk 8 tonen wij aan dat ligand-eiwit interacties als functie van toegevoegd, in plaats van vrij 
ligand, kunnen worden beschreven. Met behulp van deze methode kunnen bindingsparameters 
worden afgeleid uit verdringingscurves van ELISA-reacties en andere assays die geen radioactief 
gelabelde tracer gebruiken. Een vergelijking voor de exacte bepaling van de dissociatie constante van 
een gebonden ligand uit niet-homologe verdringingscurves, zoals verkregen in de bindingscompetitie 
experimenten met de chimere eiwitten waarin gelabeld mEGF werd gebruikt als tracer, wordt 
gepresenteerd in hoofdstuk 9. 
In de algemene discussie wordt een model gepresenteerd dat de superagonistische activiteit 
verklaart van sommige chimeren in de mitogene stimulatie assay, op basis van hun pH-
afhankelijkheid van binding en daarmee gepaard gaande mate van inductie van recycling van de 
receptor. Het gebruik van chimere eiwitten heeft zijn vruchten afgeworpen bij de bepaling van het 
domein van EGF en TGF-a dat de bindingsaffiniteit aan de kippe-EGF receptor bepaalt en heeft meer 
inzicht opgeleverd in de signaaltransductie van EGF-achtige groeifactoren. 
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